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I. Summary 
Hepatoma-derived growth factor (HDGF) is a ubiquitously expressed protein and 
involved in a variety of cellular processes. Since HDGF exhibits growth stimulating 
activity, research focused mainly on its role in cancer and tumour biology.  
Interestingly, screening the NCBI database for HDGF entries led to the discovery of two 
further alternative human HDGF isoforms, termed HDGF-B and HDGF-C in the present 
work. Even though these entries have been present in the NCBI database for quite a 
while, the respective HDGF isoforms have been neglected in HDGF research by now. 
Therefore, main aim of this thesis was the verification and initial characterisation of those 
two novel HDGF isoforms. 
HDGF-B and HDGF-C arise from the usage of an alternative first in-frame exon and the 
expressed proteins exhibit changes in their N-terminal part. The remaining C-terminal 
part is identical to that of the basic HDGF form, now termed HDGF-A. 
Since most of the known interactions and functions of HDGF-A have been assigned to its 
N-terminal part, changes in this part of the protein might have a huge impact. Indeed, the 
results of this thesis indicated that the novel isoforms carry out quite distinct functions. 
This became particularly obvious regarding the analysis of co-precipitated proteins of 
each isoform. Only HDGF-A co-precipitated the RNA binding proteins nucleolin and YB-
1, whereas HDGF-B and HDGF-C lost these interaction partners. Instead, these isoforms 
were able to co-precipitate tubulin and the motorprotein dynein and conversely these 
interaction partners were not detectable in the co-precipitate of HDGF-A. 
A further alteration was discovered in the secretion behaviour of these isoforms. HDGF-A 
is considered as a protein which leaves the cell via an alternative secretion pathway. 
Recently, some major proteomic studies detected its presence in exosomes, small 
secreted vesicles. This discovery was supported by the results of this thesis. Moreover; it 
was found that HDGF-A is located within in the lumen of those extracellular vesicles. 
Interestingly, HDGF-A was additionally detected as free protein in the surrounding 
media, suggesting that it uses an additional alternative pathway to leave the cell. By 
contrast to this the novel isoforms HDGF-B and HDGF-C were detected at the surface of 
extracellular vesicles without any evidence that these proteins are additionally present as 
free protein.  
A remarkable finding of this thesis was the discovery that truncation of the outermost 15 
N-terminal HDGF-A is sufficient to induce the same secretion and interaction behaviour 
as observed for HDGF-B and HDGF-C. The results highlighted the importance of the 
outermost N-terminal peptide in HDGF-A. A previous study revealed that N-terminal 
truncation might be controlled by dephosphorylation of serine residue 165 in HDGF-A. 
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Assumed that such a truncation mechanism exists also under physiological conditions 
the cell is able to control the mode of secretion as well as interaction behaviour not only 
by alternative splicing but also by posttranslational modifications.  
This work provides insight into new aspects of HDGF, which help to understand its 
biological function and open up new perspectives for future studies. 
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II. Zusammenfassung 
HDGF ist ein ubiquitär exprimiertes Protein, das an vielen verschiedenen zellulären 
Prozessen beteiligt ist. Aufgrund seiner wachstumsanregenden Wirkung fokussierte die 
HDGF Forschung vor allem auf seine Rolle in der Tumor und Krebsbiologie. 
Interessanterweise führte die Durchsuchung der NCBI Datenbank zu der Entdeckung 
zweier weiterer HDGF Spleißvarianten, die während dieser Arbeit als HDGF-B und 
HDGF-C bezeichnet wurden. Obwohl die Sequenzinformationen zu diesen Varianten 
schon längere Zeit in der Datenbank hinterlegt sind, wurden sie bisher in der HDGF 
Forschung weitestgehend missachtet. Aufgrund dessen lag der Hauptfokus dieser Arbeit 
in dem Nachweis und der anfänglichen Charakterisierung dieser neuen HDGF 
Isoformen. 
Diese beiden Isoformen entstehen durch die Verwendung eines alternativen ersten 
Exons, welches sich im gleichen Leseraster zu den nachfolgenden kodierenden Exons 
befindet. Die beiden Isoformen weisen somit Veränderungen im N-terminalen Bereich 
des Proteins auf, während der übrige Teil identisch zu dem C-terminalen Teil der 
ursprünglich beschriebenen HDGF Isoform ist, die nun als HDGF-A bezeichnet wird. 
Da die meisten der bekannten Interaktionen und Funktionen von HDGF-A dem N-
terminalen Bereich zugeschrieben werden, haben Veränderungen in diesem Teil des 
Proteins möglicherweise große Konsequenzen. 
Die Ergebnisse dieser Arbeit deuten tatsächlich darauf hin, dass die neuen Isoformen 
HDGF-B und HDGF-C andere Funktionen ausfüllen. Dies wurde besonders offensichtlich 
bei der Analyse der Ko-Präzipitate der Isoformen. HDGF-A ko-präzipitierte unter 
anderem die RNA-Bindeproteine Nucleolin und YB-1. HDGF-B und HDGF-C hingegen 
verloren die Fähigkeit mit diesen beiden Proteinen zu interagieren. Stattdessen waren 
sie in der Lage Tubulin und das Motorprotein Dynein zu präzipitieren, Proteine die 
wiederum im Ko-Präzipitat von HDGF-A fehlten.  
Auch das Sekretionsverhalten der neuen HDGF Isoformen zeigte sich verändert. HDGF-
A wird generell als sezerniertes Protein angesehen, welches über alternative 
Sekretionswege die Zelle verlässt. Kürzlich konnten Massenspektrometrie-Studien 
zeigen, dass HDGF sich in Exosomen, kleine sezernierte Vesikel, befindet. Diese Arbeit 
unterstützt die Entdeckung dieser Studien und konnte darüber hinaus zeigen, dass 
HDGF-A sich innerhalb dieser Vesikel befindet. Interessanterweise lag HDGF-A auch als 
freies Protein im Kulturüberstand vor, was darauf hindeutet, dass ein weiterer 
Sekretionsweg benutzt wird. Einen starken Kontrast dazu bildeten die neuen Isoformen 
HDGF-B und HDGF-C. Sie befanden sich auf der Oberfläche von extrazellulären 
Vesikeln und lagen nicht zusätzlich als freie Proteine im Kulturüberstand vor.  
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Bedeutsam war in diesem Kontext auch, dass die Trunkierung der ersten 15 N-
terminalen Aminosäuren von HDGF-A zu den gleichen veränderten Sekretionsverhalten 
führte. Dies stellt die Bedeutung des äußersten N-terminalen Peptides in HDGF heraus. 
Es wurde hierbei in einer früheren Studie gezeigt, dass die N-terminale Trunkierung von 
HDGF möglicherweise über die Dephosphorylierung der Aminosäure Serin 165 in HDGF 
gesteuert werden kann. Vorausgesetzt dass ein solcher Trunkierungsmechanismus auch 
unter physiologischen Bedingungen existiert, könnte nicht nur die Sekretion sondern 
auch das Interaktionsverhalten von HDGF sowohl über Alternatives Spleißen als auch 
durch Posttranslationale Modifikation gesteuert werden. 
Diese Arbeit gibt Einblick in neue Aspekte über HDGF, die dabei helfen seine 
biologische Rolle zu verstehen und neue Perspektiven für künftige Studien eröffnen. 
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1. Introduction 
1.1 Hepatoma-derived growth factor 
1.1.1 HDGF: Structure and function 
The Hepatoma-derived growth factor (HDGF) was originally purified as secreted factor 
from the medium of human hepatoma-derived cell line HuH-7 and described as a 25 kDa 
acidic heparin-binding protein with growth stimulating activity [1]. Meanwhile it is known, 
that this protein is expressed in a wide variety of tissues and cell lines [1-3]. HDGF 
appears to be a multifunctional protein that is involved in numerous cellular processes [4-
6]. This is mirrored by the huge number of diverse interactions partners, which were 
identified in co-precipitates of HDGF. The identified proteins participate in different 
cellular events such as ribosome biogenesis or mRNA metabolism [5, 7]. 
HDGF is the first identified member of the HDGF-related protein (HRP) family, a protein 
family which to date contains five additional members: HRP-1, HRP-2 [8] , HRP-3 [9], 
HRP-4 [10] and lens epithelium-derived growth factor (LEDGF) [11]. As shown in the 
alignment (figure 1) all members of this family exhibit a high homology in the N-terminal 
region (amino acid residues 1-98 in HDGF), termed hath region (homologous to the 
amino terminus of HDGF), while their C-terminus is variable in length and charge [8, 10]. 
human HDGF        MSRSNRQKEYKCGDLVFAKMKGYPHWPARIDEMPEAAVKSTANKYQVFFFGTHETAFLGP 
human LEDGF       -----MTRDFKPGDLIFAKMKGYPHWPARVDEVPDGAVKPPTNKLPIFFFGTHETAFLGP 
human HRP-1       -MSAYGMPMYKSGDLVFAKLKGYAHWPARIEHMT------QPNRYQVFFFGTHETAFLSP 
human HRP-2       -----MPHAFKPGDLVFAKMKGYPHWPARIDDIADGAVKPPPNKYPIFFFGTHETAFLGP 
human HRP-3       -MARPRPREYKAGDLVFAKMKGYPHWPARIDELPEGAVKPPANKYPIFFFGTHETAFLGP 
bovine HRP-4      -MSRFYRRKYKCGDLVFAKLKGYAHWPARIEQTA------EANRYQVFFFGTHETAFLGP 
                           :* ***:***:*** *****::.          *:  :***********.* 
 
human HDGF        KDLFPYEESKEKFGKPNKRKGFSEGLWEIENNPTVKAS-- 
human LEDGF       KDIFPYSENKEKYGKPNKRKGFNEGLWEIDNNPKVKFS-- 
human HRP-1       KRLFPYKECKEKFGKPNKRRGFSAGLWEIENNPTVQASS- 
human HRP-2       KDLFPYDKCKDKYGKPNKRKGFNEGLWEIQNNPHASY--- 
human HRP-3       KDLFPYKEYKDKFGKSNKRKGFNEGLWEIENNPGVKF--- 
bovine HRP-4      RHLFPYEESKEKFGKPNKRRGFSEGLWEIENNPTVQASDY 
                 : :***.: *:*:** ***:**. *****:*** ..    
Figure 1: Sequence alignment of the N-terminal hath regions of the HRP family. Multiple 
alignments obtained by clustal omega (1.2.1) [12] online tool with default mode. Accession 
numbers: HDGF: NP_004485.1; LEDGF: AAH64135; HRP-1: EAW55436; HRP-2: 
NP_001001520.1; HRP-3: NP_057157.1; HRP-4: CAB40348). Amino acid sequences are given in 
the single letter code. Asterisks (*) indicate positions which have a single, fully conserved residue, 
double dots (:) indicate conservation between groups of strongly similar properties, single dots 
indicate conservation between groups of weakly similar properties. The PHWP motif is highlighted 
by a black box. 
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While the N-terminal hath region exhibits a well-defined secondary structure, the C-
terminal part of HDGF was characterised as disordered [13]. Disordered proteins lack a 
folded tertiary structure under physiological conditions. This allows a high intramolecular 
flexibility which can confer advantages over a strict ordered structure in specific protein 
functions. Indeed, such protein regions gain more and more attention and have been 
identified in a growing number of proteins that accomplish important cellular functions 
such as cell cycle control, transcription regulation or signalling functions [14, 15].  
Yet, most known interactions of HDGF are assigned to the well structured hath region 
such as majority of the identified HDGF-protein interactions [5] as well as its DNA binding 
ability [16]. The exact function and putative interaction partners of the C-terminal part of 
HDGF are widely unknown. Interestingly, for the mitogenic activity of HDGF the non-hath 
region appears to be responsible since overexpression of C-terminal non-hath part alone 
is sufficient to enhance proliferation [17].  
The secondary structure of the N-terminal hath region, depicted in figure 2, consists of 
five β-strands and two α-helices. The five β-strands form an anti-parallel β-barrel 
followed by the two C-terminal α-helices. The PWWP domain (amino acid residue 12-68 
in HDGF), a structural protein domain, is part of this hath region in HDGF. This domain, 
first characterised from the WHSC1 gene [18, 19], was identified in a wide range of 
mostly chromatin associated proteins within the eukaryotes [20]. It has a role in protein-
protein interactions as well as in different DNA related processes such as transcriptional 
regulation [21], DNA repair [22] or DNA methylation [23]. The around 70 amino acid (aa) 
residue long domain was designated PWWP because of its central core motif ‘proline-
tryptophan-tryptophan-proline’ [18, 19]. However, the name is slightly deceptive since 
only the fourth position of this motif (proline) is conserved among all family members 
[20]. As shown in the alignment, this core motif PWWP is changed to ‘proline-histidine-
tryptophan-proline’ (PHWP) motif in HDGF, LEDGF, HRP-2 & HRP-3 and to ‘alanine-
histidine-tryptophan-proline’ (AHWP) motif in HRP-1 and HRP-4.  
The surface of the hath region exhibits large positively charged patches due to the 
presence of a series of positively charged amino acid residues. This positively charged 
surface is responsible for heparin binding [13] as well as for DNA binding [16]. Heparin is 
a highly negatively charged linear polymer consisting of repeating units of 1→4-linked 
uronic acid and glucosamine residues [24]. Yang et al. [25] showed that the PWWP 
domain of HDGF mediates the specific binding to a minimum 37 bp long DNA fragment 
within the promoter of the SMYD1 gene and thereby functions as a transcription 
repressor. 
Interestingly, the PWWP domain is also responsible for the formation of HDGF dimers 
via an unusual domain swap mechanism that involves the exchange of the first two N-
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terminal β-sheets. Resulting homodimers have higher affinity to heparin [26] but the 
exact biological role of those dimers is unknown. 
Furthermore, HDGF contains two nuclear localisation sequences (NLS) [9, 27]. NLS 1 is 
located in the hath region (amino acid residues 75-80), while the second bipartite NLS 
motif is present in the C-terminal non-hath region (amino acid residues 155-170) (figure 
2). Studies showed that the presence of the bipartite NLS 2 signal in the C-terminal part 
is essential for nuclear localisation of HDGF and simultaneously, nuclear entry is 
required for the mitogenic effect of intracellular HDGF [17, 28]. 
Despite the fact that HDGF was originally identified to be exclusively present in the 
cytoplasm [1], the subsequent majority of studies revealed that HDGF is predominantly 
present in the nucleus of cells [2, 17]. Multiple studies found that HDGF can be 
additionally detected in the cytoplasm [3, 17, 29-32], indicating that HDGF is able to 
reside in both compartments. 
 
Figure 2: Schematic illustration of present domains and motifs in HDGF. The N-terminal 
region termed hath region (grey box) (amino acids residues 1-98) encompasses the PWWP 
domain (amino acid residues 12 -68) with the core motif PHWP (light blue line). The characteristic 
secondary structure [13] is shown above. Blue arrows indicate β-sheets, red boxes represent α-
helices. The C-terminal part is termed non-hath region (dark grey box) (amino acid residues 99-
240). The first ten amino acids residues contain a putative signal peptide (red line), which seems 
to mediate secretion via an alternative pathway [33]. HDGF contains two NLS (orange line) [9, 
27]. NLS 1 (amino acid residues 75-80) is located in the hath region, NLS 2 (amino acid residues 
155-170) is located in the non-hath region. Furthermore, some of the known phosphorylation sites 
(serine residues 103, 132, 133, 165, 202) [34-36] are shown (P labelled circles). 
As mentioned before HDGF is able to stimulate the proliferation of multiple cell types 
including fibroblasts [1], endothelial cells [37, 38] and smooth muscle cells [2]. Moreover, 
it supports cell migration and invasion [39, 40].  
It is not completely understood how exactly HDGF exerts its proliferative activity on cells. 
In this regard, it is assumed that HDGF acts via two independent pathways [41] as 
depicted in figure 3. The first pathway requires nuclear localisation and depends on the 
C-terminal non-hath region [17]. The second pathway involves extracellular HDGF, which 
mediates its activity via a receptor-mediated pathway. In contrast to this first pathway the 
second pathway depends on the presence of the amino acid residues 81-100 in HDGF. 
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These amino acid residues constitute the putative binding site in HDGF for a yet 
unknown receptor which is coupled to downstream signalling pathways [41]. Recently 
Chen et al. demonstrated that HDGF can bind surface nucleolin [42]. Whether nucleolin 
is the exclusive surface receptor or also other receptor can be used is still unclear. 
 
Figure 3: Putative signalling pathways of HDGF. HDGF (grey circles) can stimulate 
proliferation by two independent pathways. First pathway (1) requires nuclear localisation and the 
C-terminal hath region. The exact mechanism which leads to cell proliferation is obscure. Second 
pathway (2) involves extracellular HDGF, which binds to an unknown plasma receptor and by that 
stimulates signalling pathways (MAPK and PI3K). Furthermore, extracellular HDGF can be 
internalised by macropinocytosis and its internalisation depends on surface heparin (3). The figure 
was adapted without permission from [4] with some modifications. 
In accordance with the assumption that HDGF acts through a receptor mediated 
signalling pathway, was the discovery that treatment of endothelial cells with exogenous 
HDGF initiates mitogen-activated protein kinase (MAPK)/ extracellular-signal-regulated 
kinases (ERK1/2) pathway already after 5 min of exposure [38, 43]. Also for ovarian 
cancer cells [44] and in osteosarcoma cells [43] stimulation of MAPK/ERK1/2 upon 
HDGF exposure was shown. Similarly, overexpression of HDGF led to stimulation of the 
same signalling pathway [45].  
Although Everett et al. excluded stimulation of phosphatidylinositol 3-kinase (PI3K)/Akt 
signalling in endothelial cells upon exogenous HDGF treatment [38], other studies were 
able to demonstrate this in osteosarcoma cells [43] as well as in fibroblast cell line 
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NIH/3T3 [46], revealing that HDGF can induce more than one intracellular signalling 
pathway. Interestingly, the neutralisation of surface nucleolin by antibodies led to the 
decrease of HDGF induced PI3K/Akt signalling [47]. 
HDGF is a phosphoprotein and, as indicated in figure 2, several different serine residues 
were experimentally identified as phosphorylation sites in HDGF [36, 48]. However, at 
the current stage not much is known about functional consequences of this 
posttranslational modification. Everett et al. could show that the phosphorylation of serine 
residue 103 enhances the mitogenic activity of HDGF [36]. Phosphorylation or 
dephosphorylation at serine residue 165 seems to be involved in secretion related 
process [33]. Apart from phosphorylation sites a SUMOylation site was identified in the 
N-terminal hath region at lysine residue K80. Strikingly, SUMOylation at this position led 
to the loss of chromatin association [49]. 
1.1.2 Biological role of HDGF  
The biological role of HDGF appears to be linked to embryonic development and 
regeneration processes. In this context it was shown that HDGF expression is 
developmentally regulated. In prenatal smooth muscle cells HDGF is highly expressed, 
while after birth HDGF expression declines [2]. This was also observed for hepatocytes 
[50]. Furthermore, HDGF is widely distributed within the developing kidney, while it 
cannot be detected in the adult kidney [37]. Other studies implied that HDGF plays a role 
in lung [51], liver [50], brain [3], gut [7] and heart [27] development.  
By contrast, Gallitzendörfer et al. [52] generated HDGF deficient mice, which did not 
show apparent differences to the wild type mice, indicating that HDGF is dispensable in 
mice for the development and growth. 
Besides, HDGF might be also involved in processes of organ repair and remodelling 
after injury. In smooth muscle cells HDGF is highly expressed after vascular injury and 
seems to play a role in their subsequent proliferation [39]. Furthermore, Enomoto et al. 
suggested that HDGF is involved in liver regeneration as autocrine factor [53]. Similarly it 
might participate in intestine regeneration [54]. In addition, HDGF is able to promote 
angiogenesis [2, 38, 55-58]. 
Like for other growth factors misregulation of HDGF has a significant impact on 
tumourigenesis and cancer progression. An increasing number of studies demonstrated 
elevated HDGF expression in a wide variety of human tumours including hepatocellular 
cancer [31], non-small cell lung cancer [59], pancreatic cancer [60] or gastric cancer [61]. 
Overexpression of HDGF correlates with aggressiveness of cancer as well as poor 
clinical outcome and, therefore, HDGF can be considered as a prognostic tool for some 
cancer types, e.g. non-small cell lung cancer [62], pancreatic cancer [60] or 
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glioblastomas [63]. In accordance, suppressing HDGF by small interfering RNA (siRNA) 
lead to slower cell growth [40, 64] and decreased invasiveness [64], as well as reduced 
metastasis formation [65] which makes HDGF a putative therapeutic target. 
Recently it was found that HDGF overexpression as well as exogenous HDGF supply 
induces epithel-mesenchymal transition (EMT) [66]. EMT is a transition process by which 
epithelia cells lose their typical characteristic such as cell-cell adhesion and cell polarity 
to become mesenchymal cells, which are featured by more migratory and invasive 
properties [67]. This process is directly linked to cancer invasiveness and metastasis [68] 
and it seems that HDGF increases migratory and invasiveness of cancer cells by 
modulating EMT [65, 66, 69]. 
Related to its pathophysiological role in different cancers is the fact that HDGF may act 
as a survival factor. Blocking HDGF by antibodies or siRNA induces apoptosis in HepG2 
cells as well as in human colorectal carcinoma cells [70-72] and gastric cancer cells [73].  
1.1.3 HDGF and secretion 
Several proteins are able to function on both sides of the membrane and thus fulfil extra- 
and intracellular tasks [74]. Such a dual role was described for heat shock proteins [75] 
as well as for high-mobility group protein B1 (HMGB1) [76], which shares a high degree 
of similarity with HDGF particularly in the acidic C-terminal region [1]. Since HDGF exerts 
its function as intracellular and extracellular protein [17, 41], it can be sorted into the 
same group of proteins with a dual role. 
To realize extracellular tasks, release into the extracellular space is required. Indeed, 
HDGF was originally isolated from the medium of HuH-7 cells [1] and also other studies 
demonstrated that HDGF can be found in the surrounding medium of a wide variety of 
cells including neurons [77], endothelial cells [37], skeletal muscle cells [78] or keloid 
keratinocytes [79]. In this regard, HDGF was also identified blood serum collected from 
non-small lung cancer patients and moreover, extracellular HDGF levels were elevated 
compared to the serum from healthy patients [80]. According to Radisky et al. [74] the 
release via non-classical secretion pathways is typical for such proteins, which fulfil dual 
tasks inside and outside of cells. In line with this is the fact that HDGF does not contain a 
hydrophobic secretion signal which mediates the classical secretion pathway.  
Some studies discussed HDGF as a protein which is mainly passively released from 
cells which undergo necrosis, while it remains in the nucleus of apoptotic cells [44, 77]. 
Such a passive release was also described for HMGB1 [81] and both proteins were 
classified as potential alarmins, passively released proteins which are involved in 
signalling cell and tissue damage to the immune system [82, 83]. 
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Interestingly, HDGF release can be controlled, which suggests an underlying active 
secretion process. Thakar et al. [33] were able to show that one single putative 
phosphorylation site in HDGF seems to play a regulative role in its secretion. Serine 
residue 165 is conserved in human and mouse HDGF and independent studies 
demonstrated experimentally that in human and murine HDGF serine residue 165 is 
phosphorylated [34, 48, 84-86]. 
Strikingly, when changing the serine at position 165 to alanine, the resulting HDGF 
mutant S165A cannot be detected in the cell supernatant after 24 h, although a clear 
signal is present in case of HDGF wt [33]. In comparison to the wild type, the S165A 
mutant has a faster electrophoretic mobility due to a loss of the first N-terminal amino 
acids. Likewise, truncated HDGF forms deleted in first N-terminal 11 or more amino 
acids cannot be detected after 24 h in the culture medium. This led to the hypothesis that 
the loss of phosphorylation site S165 promotes N-terminal truncation and in turn 
prevents secretion. Interestingly, the N-terminal 10 amino acids long peptide is able to 
act as mediator for secretion, when fusing it to reporter proteins like EGFP or SNAP [33]. 
However, the question remains how HDGF leaves the cell. Several alternative secretion 
pathways have been described in literature. Recently, HDGF was identified in exosomes, 
small secreted vesicles [87-89]. Because of this, this pathway is described in more detail 
in the next chapter. 
1.2 Alternative secretion: HDGF in exosomes 
A universal feature of all cells is that they are surrounded by a membrane, which serves 
as selective barrier between the environment and the inside of the cell. Proteins, which 
are destined for secretion, have to cross this barrier [90]. Within the eukaryotic cell 
several pathways are possible. The majority of secretory proteins contain a specific N-
terminal signal sequence, which mediates classical secretion via ER-Golgi dependent 
route [91]. For an increasing number of proteins, alternative secretion pathways have 
been identified. These proteins lack the classical signal peptide and their secretion is not 
inhibited by brefeldin A (BFA) [92], a well known inhibitor of the classical secretion route 
[93]. 
A growing number of proteins have been identified in exosomes; including HDGF. 
Complex proteome analyses have identified HDGF in exosomes collected from colon 
cancer [89, 94] and ovarian cancer cells [88] leading to its entry in the Exocarta database 
(www.exocarta.org) [95]. 
Exosomes are 40-100 nm vesicles, that are released in the extracellular space by the 
majority of cell types including epithelial cells [96], reticulocytes [97], dendritic cells [98] 
or various tumour cell lines [99]. To date, exosomes are the only known secreted 
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vesicles which derive from an internal membrane [100]. As illustrated in figure 4, the 
biogenesis of exosomes involves the maturation of early endosomes to multivesicular 
bodies. This maturation process is accompanied by inward budding of endosomal 
membranes and the subsequent creation of intralumina vesicles (ILV) [101, 102]. 
‘Degradative’ MVBs can be targeted for degradation by fusing with lysosomes [103, 104]. 
On the other side the intraluminal vesicles (ILV), along with their cargo, can be released 
into the extracellular space as result of the fusion of ‘exocytic’ MVBs and plasma 
membrane [97, 105]. However, a specific mechanism which determines the fate of the 
MVBs is still unknown [100]. 
 
Figure 4: Generation of exosomes.  Early endosomes, generated at the plasma membrane can 
either fuse with the plasma membrane or form MVBs. Inward budding at the limiting membrane of 
MVBs results in the formation of intraluminal vesicles (ILV). MVBs can have distinct fates, either 
they evolve into lysosomes or they can fuse with the plasma membrane and release their ILVs 
into the extracellular space. Those microvesicles are termed exosomes. Vesicles derived by 
blebbing of the plasma membrane are termed shedding microvesicles. The illustration was 
adapted from [106] without permission. 
Exosomes contain a unique protein and lipid composition. The exact composition varies 
depending on the cell type but some proteins such as tetraspanins CD63 or CD81 are 
specifically enriched in exosomes and are useful as marker proteins [107, 108].  
Sorting into ILV is regarded as selective process but underlying mechanisms are not well 
understood [109]. The best characterised mechanism for incorporation of proteins into 
ILVs involves a multi-enzyme complex termed endosomal sorting complex required for 
transport (ESCRT). Cargo proteins, which are incorporated by this mechanism, are 
usually ubiquitinated [110]. This sorting process was mainly described for proteins, which 
are destined for the degradative MVBs [109, 111] and its involvement in exosome 
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secretion is still unclear. Moreover, a tetraspanin and lipid-dependent mechanism which 
is independent from the ESCRT machinery, has been described [112]. 
The biological role of exosomes is diverse. Early studies of reticulocytes indicated that 
the secretion of exosomes is an alternative way to discard obsolete membrane proteins 
such as transferrin receptors [97]. To date it becomes more and more evident, that 
exosomes participate in cell-cell communication. Recent studies demonstrated that 
exosomes are not only able to transfer proteins and lipids, but are also able to deliver 
mRNAs and microRNAs to specific recipient cells [113]. In this context it has been shown 
that exosomes affect recipient cells in various ways and elicit cell specific responses 
[114, 115]. 
1.3 Scope of this thesis 
HDGF is a ubiquitously expressed protein that was reported to be involved in a variety of 
functions such as cell proliferation, cell migration, RNA processing or ribosome 
biogenesis. Like the majority of human genes it undergoes alternative splicing, a 
mechanism which may contribute to the functional diversity of HDGF by the generation of 
alternative isoforms. Screening the NCBI database revealed the presence of several 
alternative human HDGF transcripts, generated by alternative splicing. Despite their 
entry in the NCBI database, these HDGF isoforms have remained mostly unnoticed in 
the HDGF research field by now. Therefore, one of the main objectives of this thesis was 
the verification and initial characterisation of two novel HDGF isoforms, termed HDGF-B 
and HDGF-C. 
The two alternative variants exhibit differences in the N-terminal part compared to the 
well described original HDGF form, now termed HDGF-A in the further course of this 
thesis. Since most functions and protein interactions of HDGF-A are assigned to the N-
terminal hath region, the alteration in this part of the protein by alternative splicing might 
have huge impact on the function. To characterise these novel HDGF isoforms and to 
get an impression about their functional role, different assays were performed with 
respect to known features of HDGF-A. Moreover, a central point was the identification of 
interaction partners of the novel isoforms, since this might reveal insight into their 
biological role. 
A second important aspect of this thesis was the secretion of HDGF-A. Although 
numerous studies demonstrated that HDGF can be detected in the surrounding of cells 
and moreover exogenous HDGF-A realizes extracellular tasks, it is still obscure how 
HDGF leaves the cell.  
With regard to the finding that exosomes are a vehicle of HDGF, the identification of 
HDGF-A as well as of its alternative isoforms HDGF-B and HDGF-C in exosome 
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enriched fractions was one aspect. Proteins can be localised within extracellular vesicles 
or present on the surface and this localisation is essential with regard to potential 
downstream cell communication processes. Therefore, the localisation in such 
extracellular vesicles was a further aspect. Since posttranslational dephosphorylation at 
serine residue 165 in HDGF-A appears to influence secretion of HDGF-A, this mutant 
variant of HDGF-A was included in the present study. 
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2. Material and Methods 
2.1 Methods 
2.1.1 Nucleic acids preparation 
2.1.1.1 RNA isolation from cultured cells using Trifast reagent 
Total RNA was isolated according to the manufacturer’s guidelines from following 
cultured cells: HepG2, HeLa, MCF-7, MDA-MB-231 or primary human dermal fibroblasts. 
Cells were grown on 3.5 cm tissue culture plates. Confluent grown cells were lysed in 
1 mL of Trifast reagent and lysates were transferred into 1.5 mL tubes. To achieve 
dissociation of nucleoprotein complexes, lysates were incubated for 5 min at RT. Next, 
200 µL of chloroform were added to the cell lysates followed by incubation for 10 min at 
room temperature (RT). The samples were centrifuged at 12 000 x g for 5 min to 
separate the mixture into the lower red phenol-chloroform phase, the interphase and the 
colourless upper aqueous phase. The aqueous phase, containing RNA, was transferred 
into a new 1.5 mL tube. RNA was precipitated by adding 0.5 mL of isopropanol and 
samples were kept for 10 min on ice followed by centrifugation at 12 000 x g for 10 min 
at 4 °C. The obtained pellet was subsequently washed with 75 % (v/v) ethanol 
(ethanol/H2O) and once more centrifuged at 12 000 x g for 10 min at 4 °C. Finally the 
pellet was resuspended in 50 µL of RNAse free water. 
Quality and concentration was determined by measuring the absorbance using the 
Nanodrop. 
2.1.1.2 Synthesis of cDNA by reverse transcription 
Thermo Scientific RevertAid First Strand cDNA Synthesis Kit was used to transcribe 
RNA into complementary DNA (cDNA) following the manufacturer’s guidelines. 
Therefore, 2 µg of total RNA was mixed with 1 µL of oligo (dT)18 primer (100 µM), 4 µL of 
the provided Reaction buffer (5x), 1 µL of RiboLock RNase Inhbitor (20 U/µL), 2 µL of 
dNTP mix (10 mM) and 1 µL of RevertAid M-MuLV RT (200 U/µL). Nuclease-free water 
was added to a final volume of 20 µL, samples were briefly mixed and centrifuged, 
followed by an incubation at 42 °C for 45 min. Finally the reaction was terminated by 
heating at 70°C for 5 min and samples were stored at -20 °C. 
2.1.1.3 Polymerase chain reaction  
Polymerase chain reaction (PCR) is one of the most important technologies in molecular 
biology with widespread applications. In general the technology is based on the 
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amplification of DNA fragments by a thermostable DNA polymerase. Pfu DNA 
polymerases possess 3' to 5' exonuclease proofreading activity, which leads to low error 
rates. Therefore, this enzyme was used for reactions which required high fidelity. PCR 
reaction mixture (total volume of 50 µL) was set up on ice with following components. 
 
1 ng DNA 
1 µL sense primer (100 pmol) 
1 µL antisense primer (100 pmol) 
1 µL dNTP’s (10mM)  
5 µL 10X Pfu Buffer with MgSO4 
0.5 µL Pfu-Polymerase (2.5 U/µL) 
H2O up to 50 µL 
 
PCR samples were briefly mixed and spinned down. Then PCR reaction was performed 
in a thermocycler using the following cycling conditions (table 1). 
Table 1: Cycling conditions for PCR. 
PCR programme Temperature (°C) Time Number of cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 30 sec  
Annealing 62 30 sec 30 
Elongation 72 2 min  
Final extension 72 5 min 1 
Hold 4 ∞  
 
2.1.1.4 Agarose gelelectrophoresis 
Agarose gelelectrophoresis is used for separation of DNA fragments according to their 
length. To visualise DNA in the gel, fluorescent dyes such as ethidium bromide or less 
toxic DNA stain G are added to the gel. These dyes bind to DNA, which allows the 
visualisation of DNA fragments. 
To prepare agarose gels, respective amount of agarose was weighed into a specific 
volume of 1x TAE (tris-acetate-EDTA) buffer to obtain the gel concentration of choice. 
The solution was heated in a microwave until agarose was dissolved completely. After 
cooling down to about 60 °C, DNA stain G was added to the agarose solution in a 
working dilution of 1:20 000, the solution was poured into gel cassettes, and combs were 
inserted. After polymerization, the comb was removed, and the gel was covered with 1 x 
TAE buffer. Samples, mixed with Mass Ruler DNA loading Dye (6 x) in a 1:6 ratio, and 
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Mass Ruler DNA Ladder Mix were loaded into the wells. Electrophoresis was performed 
at 100 V for approximately 45 min. Finally, gels were illuminated with UV light to detect 
DNA fragments. To document results, a picture of the gel was captured. 
2.1.1.5 Real-time quantitative PCR 
Real-time quantitative PCR (qPCR) allows quantification of mRNA expression. It includes 
the reverse transcription of mRNAs (section 2.1.1.2) followed by quantitative PCR. 
Because of the high sensitivity, this method allows quantification of rare target transcripts 
as well as the detection of small changes in expression [116]. To monitor amplification of 
products during each cycle, the fluorescent dye SYBR Green, which intercalates in 
double stranded DNA [117], was used. Each reaction set up was prepared as triplicate 
and contained 5 µL of Power SYBR Green Mastermix (2 x), 1.25 pmol forward primer, 
1.25 pmol reverse primer and 10 ng cDNA in a total volume of 10 µL. Reaction was 
performed with the StepOnePlus™ Real-Time PCR cycler.  
In this work relative expression was determined by the comparative 2-ΔΔCT method [118]. 
As reference gene microglobulin was used. Efficiency of each primer pair was 
determined from standard curves. Therefore, five serial 10 fold dilutions of cDNA were 
prepared. The obtained CT values were plotted against the cDNA input and efficiencies 
were calculated from the slope of the obtained standard curves. The PCR programme 
(table 2) was optimised for each primer pair in such a way that resulting calculated PCR 
efficiencies were between 95 – 100 %. 
Table 2: Real-time quantitative PCR programme. 
PCR programme Temperature (°C) Time Number of cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 15 sec  
Annealing *Primer dependent 30 sec 40 
Elongation 72 30 sec  
Melting curve Default settings   
 
* Annealing temperature: 
HDGF A/ HDGF B: 60 °C 
HDGF C: 60.5 °C 
Microglobulin: 62 °C 
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2.1.2 Methods for preparing recombinant plasmids 
2.1.2.1 Restriction enzyme digestion 
Restriction enzymes are able to cleave DNA at specific recognition sites. Wide variety of 
enzymes with different target sequences is commercially available, allowing diverse 
cloning strategies. Depending on the used restriction enzyme, restriction digest can 
result in double stranded DNAs with blunt end or sticky ends, which have either a 3’ or 5’ 
nucleotide overhang. 
Restriction digest was set up in 20 µL containing 2 µL 10 x FastDigest Green Buffer, 1 µg 
of DNA, and 0.5 U of restriction enzyme. In case of double digest, the second restriction 
enzyme was added to the same set up. Mixture was incubated for 60 min at 37 °C.  
2.1.2.2 Gel extraction from agarose gels 
To isolate a specific fragment from agarose gels following agarose gel electrophoresis 
(section 2.1.1.4), the GeneJet Gel Extraction Kit was used according to the 
manufacturers’ guidelines. The stained gel was illuminated with blue light in order to 
visualise the DNA. Desired band was excised with a scalpel and transferred to a pre-
weighed 1.5 mL tube. The weight of the gel slice was determined and Binding Buffer was 
added in a ratio of 1:1 (weight: volume). After incubating the mixture for 10 min at 50 – 
60 °C, the solubilised gel solution was transferred to a GeneJet purification column 
followed by centrifugation with a table-top microcentrifuge at full speed for 1 min at RT. 
The flow through was discarded and 700 µL of wash buffer was added to the column. 
After centrifugation at same conditions, the flow through was discarded and 
centrifugation was repeated to remove residual wash buffer. Finally the column was 
placed into a new 1.5 mL tube, 50 µL of Elution Buffer was added to the column and the 
sample was centrifuged under same conditions. Concentration of purified DNA was 
determined using Nanodrop instrument and the sample was stored at -20 °C. 
2.1.2.3 Ligation 
DNA ligases catalyze the formation of phosphodiester bonds between two DNA 
molecules. Therefore, these enzymes can be used to link insert DNA, containing the 
sequence of interest, into the respective vector DNA. 
Ligation reaction set up was prepared in 20 µL total volume containing 2 µL of 10 x 
ligase buffer, 2 µL of T4 Ligase enzyme and 25 ng vector DNA. Insert DNA were added 
in a molar ratio of approximately 1:3 (insert : vector). After mixing components briefly, the 
set up was incubated for 2 h at RT. Reaction was heat inactivated at 65 °C for 10 min. 
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2.1.2.4 Transformation of competent bacterial cells 
Introducing foreign DNA into bacterial cells is termed transformation. This widely used 
technique allows the amplification of recombinant plasmid DNA. To facilitate this, 
plasmids usually carry a bacterial origin of replication. In addition, plasmids contain an 
antibiotic resistance gene to allow selection of positive clones. 
200 μL of half thawed chemically competent E. coli cells were gently mixed with 5 – 10 
ng of plasmid DNA. After incubating the mixture for 10 min on ice, the tube was 
transferred to a 37 °C heat block for 90 sec (heat shock). The transfection mixture was 
incubated for 2 min on ice before 1 mL of pre-warmed SOC medium was added. The 
mixture was incubated in the 37 °C shaker for 45 min. Finally the culture was spread on 
a pre-warmed LB-agar plate. Depending on the antibiotic resistance encoded by the 
respective plasmids, LB-agar plates containing the respective antibiotic (50 µg/mL 
ampicillin or 50 µg/mL kanamycin) were selected. 
2.1.2.5 Mini-preparations of plasmid DNA 
The mini-preparation of plasmid DNA allows the isolation of plasmids from bacteria in 
small scales and is used to screen for positive clones. 
GeneJET Plasmid Miniprep Kit was used according to the manufacturers’ guidelines. 
5 mL of LB-medium containing the appropriate selection antibiotic was inoculated with 
the respective clone and incubated over night at 37 °C under shaking conditions. In 
parallel, the same clone was transferred to a new LB-agar plate with numbered spots. 
Next day, the overnight culture was centrifuged at 6 000 x g for 5 min at RT to harvest 
bacterial cells. The pellet was resuspended in 250 µL of Resuspension solution and 
transferred to a 1.5 mL tube. To achieve lysis of bacterial cells, the resuspension was 
mixed with 250 µL of Lysis solution. After 5 min incubation at RT, 350 µL of 
Neutralization solution was added, and cell debris removed by centrifugation in a table-
top microcentrifuge at 12 000 x g for 5 min at RT. The obtained supernatant was 
transferred to a GeneJET spin column and centrifuged at full speed for 1 min. Flow 
through was discarded and 500 µL of Wash Solution was added to the column followed 
by a second centrifugation (1 min, 20 000 x g, RT). The column was centrifuged for a 
second time to remove residual Wash solutions. Finally the column was placed into 
1.5 mL tube, 50 µL of Elution buffer was added to centre of the column and after 
incubation of 2 min, the column was centrifuged (1 min, 20 000 x g, RT). Purified plasmid 
DNA was stored at -20 °C. 
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2.1.2.6 Plasmid purification 
Plasmids were purified from bacterial cultures by using NucleoBond Xtra Midi kit 
(Machery-Nagel) according to the manufacturers’ guidelines. A clone containing the 
plasmid with the correct insert was transferred to 200 mL of sterile LB-medium. 
Depending on the antibiotic resistance encoded by the plasmid, the respective antibiotic 
was added to the liquid culture to a final concentration of 50 µg/mL. This culture was 
incubated at 37°C over night under shaking conditions (250 rpm). 
The next day, the overnight culture was centrifuged at 6000 rpm for 10 min at 4 °C to 
harvest bacterial cells. While the supernatant was completely removed and discarded, 
the obtained cell pellet was resuspended in 8 mL of the provided buffer RES (+RNase 
A). The cell suspension was transferred into a new 50 mL tube. For cell lysis 8 mL of the 
provided buffer LYS was added and the solution was mixed by inverting the tube several 
times. After incubation for 5 min at RT, bacterial cell lysate was neutralised by adding 
6 mL of Buffer NEU. The resulting precipitate was mixed several times by inverting the 
tube. Meanwhile, the column and filter were pre-equilibrated with 12 mL of the provided 
buffer EQU and the precipitate was loaded to the column. After the cell lysate flowed 
completely through the column, the column was washed with 5 mL of the buffer EQU. 
Before the column was washed with 5 mL of buffer WASH, the filter unit was discarded. 
The collected flow through was also discarded and the column with the bound DNA was 
transferred to a new 50 mL tube. Finally the bound DNA was eluted by adding 5 mL of 
buffer ELU to the column. To concentrate the plasmid containing eluate, the eluate was 
mixed with 3.5 mL isopropanol, vortexed, and incubated for 2 min at RT. In the meantime 
the plunger of a 30 mL syringe was removed and a NucleoBond finalizer was attached to 
the outlet of the syringe. After filling the syringe with the precipitation mixture, the mixture 
was slowly pressed through the NucleoBond finalizer. The resulting flow through was 
discarded and the NucleoBond finalizer was washed with 2 mL 70 % (v/v) ethanol 
(ethanol/H2O). Prior to DNA elution, the NucleoBond finalizer was completely dried. 
Therefore, Nucleobond finalizer was detached from the syringe, the plunger was inserted 
and after reattaching the Nucleobond finalizer to the syringe, air was pressed through the 
finalizer several times. Finally the NucleoBond finalizer was attached to 1 mL syringe. 
The syringe was filled with 800 µL of redissolving buffer TRIS and solution was slowly 
pressed through the NucleoBond finalizer. 
To determine the concentration and quality of the obtained plasmid solution, the Nandrop 
instrument was used. 
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2.1.2.7 Sequencing of DNA segments 
To verify constructs, sequencing reactions were performed. Reaction mixture was set up 
with 20 – 50 ng of the plasmid DNA containing the sequence of interest, 2 µL of Big Dye 
Terminator and 50 pmol primer in a total volume of 11 µL. Reaction was performed in 
PCR cycler over night as shown in table 3. 
Table 3: Sequencing reaction 
PCR Programme Temperature (°C) Time Number of cycles 
Initial denaturation 95 2 min 1 
Denaturation 95 15 sec  
Annealing 56 15 sec 60 
Elongation 60 4 min  
Hold 4 ∞  
 
The next day, 9 µL of distilled H2O was added to the reaction mixture and sequencing 
reaction was purified via gel filtration using 96 well spin plates (supplied by the Max 
Planck Institute for Marine Microbiology). Purified samples were analyzed in Max Planck 
Institute for Marine Microbiology (Bremen). 
2.1.3 Cell culture 
All work with mammalian cells was performed under sterile conditions. Only sterile 
filtered media and solutions were used and the work was performed under a sterile 
bench. Buffers, solution, and media were pre-warmed to 37 °C before usage. All cells 
were cultured at 37 °C in a humidified atmosphere of 5 % (v/v) CO2. 
2.1.3.1 Culture of immortalised cells 
For this work several immortalised cells were used. Cos7, HepG2, HeLa , MCF-7, MDA-
MB-231 and HaCat cells grow as adherent monolayer in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % heat-inactivated fetal calf serum (FCS) and 
50 µg/mL gentamicin. For passaging cells, the old medium was aspirated and cells were 
washed with phosphate buffered saline (PBS). To dissociate cells, trypsin was added to 
the flask (approximately 1 mL per 10 cm2) and cells were incubated for 3-10 min at 37 °C 
(exact incubation time varied with used cell line). Detached cells were resuspended in 
new medium and centrifuged for 5 min at 400 x g.  Cell pellets were resuspended in 
fresh media and distributed onto new plates.  
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2.1.3.2 Human dermal fibroblast primary culture 
The experiments were undertaken with the understanding and written consent of each 
subject. The study methodologies conformed to the standards set by the Declaration of 
Helsinki. The Ethics Committee of the Medical Chamber of Bremen (No. 336/12) 
approved the study. 
Skin was derived from reduction surgery of healthy Caucasian patients. After removal the 
fat-free skin was stored at 4°C in 0.9 % NaCl (saline) until cell isolation. Isolation was 
performed within 4 h after surgical intervention. First, skin was immersed several times in 
PBS containing penicillin-streptomycin (50 µg/mL) and cut into smaller pieces. To 
facilitate separation of dermis and epidermis, skin pieces were incubated in Dispase II 
solution at 4 °C overnight. Next day dermis was mechanically separated from epidermis 
by forceps. To achieve single cell population, dermis was minced into smaller pieces with 
scissors, transferred into collagenase type 2 solution and incubated for 2 h in a 37 °C 
water bath under shaking conditions. The mixture was filtered through cell strainer (pore 
size 70 μm), and the filtrate was centrifuged at 400 x g for 5 min at RT. The obtained cell 
pellet was resuspended in culture medium DMEM/Ham´s F12, supplemented with FCS 
(10 % v/v), L-glutamine (5 mM), penicillin/streptomycin (100 µg/mL) and cells were 
seeded into culture dishes. Fibroblasts were cultured at 37 °C in a humidified 
atmosphere of 5 % (v/v) CO2. For passaging cells, same protocol as for immortalised 
cells (section 2.1.3.1) was performed. 
2.1.3.3 Cryopreservation of cells 
Cells (immortalised cells lines and primary human fibroblasts) which reached confluence 
were harvested from 10 x 10 cm plates (as described in section 2.1.3.1). The obtained 
cell pellet was resuspended in freezing medium containing DMEM supplemented with 
20 % FCS, 10 % DMSO (1 mL per 10 cm2 plate) and collected in freezing vials. Before 
freezing cells for long time storage in liquid nitrogen, cells were stored for 30 min at 4 °C 
and then for several days at - 80 °C. 
2.1.3.4 Transient transfection of HepG2 and Cos7 cells  
Polyethylenimine (PEI) is a stable cationic polymer that can deliver DNA into cells. PEI 
complexes DNA into positively charged particles that bind to anionic cell surfaces. Such 
complexes can enter the cell by endocytosis [119]. 
For transfection cells have ideally reached a density of around 80 % confluence. Prior to 
transfection, the medium was changed to DMEM supplemented with 2 % FCS (v/v). To 
transfect cells on 10 x 10 cm plates, 15 µg of plasmid DNA, containing the gene of 
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interest, were mixed with 1 mL of NaCl solution (150 mM). For transfection of cells grown 
on 24 well plates, 1.5 µg of plasmid DNA were added to 100 µL NaCl solution. Cells on 
96 well plates were supplemented with 150 ng of plasmid DNA in 10 µL of NaCl solution. 
PEI stock solution in a dilution of 1/750 (v/v) in 150 mM NaCl were prepared prior to 
transfection. 25 µL (10 cm plate), 2.5 µL (24 well plate) or 0.25 µL (96 well plate) of PEI 
stock solution were added to the transfection mixture. After vortexing for 10 sec, the 
mixture was incubated for 10 min at RT. As next, transfection mixture was added to the 
cells and cells were incubated for approximately 4 h at 37 °C with 5 % (v/v) CO2 in the 
incubator before the medium was changed to serum-free DMEM.  
In case of co-transfection with two plasmids encoding two different constructs, half of the 
indicated amount per plasmid was used, so that the sum of both corresponded to that of 
a single transfection. 
2.1.4 Immunofluorescence analysis 
Immunofluorescence is a microscope based technique that allows visualisation of 
intracellular proteins and structures. It utilizes fluorescent-labelled antibodies to detect 
specific target proteins. 
Cells, grown on coverslips in a 24 well plate, were washed two times with PBS. In order 
to fix cells, cells were incubated in 4 % PFA solution (300 µL/ well). After removing the 
PFA solution from the cells, cells were incubated in ice-cold methanol (100 %) 
(250 µL/ well) for 2 min at RT. Fixed and permeabilised cells were washed two times with 
PBS containing 2 % BSA (w/v). To block the non-specific binding of antibody to the 
specimen, DMEM containing 10 % FCS (v/v) was used. Blocking lasted 30 min (at RT). 
Then primary antibody was added to the cells and cells were incubated for 1.5 h at RT. 
The used antibody concentration varied from type to type (concentrations are given in 
section 2.2.10). After this incubation cells were again washed with PBS (2 % BSA) 
before secondary antibody was added and cells were incubated for 1.5 h at RT in the 
dark. The secondary antibody (donkey anti-rabbit antibody Cy3 and donkey anti-mouse 
antibody Cy5 conjugate) was diluted 1/500 (v/v) in PBS / 2 % BSA (w/v). Finally cells 
were washed twice with PBS. To preserve specimens, the cells were embedded in 
Fluoro-Gel II. Images were captured with an Apotome fluorescence imager. 
2.1.5 Functional assays 
2.1.5.1 BrdU proliferation assay 
For proliferation studies Cos-7 cells were plated at a density of 2500 cells per well in a 96 
well plate. Cells were transiently transfected with plasmids coding for untagged HDGF-A, 
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HDGF-B, HDGF-C or with the respective empty vector as described in section 2.1.3.4. 
For one experiment 10 replicates per condition were examined. 4 h after transfection 
medium was changed to serum free media followed by further incubation for 20 h at 
37 °C with 5 % CO2. To measure proliferation rates, the Cell Proliferation ELISA kit 
(Roche) was used according to the manufacturers’ instructions. Bromodeoxyuridine 
(BrdU) was added to the media followed by 6 h incubation at 37 °C with 5 % CO2. After 
this labelling period, the labelling medium was removed and cells were fixed by adding 
100 µL of FixDenat reagent to the cells for 30 min at RT. Then FixDenat solution was 
removed completely and cells were covered with anti-BrdU-POD-working solution for 
1.5 h at RT. Finally cells were washed 5 times with PS to remove residual antibody. To 
measure the intensity of cell proliferation, 100 µL of substrate solution was added to 
each well with a multichannel pipette. After 10 min of incubation at RT the reaction was 
stopped by adding 25 µL 2 M H2SO4. The absorbance at 450 nm was recorded. 
2.1.5.2 Chromatin-binding assay 
In order to determine association to chromatin of the target protein, the chromatin-
binding assay was performed as described by Thakar et al. [49] with some minor 
modifications. Therefore, HepG2 on 10 x 10 cm plates were transiently transfected as 
described in section 2.1.3.4. 24 h after transfection, cells were lysed for 10 min on ice in 
1 mL of ice cold CSKI buffer. Then cells were scraped using a cell scraper and 
corresponding lysates were transferred to a 1.5 mL tube. An aliquot of 100 µL was 
removed from this fraction and mixed with the same volume of RIPA buffer. This fraction 
represented the total volume (T). The remaining cell lysate was divided into two equal 
portions which were centrifuged at 450 x g at 4°C for 3 min. The supernatants were 
collected and pooled. To obtain the S1 fraction, the pooled supernatants were 
centrifuged a further time for 10 min at 12 000 x g. The remaining pellets, obtained after 
450 x g centrifugation step, contained chromatin-bound, nuclear matrix bound, and 
insoluble proteins. To remove possible contaminations, pellets were washed with CSKI 
buffer, followed by a second centrifugation at 450 x g at 4 °C for 3 min. CSK I buffer was 
completely removed and one of the pellets was resuspended in RIPA buffer to get the P1 
fraction. The second pellet was resuspended in 200 µL of CSK II buffer und the 
resuspension was treated with 6 U/µL DNase for 30 min at RT. NH4SO4 was added to a 
final concentration of 250 mM followed by incubation for 10 min at RT. The sample was 
then centrifuged at 1 200 x g for 6 min at 4°C and the supernatant containing DNase-
released chromatin-associated proteins (S2) was transferred to a new 1.5 mL tube. The 
pellet, which consisted of insoluble, cytoskeletal, and nuclear matrix proteins, was 
washed with CSKII buffer and centrifugation was repeated at 1 200 x g for 6 min at 4 °C. 
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The supernatant was completely discarded and the obtained P2 pellet was resuspended 
in 100 µL RIPA buffer. Finally protein concentration of each fraction was determined by 
BCA assay (section 2.1.9.3) and 20 µg of each fraction were mixed with 2 x sample 
buffer supplemented with DTT, boiled for 5 min at 95 °C and subjected to SDS PAGE 
followed by Western blot analysis. 
2.1.5.3 Bimolecular fluorescence complementation (BiFC) assay 
Cos7 cells were grown on cover slips in 24 well plates. Transient transfection was carried 
out as described under section 2.1.3.4. The used plasmids encoded the HDGF isoforms 
(-A, -B, -C) fused to the N-terminal part (aa 1-172) or the C-terminal part (aa 173-238) of 
enhanced yellow fluorescent protein (EYFP). 24 h after transfection, cells were 
transferred from 37 °C incubation conditions to 30 °C for 30 min to promote fluorophore 
maturation. Controls were incubated for 90 min under the same conditions. Prior to 
fixation with 4 % PFA solution for 10 min at RT, cells were washed twice with PBS. Fixed 
cells on cover slips were embedded in Fluoro-Gel II containing DAPI (4',6-diamidino-2-
phenylindoledihydrochloride) to stain the nuclei. Stained cells were imaged with a 
fluorescent microscope (Olympus). 
2.1.6 Inhibitor studies 
In the case of inhibitor studies, transfected HepG2 cells were exposed to the inhibitor 5-
(N, N-dimethyl) amiloride (DMA) or Monensin (Mon). Transient transfection was 
performed as described under section 2.1.3.4. 3 h after transfection, the transfection 
mixture were aspirated and medium containing the following inhibitors were added: DMA 
in a final concentration of 15 nM (stock solution 15 µM in DMSO); Monensin 100 µM 
(stock solution 100 mM in EtOH). Cells were incubated for further 24 h or 40 h in the 
incubator (37 °C, 5 % CO2) before supernatant and cell lysate were collected for 
subsequent analysis. Collected supernatants were concentrated by acetone precipitation 
(section 2.1.9.2). 
2.1.7 LDH assay 
Lactate dehydrogenase (LDH) assay is a method to quantify the cell viability. LDH is a 
ubiquitously expressed cytoplasmic protein that catalyzes the redox reaction of pyruvate 
to lactate in the presence of NADH. After the loss of membrane integrity due to cell 
death, LDH is passively released like other cytoplasmic proteins in the surrounding 
medium. Therefore, the measurement of extracellular LDH activity can be used as 
indicator for cell death [120]. 
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The activity of LDH can be determined by measuring the decrease of NADH 
photometrically at 340 nm. The respective protocol was adapted from Dringen et al. [121] 
with some modifications. 
10 µL of the incubation medium was mixed with 170 µL LDH buffer on a 96-well 
microtitre plate. Directly after addition of 180 µL fresh prepared LDH reaction buffer the 
decrease of absorbance at 340 nm was measured with a microtitre plate reader (Sunrise, 
Tecan, Austria) for 10 min in 30 sec intervals. To obtain a percental value, the measured 
activity was compared with 100 % LDH activity after total lysis. For total lysis Triton X-
100 was added to the incubation medium to a final concentration of 1 % (w/v) and cells 
were incubated for 30 min at RT, before an aliquot was taken for the photometrical 
measurement. This 100 % LDH activity corresponds to 0 % cell viability. Measurement 
was performed in triplicates; values are given in % of total LDH ± standard deviation. 
2.1.8 Exosomes  
2.1.8.1 Isolation and sample preparation 
To isolate exosomes from cell culture supernatants, the standard ultracentrifugation 
protocol for the isolation and enrichment of exosomal vesicles from Théry et al. [99] was 
used. The protocol consisted of several different centrifugation steps as depicted in 
figure 5.  
 
Figure 5: Centrifugation protocol for exosome isolation. Exosomes were isolated by a series 
of centrifugation steps. During each step an aliquot of the supernatant (SN1-5) was collected. The 
final pellet (exosome-enriched fraction, Ex) was resuspended in PBS. 
Depending on the initial issue, exosomes were isolated from transiently transfected 
HepG2 cells or several non-transfected cell lines. Since FCS contains exosomes [99], 
cells were incubated in medium without FCS in order to avoid any contaminations by 
FCS derived exosomes. For one exosome preparation cells were seeded on 10 cm2 cell 
plates and after cells reached approximately 80 % confluency, medium was changed to 
serum free medium. In the case of transfected cells, medium was changed 4 h after the 
transient transfection of cells (section 2.1.3.4). Cells were incubated 35-40 h at 37 °C 
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and 5 % CO2. For each exosome isolation the medium from seven 10 c cm
2 plates were 
collected (approximately 70 mL of conditioned medium). The collected supernatant was 
directly subjected to centrifugation at 300 x g for 10 min at 4 °C to remove dead cells and 
large cell debris. The obtained supernatant was transferred to a new tube and the next 
centrifugation was performed at 2 000 x g, for 20 min at 4 °C. Again the obtained pellet 
was discarded. For the following centrifugation steps the ultracentrifuge (Ultracentrifuge 
Le-80K, Ti45 rotor) was used. The supernatant was centrifuged at 15 000 x g at 4 °C for 
30 min and the resulting supernatant was transferred to new tubes. In order to separate 
exosomes from the supernatant, the supernatant was centrifuged at 120 000 x g at 4 °C 
for at least 2 h. The pellet was resuspended in 1 mL of PBS and pellet suspensions of 
the same cell type were pooled. To eliminate contaminating proteins, the tube was 
completely filled with PBS and centrifuged again (120 000 x g, 4 °C, at least 2 h). The 
final pellet was resuspended in 100 µL of PBS. For SDS PAGE 100 µL of 2x SDS 
Sample buffer + DTT were added and the mix was boiled for 5 min at 95 °C. During each 
step an aliquot of 250 µL was taken from the supernatants as illustrated in figure 5. In 
order to concentrate collected supernatants they were acetone precipitated as described 
in section 2.1.9.2. 
In order to deplete supernatants from vesicles, an aliquot of 1 mL was collected from 
SN5 and were ultracentrifuged at 112 000 x g for 24 h (Ultracentrifuge Optima MaxE, 
TLA 55 rotor). The obtained vesicle-depleted supernatant (termed SN5*) was also 
acetone precipitated (section 2.1.9.2).  
2.1.8.2 Dynamic light scattering measurement of exosomes 
To characterise the isolated exosome fraction, the hydrodynamic diameter of the vesicles 
was determined by dynamic light scattering in a Beckman Coulter (Krefeld, Germany) 
DelsaTM Nano C particle analyser at scattering angles of 165 and 15° at 25 °C. Fresh 
prepared exosomes were diluted in filtrated PBS. The sample temperature was allowed 
to equilibrate for 30 min before each measurement. The light scattering was recorded for 
900 s with six replicate measurements. 
2.1.8.3 Pull down assay of exosome fraction 
The pull down assay was applied immediately after the exosome isolation. An aliquot of 
the exosome enriched fraction was disrupted by 1 % Triton X-100 (v/v) for 30 min at 
4 °C. Equal volumes of disrupted and intact exosomes (20 μL) were then subjected to 
trypsin digestion at 37 °C for 30 min. Trypsin (stock solution 150 µg/ml) was used in a 
final concentration of 15 µg/mL. After the trypsin digestion, the samples were mixed with 
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an equal volume of 2 x sample buffer. After boiling samples at 95 °C for 5 min samples 
were stored at -20 °C until they were subjected to Western blot analysis. 
2.1.9 Sample preparation and analysis 
2.1.9.1 Preparation of total cell lysates 
Confluent grown cells on 10 x 10 cm culture dishes cold were washed twice with PBS 
twice. To lyse cells, 1 mL of cold TNE lysis buffer containing freshly added protease 
inhibitor (Complete Mini, EDTA free) was added to each plate. After incubation for 10 min 
on ice, the cells were scraped from the plate and the cell homogenate was transferred to 
a new reaction tube. A second incubation on ice followed for 10 min. Finally the 
homogenate was centrifuged at 20 000 x g for 20 min at 4 °C and the subsequent 
supernatant was transferred into a new tube while the pellet was discarded. For SDS 
PAGE an aliquot was taken, mixed with an equal volume of 2 x sample buffer, and boiled 
for 5 min at 95 °C. The samples were stored at -20 °C until they were subjected to SDS 
PAGE gels.  
2.1.9.2 Acetone precipitation 
In order to concentrate proteins from solutions, they were acetone precipitated. The 
collected samples were mixed with acetone in a ratio of 1:4 (sample: acetone) and stored 
at -20 °C for at least 12 h. Then, the samples were centrifuged at 20 000 x g at 4 °C for 
20 min. The supernatant was discarded while the obtained pellet was resuspended in 
40 µL of 2 x sample buffer. After boiling the samples at 95 °C for 5 min the samples were 
either stored at -20 °C or directly subjected to SDS PAGE analysis (section 2.1.9.6). 
2.1.9.3 BCA assay 
In order to determine the protein concentration, the Pierce BCA Protein Assay Kit was 
used according to the manufacturer’s guidelines. The principle of the bicinchoninic acid 
assay (BCA) relies on a colour reaction which is proportional to the amount of protein 
present [122]. 
At the beginning a set of protein standards containing albumin in known concentration 
were prepared as serial dilution. Then 12.5 µL of each standard or unknown sample 
replicate was pipetted into a microplate well (working range = 20-2000 µg/mL). To 
prepare the working reagent, 50 parts of solution A was mixed with 1 part of solution B. 
To each well 100 µL of the working reagent was added, the plate was covered with a 
sheet of parafilm and, after mixing the plate on a shaker, the plate was incubated for 
30 min at 37 °C. Finally absorbance was recorded with a plate reader at 560 nm. 
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2.1.9.4 Immunoprecipitation 
This technique allows the precipitation of proteins out of a solution by using a protein 
specific antibody. The resulting antibody/antigen complex can be isolated by the use of 
protein A sepharose beads. While precipitating the target protein, possible interaction 
partners can be co-precipitated. 
Samples of interest, in this case, total cell lysates were prepared from 10 x 10 cm culture 
dishes of confluent grown HepG2 cells as described under section 2.1.9.1. Protein A 
sepharose beads were pre-equilibrated by washing beads 3 times with TNE lysis buffer. 
During each washing step, samples were centrifuged at 1 200 x g at RT for 15 sec in 
order to sediment the protein A beads. To prevent unspecific contaminations, the cleared 
lysates were pre-cleared. Therefore, 1 mL of cell lysate was mixed with 100 µL of pre-
equilibrated protein A sepharose beads and incubated for 2 h under rotary agitations at 
4 °C. Beads were centrifuged at 1 200 x g for 15 sec at RT and the pre-cleared 
supernatant was collected for the precipitation. The pre-cleared control fraction for 
Western blot analysis was prepared as follows: The beads were washed five times with 
1 mL of TNE lysis buffer. Finally supernatant was completely removed and 100 µL of 2 x 
sample buffer was added. Beads were boiled for 10 min at 95 °C. Finally the sample was 
centrifuged (1 200 x g, 30 sec, RT) and the supernatant was collected and stored at 
-20 °C. 
To the pre-cleared cell lysates 50 µg of isoform specific antibodies anti-HDGF-A, anti-
HDGF-B, anti-HDGF-C or 20 µg of goat anti pan-HDGF was added. After an incubation 
of 2 h on ice 100 µL of pre-equilibrated protein A beads were added. The lysate/-beads 
mixture was incubated over night at 4 °C under rotary agitation. The next day, the protein 
A sepharose beads were treated as described for the pre-cleared control fraction. 
2.1.9.5 StrepTactin co-precipitation 
In general a similar protocol as described for immunoprecipitation was used (section 
2.1.9.4). HepG2 cells on 10 x 10 cm culture dishes, transiently transfected with plasmids 
encoding Strep-tagged proteins were lysed and cleared lysates were mixed with 50 µL of 
pre-equilibrated StrepTactin beads. The lysate/-beads mixture was incubated over night 
at 4 °C under rotary agitation. The washing and elution procedure resembled that 
protocol for immunoprecipitation. 
In case of RNAse digest experiments, the protocol from Bremer et al. was used [123]. 
Protein lysates from HDGF-A/B/C-Strep expressing HepG2 cells were pre-incubated with 
or without RNAse A (25 µg/ mL) at 4 °C over night followed by StrepTactin precipitation 
as described before. 
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2.1.9.6 SDS PAGE 
SDS PAGE (sodium dodecylsulfate polyacrylamide gel electrophoresis) was performed 
according to Laemmli with slight modifications [124]. This technique separates proteins 
mainly according to their molecular weights. The anionic detergent sodium dodecyl 
sulfate (SDS) binds to the polypeptide chain, causes the denaturation of proteins and 
imparts an even distributed charge to the protein. The addition of dithiothreitol (DTT), a 
strong reducing agent, causes the disruption of disulfide bonds  
First, the gels were prepared. Glass plates were cleaned with 70 % (v/v) (ethanol/H2O) 
followed by assembling the gel cassettes according to the manufacturers’ guidelines. To 
prepare 12 % gels the ingredients, listed in table 4, were mixed. Obtained solution was 
transferred to the gel cassette and the gel was overlaid with water-saturated butanol. 
After the polymerisation of the separation gel, the butanol layer was removed and gels 
were rinsed with water to remove residual butanol. Finally the stacking gel was prepared 
on top of the separation gel according to the ingredient list in table 1 and appropriate 
comb was inserted. After polymerisation the comb was removed, the electrophoresis unit 
was assembled, and the electrophoresis chamber was filled with SDS PAGE running 
buffer. 
Samples were mixed with 2 x sample buffer and were directly boiled for 5 min at 95 °C 
before loading. When samples were analyzed under non-reducing conditions, 2 x sample 
buffer without DTT was used. This was the case for samples that were immunodetected 
with anti-CD63 antibody. 
20 µL of the prepared samples as well as 5 µL of pre-stained protein marker (Thermo 
Scientific GmbH) were loaded on the gels. An electric current of 15 mA was applied on 
the gel until the running front reached the end of the gel. 
Table 4: Used ingredients for SDS PAGE gel. 
Ingredients 4 % Stacking gel 12 % Separation gel 
Acrylamide, 30 % 333 µL 1.98 mL 
H2O 1.52 mL 1.77 mL 
4x Stacking/Separation gel buffer 625 µL 1.25 mL 
TEMED 2.5 µL 2.5 µL 
10 % APS 12.5 µL 25 µL 
 
If no subsequent Western blot analysis was performed, the gel was stained with PAGE 
Blue Protein staining solution. PAGE Blue contains the dye Coomassie Brilliant Blue, 
which binds non-specifically to proteins primarily through basic amino acids. In order to 
stain the polyacrylamidgel, it was briefly washed with deionised water and then incubated 
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in PAGE Blue for 45 min at RT on a shaker. Before scanning the gel, it was de-stained 
with deionised water to obtain a clear background. 
2.1.9.7 Western blotting and immunodetection 
Western Blotting was performed subsequent to SDS PAGE (section 2.1.9.6). For this 
purpose the polyacrylamide gel containing the separated proteins, was released from the 
glass plates and was transferred into blotting buffer for 10 min on a shaker at RT. In the 
meantime the PVDF membrane was pre-wetted in methanol, then directly washed in 
distilled water for 2 min and finally equilibrated in blotting buffer for 10 min. For the 
transfer the gel was placed on one filter pad and two filter papers, each pre-equilibrated 
in blotting buffer. The PVDF membrane was placed on top of the gel, followed by two 
filter papers and one filter pad. The transfer was performed for 1 h at 100 V under 
cooling conditions. 
After the transfer the membranes were briefly washed with Tris-buffered Saline + 0.15 % 
Tween (v/v) (TBST) to remove gel pieces. To prevent unspecific binding, the membrane 
was blocked in blocking buffer containing TBST + 3 % BSA (w/v) for 1 h at RT on a 
shaker. After washing with TBST, the membrane was placed on parafilm. For 
immunodetection 1 mL of primary antibody, diluted in blocking buffer, was added and the 
membrane was covered with a second sheet of parafilm and was incubated over night at 
4 °C. The used concentrations of each primary antibody are listed in section 2.2.10. After 
several washes with TBST at RT on the shaker for at least 45 min, the membrane was 
incubated with the corresponding secondary antibody, diluted in blocking buffer, for 1.5 h 
at RT on a shaker. Prior to detection membranes were washed 6 times with TBST for 1 h 
at RT. 
Membranes were incubated either in Pierce ECL Western Blotting Substrate or Select 
ECL Western Blotting Substrate. Both solutions contained substrate for the horseradish-
peroxidase (POD), an enzyme which is linked to the secondary antibody. The 
subsequent reaction produces chemiluminescence, which can be captured by the use of 
X-ray films. 
In the case of Pierce ECL Western Blotting substrate, 500 µL of solution A and 500 µL of 
solution B were mixed. In the case of Select ECL, which was used for weaker signals, 
900 µL of TBS-T, 50 µL of solution A and 50 µL of solution B were mixed with each 
other. The mixture was placed on a sheet of parafilm and the membrane was placed with 
the protein side into the detection solution for 5 min. Afterwards the membrane was 
sealed into a plastic foil, placed in a cassette and covered with X-ray film for a specific 
time period. The film was developed in the developer machine (Kodak, Stuttgart). 
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2.1.9.8 MALDI TOF-MS  
Samples for MALDI TOF-MS were separated by SDS PAGE electrophoresis and 
Coomassie Blue-stained protein bands were excised from the gel. The gel trypsin 
digestion was performed as described by Shevchenko et al. [125]. Briefly, gel pieces 
were dehydrated in acetonitril followed by drying in a speedvac. Dried gel pieces were 
transferred in 50 mM NH4HCO3 containing 10 mM DTT for 1 h at 56 °C to reduce 
proteins. After cooling to RT, excess solution was removed and gel pieces were covered 
by 55 mM iodoacetamide in 50 mM NH4HCO3 for 45 min at RT in the dark. The gel 
pieces were washed with 100 µL of 50 mM NH4HCO3 for 10 min. Then, gel pieces were 
dehydrated with acetonitril for 10 min at RT, followed by a rehydration step with 50 mM 
NH4HCO3 and a further dehydration step with acetonitril. The excess solution was 
removed and gel pieces were completely dried in the speedvac. After drying the gel 
pieces were covered with digestion buffer containing 25 mM NH4HCO3, 5 mM CaCl2, and 
12.5 ng/µL of trypsin for 45 min at 4 °C. Excess trypsin solution was removed and 5-
10 µL of the digestion buffer without trypsin was added followed by incubation over night 
at 37 °C. Next day gel pieces were washed for 20 min in 20 mM NH4HCO3 followed by 
peptide extraction with three changes of 5 % formic acid in 50 % acetonitril (20 min 
incubation for each change). The obtained gel pieces were finally dried. 
For further analysis the lyophilised peptides were redissolved in 10 µL millipore water 
and sonicated for 10 min. 1 µL of the undiluted peptide solution as well as 1 µL of a 
1:10 (v/v) dilution was spotted on a MTP 384 well ground steel target plate and mixed 
with MALDI matrix, which contained α-cyano-4-hydroxycinnamic acid dissolved in 50 % 
acetonitril and 0.2 % TFA at a concentration of 7 mg/mL.  
MALDI-TOF was performed by Dr. Janina Oetjen. After crystallisation, mass spectra 
were acquired in the positive reflector mode on an autoflex speed MALDI-TOF mass 
spectrometer using flexControl software version 3.4 (Bruker Daltonics). Each spectrum is 
the sum of 500-1000 laser shots using a SmartbeamTM laser (Bruker Daltonics) using the 
medium laser focus, a repetition rate of 1000 Hz and the random walk option set on. The 
spectra were acquired in the mass range of 700-4000 m/z and a deflection of 500 m/z. 
The external calibration was performed using the monoisotopic peaks of Peptide 
Calibration Standard II (Bruker Daltonics) consisting of Bradykinin 1-7 [M+H+, 757.40], 
Angiotensin II [M+H+, 1046.54], Angiotensin I [M+H+, 1296.68], Substance P [M+H+, 
1347.74], Bombesin [M+H+, 1619.82], Renin Substrate [M+H+, 1758.93], ACTH clip 1-17 
[M+H+, 2093.09], ACTH clip 18-39 [M+H+, 2465.20], Somatostatin 28 [M+H+, 3147.47]. 
The Cubic Enhanced calibration mode (Bruker Daltonics) was applied. 
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2.1.9.9 MALDI-TOF MS data processing and protein identification 
The peptide mass fingerprints for protein identification was used and MALDI-TOF mass 
spectra were processed using the flexAnalysis software version 3.4 (Bruker Daltonics). 
The Bruker Snap algorithm was used for peak detection with a signal to noise threshold 
of 6. Maximal 100 peaks in the mass range of 800-4000 were detected. The resulting 
mass list was searched against the online version of the Mascot peptide mass fingerprint 
database (Matrix Science, London, UK) using the following settings. Trypsin was 
selected as enzyme allowing up to 1 missed cleavage. The search was performed 
against the SwissProt database 2015_3 selecting the protonated ion species and 
monoisotopic masses. The database entries were reduced to human sequences from 
HepG2 cells. Propionamid modified cysteine residues and methionine oxidation was 
selected as variable modifications. The peptide mass tolerance was set between 60-
100 ppm. 
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2.2 Material 
2.2.1 Chemicals 
Chemical Company 
α-cyano-4-hydroxycinnamic acid Sigma Aldrich, St. Louis 
1-Butanol Thermo Fisher Scientific, Waltham 
5-(N,N-Dimethyl)-amiloride hydrochloride  Sigma Aldrich, St. Louis 
Acetone Sigma Aldrich, St. Louis 
Acetonitril VWR Chemicals, Radnor 
Acrylamide, 30 % (v/v) Sigma Aldrich, St. Louis 
Agarose Biozym, Oldendorf 
Ammonium bicarbonate Sigma Aldrich, St. Louis 
Ammonium sulfate Sigma Aldrich, St. Louis 
Ammoniumpersulfate (APS) Sigma Aldrich, St. Louis 
Big Dye Terminator Thermo Fisher Scientific, Waltham 
Bovine Serum Allbumin (BSA fraction V) Thermo Fisher Scientific, Waltham 
Bromphenol blue Sigma Aldrich, St. Louis 
Chloroform VWR Chemicals, Radnor 
Collagenase II Sigma Aldrich, St. Louis 
Developer G153 (Solution A & B) AGFA-Gaeverd, Mortsel 
Dispase II Roche, Mannheim 
Dithiothreitol (DTT) Thermo Fisher Scientific Waltham 
Dimethyl sulphoxide (DMSO) Sigma Aldrich, St Louis 
Dipotassium phosphate Sigma Aldrich, St Louis 
DNase I Boehringer Ingelheim, Mannheim 
DNA Stain G Serva GmbH, Heidelberg 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
Thermo Fisher Scientific, Waltham 
EDTA Merck KGaA, Darmstadt 
Ethanol, absolute Riedel-de-Haen, Seelze 
FastDigest restriction enzymes Thermo Fisher Scientific, Waltham 
Fetal calf serum (FCS) Thermo Fisher Scientific, Waltham 
Fixing solution AGFA Gaeverd , Mortsel 
Fluoro-Gel II EMS, Hatfield 
Formic acid VWR Chemicals, Radnor 
Gentamicin PAA Laboratories GmbH, Pasching 
Glutamine Thermo Fisher Scientific, Waltham 
Glycerol Thermo Fisher Scientific, Waltham 
Glycine Applichem GmbH, Darmstadt 
Hanks Balanced Salt Solution Thermo Fisher Scientific, Waltham 
HEPES Sigma Aldrich, St Louis 
Iodacetamide Sigma Aldrich, St Louis 
Isopropanol Sigma Aldrich, St Louis 
IPTG (isopropyl-1-thio D galactopyranoside) Sigma Aldrich, St Louis 
Magnesium chloride Sigma Aldrich, St Louis 
MassRuler DNA Loading Dye Thermo Fisher Scientific, Waltham 
Methanol Sigma Aldrich, St. Louis 
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Chemical Company 
Nicotinamide dinucleotide (disodium salt) 
(NADH) 
Applichem GmbH, Darmstadt 
NP-40 Sigma Aldrich, St. Louis 
Page Blue Protein Staining Solution Thermo Fisher Scientific, Waltham 
PeqGOLD TriFast PEQLAB, Erlangen 
Pfu Polymerase Thermo Fisher Scientific, Waltham 
Piperazine-1,4-bis (2-ethanesulfonic acid) 
(PIPES) 
Roth GmbH, Karlsruhe 
Polyethylenimine (PEI) Sigma Aldrich, St. Louis 
Power SYBR Green Master Mix Thermo Fisher Scientific, Waltham 
Protease Inhibitor (Complete Mini, EDTA 
free) 
Roche, Mannheim 
Protein A Sepharose Beads Sigma Aldrich, St. Louis 
PAGE Blue Protein staining solution Thermo Fisher Scientific, Waltham 
Sodium Chloride Sigma Aldrich, St. Louis 
Sodium dodecyl sulfate SERVA Electrophoresis GmbH, 
Heidelberg 
Sodium deoxycholate Sigma Aldrich, St. Louis 
Sodium dihydrogen phosphate Sigma Aldrich, St. Louis 
Sodium hydrogen carbonate Sigma Aldrich, St. Louis 
Sodium pyruvat Merck KGaA, Darmstadt 
StrepTactin sepharose beads IBA GmbH, Göttingen 
Sucrose Sigma Aldrich, St. Louis 
Sulfuric acid Sigma Aldrich, St. Louis 
T4 DNA Ligase Thermo Fisher Scientific, Waltham 
Taq DNA Polymerase Thermo Fisher Scientific, Waltham 
Tetramethylethylendiamin Thermo Fisher Scientific, Waltham 
Trifluoroacetic acid (TFA) Sigma Aldrich, St. Louis 
Trizma Base (Tris/Cl) Sigma Aldrich, St. Louis 
Triton X-100 USB corporation, Cleveland 
Trypsin PAA Laboratories GmbH, Pasching 
Tween 20 Sigma Aldrich, St.Louis 
Yeast extract Sigma Aldrich, St. Louis 
 
2.2.2 Buffer and solutions 
Buffer name Components 
Blocking Solution 
 
10 mM Tris/Cl 
150 mM NaCl 
1.5 % (v/v) Tween 
3 % (w/v) BSA 
CSK I buffer 10 mM PIPES    pH 6.8  
100 mM NaCl  
1 mM EDTA 
300 mM Sucrose 
1 mM MgCl2 
1 mM DTT 
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Buffer name Components 
CSK II buffer 10 mM PIPES   pH 6.8  
50 mM NaCl 
300 mM Sucrose 
6 mM MgCl2 
1 mM DTT 
LDH Buffer 
 
200 mM NaCl 
80 mM Tris/Cl   pH 7.2 
LDH reaction mix 
 
LDH buffer 
10 mM NADH 
16 mM Sodium pyruvate 
PBS (Phosphate buffered saline) 37 mM NaCl 
2.7 mM Na2HPO4 
1.5 mM K2HPO4 
RIPA buffer 150 mM Tris/Cl  pH 8.0  
150 mM NaCl  
0.5 % (w/v) Sodium deoxycholate  
0.1 % (w/v) SDS,  
1 % (v/v) NP-40 
SDS- PAGE running buffer (10x) 
 
192 mM Glycine 
25 mM Tris/Cl 
0.1 % (w/v) SDS 
SDS-PAGE sample buffer (2x) 
 
10 % (v/v) Glycerol 
4 % (w/v) SDS 
50 mM DTT 
0.02 % (w/v) Bromphenolblue 
125 mM Tris/Cl 
Stacking Buffer (4x) 
 
0.1 % (w/v) SDS 
125 mM Tris/Cl  pH 8.8 
Stripping solution for Western blot 100 mM Glycine, pH 3.0; adjusted with 
HCL 
TAE Buffer (50 x) (Tris-acetate-EDTA) 2.5 mM Tris  acetate 
50 mM EDTA    pH 8.3  
TBS-T (Tris buffered saline + 1,5 % 
Tween) (10x) 
 
10 mM Tris/Cl 
150 mM NaCl 
1.5 % (v/v) Tween  pH 7.4 
TNE lysis buffer 
 
20 mM Tris/Cl 
150 mM NaCl 
5 mM EDTA 
1 % (v/v) NP-40  pH 7.4 
Western blotting buffer 25 mM Tris/Cl 
192 mM Glycine 
20 % (v/v) Methanol   
 
2.2.3 Cell lines 
Name Description Reference Source 
Cos7 Kidney fibroblasts from the African 
green monkey Cercopithecus aethiops 
[126] AG Kelm 
HaCat Immortal human keratinocyte cell line 
(Homo sapiens) 
[127] AG Kelm 
HeLa Human cervical cancer cells [128] AG Kelm 
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Name Description Reference Source 
HepG2 Human cell line derived from a liver 
tissue with differentiated hepatocellular 
carcinoma (Homo sapiens) 
[129] AG Kelm 
MCF-7 Human breast adenocarcinoma cell line [130] Prof. Dr. Jörn 
Bullerdiek, Centre 
for Human 
Genetics, Bremen 
MDA-
MB-231 
Human breast adenocarcinoma, 
mammary gland, 
[131] Prof. Dr. Martin 
Götte, Department 
of Gynecology and 
Obstetrics, 
University Medical 
Centre Münster 
 
2.2.4 Bacteria strains 
Name Description Company 
Xl1-Blue Chemically competent E. 
coli for all cloning and DNA-
related work 
StrataGene, Santa Clara 
 
2.2.5 Media and solutions for cell culture  
Media Components 
Cell culture freezing medium 10 % (v/v) DMSO 
20 % (v/v) FCS 
In DMEM 
Collagenase type 2 solution 2.5 mg/mL collagenase (Sigma Aldrich, 
St. Louis)  
25 mM Hepes, pH 7:0 
in Hanks´ Balanced salt solution (sterile 
filtrated) 
Dispase II solution 2 U/mL Dispase II (Roche, Mannheim) in 
PBS 
Dulbecco's Modified Eagle's Media (DMEM) 13.37 g/L DMEM 
3.70 g/L NaHCO3 
Dulbecco's Modified Eagle's Media 
(DMEM)/Ham´s F12  
Thermo Fisher Scientific, Waltham  
LB agar 
 
15 g/L Tryptone 
5 g/L Yeast extract 
5 g/L NaCl 
15 g/L Agar 
LB medium 15 g/L Tryptone 
5 g/L Yeast extract 
5 g/L NaCl 
SOC medium 
 
20 g/L tryptone 
5 g/L yeast extract 
0.5 g/L NaCl 
2.5 mM KCl  
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2.2.6 Primer 
Primers were synthesised by Eurofins MWG Biotech (Ebersberg). 
 
Primer Name Sequence (5’ – 3’) 
sense HDGF-A (BamH1) CGGGATCCATGTCGCGATCCAACCGGCAG 
sense HDGF-B (BamH1) CGGGATCCATGCACCCGGAAGGTGGC 
sense HDGF-C(BamH1) CGGGATCCATGGAGCAGAGGGCAGGC 
anti-sense HDGF A/B/C primer 
(EcoRI) 
CGGAATTCCAGGCTCTCATGATC 
anti-sense HDGF A/B/C primer 
(HindIII) 
CGAAGCTTCTACAGGCTCTCATGATC 
sense-EGFP (EcoRI) CGGAATTCGATGATTGAACAAGATGGATTG 
anti-sense- EGFP(BamH1) CGGGATCCCTTGTACAGCTCGTCCATGCC 
sense primer EYFP (EcoRI) CGGAATTCGAATGGTGAGCAAGGGCGAGGA 
anti-sense primer EYFP (XhoI) CGCTCGAGTCACTTGTACAGCTCGTCCAT 
sense primer CEYFP173 (EcoRI) CGGAATTCGAATGGAGGACGGCAGCGTGCAG 
anti-sense primer NEYFP173  (XhoI) CGCTCGAGTCAGATGTTGTGGCGGATCTTGAA 
sense primer HDGF-A (HindIII) CGAAGCTTATGTCGCGATCCAACCGGCAG 
sense primer HDGF-B (HindIII) CGAAGCTTATGCACCCGGAAGGTGGC 
sense primer HDGF-C (HindIII) CGAAGCTTATGGAGCAGAGGGCAGGC 
anti-sense primer HDGF (BamHI) CGGGATCCCAGGCTCTCTCATGATCT 
Real time qPCR Primer A (sense) ACCGGCAGAAGGAGTACAAA 
Real-time qPCR Primer B (sense) TTGTGCCTCAACTCCTTGG 
Real-time qPCR Primer C (sense) GCGGAAACCGTGTACAGAC 
Real-time qPCR Primer A/B/C 
(antisense) 
TTGGTATTTGTTGGCTGTTGA 
Real-time qPCR Microglobulin 
sense 
TTTACTCACGTCATCCAGCAGA 
Real-time qPCR Microglobulin anti-
sense 
CGGCAGGCATACTCATCTTT 
 
2.2.7 Plasmid vectors 
Name Description Source/ 
Reference 
HDGF-A 
(untagged) 
Human HDGF-A sequence was cloned into 
EcoRI / BamHI digested pcDNA3Amp vector 
[132] 
HDGF-A-Strep Human HDGF-A sequence was cloned into 
BamHI / EcoRI pcDNA3 Amp Strep-tag vector 
[132] 
HDGF-A_CEYFP CEYFP (aa 173-238 of EYFP) fragment was 
cloned using EcoRI and XhoI restriction sites of 
pcDNA3 Amp followed by in frame cloning of the 
HDGF-A using HindIII and BamHI restriction 
 
HDGF-A_NEYFP NEYFP (aa 1-172 of EYFP) fragment was cloned 
using EcoRI and XhoI restriction sites of pcDNA3 
Amp followed by in frame cloning of the HDGF-A 
using HindIII and BamHI restriction 
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Name Description Source/ 
Reference 
HDGF-B 
(untagged) 
Human HDGF-B sequence was cloned into 
EcoRI / BamHI digested pcDNA3Amp vector 
[132] 
HDGF-B-Strep Human HDGF-B sequence was cloned into 
BamHI / EcoRI pcDNA3 Amp Strep-tag vector 
[132] 
HDGF-B_CEYFP CEYFP (aa 173-238 of EYFP) fragment was 
cloned using EcoRI and XhoI restriction sites of 
pcDNA3 Amp followed by in frame cloning of the 
HDGF-B using HindIII and BamHI restriction 
 
HDGF-B_NEYFP NEYFP (aa 1-172 of EYFP) fragment was cloned 
using EcoRI and XhoI restriction sites of pcDNA3 
Amp followed by in frame cloning of the HDGF-B 
using HindIII and BamHI restriction 
 
HDGF-C 
(untagged) 
Human HDGF-C sequence was cloned into 
EcoRI / BamHI digested pcDNA3Amp vector 
[132] 
HDGF-C-Strep Human HDGF-C sequence was cloned into 
BamHI / EcoRI digested pcDNA3 Amp Strep-tag 
vector 
[132] 
HDGF-C_CEYFP CEYFP (aa 173-238 of EYFP) fragment was 
cloned using EcoRI and XhoI restriction sites of 
pcDNA3 Amp followed by in frame cloning of the 
HDGF-C using HindIII and BamHI restriction 
 
HDGF-C_NEYFP NEYFP (aa 1-172 of EYFP) fragment was cloned 
using EcoRI and XhoI restriction sites of pcDNA3 
Amp followed by in frame cloning of the HDGF-C 
using HindIII and BamHI restriction 
 
Human HDGF-A 
S165A (untagged) 
Human HDGF S165A was generated by site-
directed mutagenesis and sequence was cloned 
into EcoRI / BamHI digested pcDNA3 Amp vector 
Frank Dietz 
Lamin B1-Strep Lamin B1 was amplified as described in [49] and 
sequence was cloned N-terminal in frame to the 
Strep tag into the digested BamHI/EcoRI pcDNA3 
Amp Strep-tag vector 
Frank Dietz 
Luciferase-Strep pMCS-Gaussia Luc vector (Thermo Scientific, 
Schwalbach, Germany) was used as a template 
to amplify the Gaussia luciferase (GLuc) GLuc 
sequence was cloned into BamHI/EcoRI digested 
pcDNA3 Strep vector 
Frank Dietz 
Murine HDGF wt 
(untagged) 
Murine HDGF sequence was cloned into HindIII / 
BamHI digested pcDNA3Amp vector 
[33] 
Murine HDGF 
C12A 
(untagged) 
HDGF mutants were generated by site-directed 
mutagenesis and cloned into pcDNA3 Amp 
vector 
[33] 
Murine HDGF 
C108A 
(untagged) 
Mutant of murine HDGF was generated by site 
directed mutagenesis and cloned into pcDNA3 
Amp vector 
[33] 
Murine HDGF 
C12/108A 
(untagged) 
Mutant of murine HDGF was generated by site 
directed mutagenesis and cloned into pcDNA3 
Amp vector 
[33] 
Murine HDGF 
S102/103A 
(untagged)  
Mutant of murine HDGF was generated by site 
directed mutagenesis and cloned into pcDNA3 
Amp vector 
[33] 
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Name Description Source/ 
Reference 
Murine HDGF 
S132A (untagged) 
Mutant of murine HDGF was generated by site 
directed mutagenesis and cloned into pcDNA3 
Amp vector 
[33] 
Murine HDGF 
S133A (untagged) 
Mutant of murine HDGF was generated by site 
directed mutagenesis and cloned into pcDNA3 
Amp vector 
[33] 
Murine HDGF 
S132/S133A 
(untagged) 
S132A was used as template for preparation of 
the double mutants by performing site directed 
mutagenesis. Sequence was cloned into EcoRI / 
BamHI digested pcDNA3 Amp vector 
Frank Dietz 
Murine HDGF 
S165A 
(untagged) 
Mutant of murine HDGF was generated by site 
directed mutagenesis and cloned into pcDNA3 
Amp vector. Sequence was cloned into EcoRI / 
BamHI digested pcDNA3 Amp vector 
[33] 
Murine HDGF 
S132/S165A 
(untagged) 
S132A was used as template for preparation of 
the double mutants by performing site directed 
mutagenesis as described by [33]. Sequence was 
cloned into EcoRI / BamHI digested pcDNA3 
Amp vector 
Frank Dietz 
Murine HDGF 
S132/S133/S165A 
(untagged) 
S132/133A mutant was the base for the triple 
mutant by performing site directed mutagenesis 
as described by [33]. Sequence was cloned into 
EcoRI / BamHI digested pcDNA3 Amp vector. 
Frank Dietz 
Murine HDGF 
K8R Strep 
Murine HDGF-Strep was used as template for the 
prepration of K8R by performing site directed 
mutagenesis as described by [33]. Sequence was 
cloned into EcoRI / BamHI digested pcDNA3 
Amp vector 
Frank Dietz 
Murine HDGF 
K11R Strep 
Murine HDGF-Strep was used as template for the 
prepration of K11R by performing site directed 
mutagenesis as described by [33]. Sequence was 
cloned into EcoRI / BamHI digested pcDNA3 
Amp vector. 
Frank Dietz 
NΔ8 HDGF 
(untagged) 
Murine HDGF N-terminally truncated fragment, 
deleted in first 8 N terminal amino acids, was 
cloned into BamHI / EcoRI digested vector 
pcDNAIII Amp  
Frank Dietz 
NΔ10 HDGF 
(untagged) 
Murine HDGF N-terminally truncated fragment, 
deleted in first 10 N terminal amino acids, was 
cloned into BamHI /EcoRI digested vector 
pcDNAIII Amp 
Frank Dietz 
NΔ11 HDGF 
(untagged 
Murine HDGF N-terminally truncated fragment, 
deleted in first 11 N terminal amino acids, was 
cloned into BamHI / EcoRI digested vector 
pcDNAIII Amp 
[33] 
NΔ12 HDGF 
(untagged) 
Murine HDGF N-terminally truncated fragment, 
deleted in first 12 N terminal amino acids, was 
cloned into BamHI / EcoRI digested vector 
pcDNAIII Amp 
[33] 
NΔ15 HDGF-A 
(Strep-tagged) 
Murine HDGF N-terminally truncated fragment, 
deleted in first 15 N terminal amino acids, was 
cloned N-terminal in frame to the Strep-tag into 
the BamHI / EcoRI digested pcDNA3 Strep 
Frank Dietz 
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Name Description Source/ 
Reference 
N10 HDGF 
SNAP- Strep 
N-terminal HDGF sequence, containing the first 
10 aa of HDGF, was obtained as described by 
[33] and cloned N-terminal into the EcoRI/NotI 
digested pcDNA3 Amp vector. Simultaneously, 
the coding sequence of the hAGT protein (SNAP) 
was amplified using the pSNAP-tag (m) vector 
(NEB, Ipswich) as a template and subcloned in 
frame into BamHI/EcoRI digested pcDNA3 Strep 
vector. Vector was BamHI/NotI double digested 
to obtain SNAP-StrepTag sequence and this 
sequence was ligated to BamHI/ 
NotI digested pcDNA3, containing the N-terminal 
peptide of HDGF.  
[33] 
N15 HDGF 
SNAP-Strep 
N-terminal sequence, containing the first 15 aa, 
was amplified from HDGF and cloned into 
EcoRI/NotI digested pcDNA3 Amp vector. As 
described above, SNAP-Strep sequence was 
cloned in frame to the HDGF peptide using 
BamHI and NotI restriction site. 
Frank Dietz 
N30 HDGF 
SNAP-Strep 
N-terminal sequence, containing the first 30 aa of 
HDGF, was amplified from HDGF and cloned into 
EcoRI/NotI digested pcDNA3 Amp vector. As 
described above, SNAP-Strep sequence was 
cloned in frame to the HDGF peptide using 
BamHI and NotI restriction site. 
Frank Dietz 
pcDNA3 Amp Mammalian Expression Vector (vector map in the 
appendix) 
Invitrogen, 
Carlsbad 
pcDNA3 Strep Mammalian Expression Vector [49] 
pEGFP N3 Mammalian Expression Vector (vector map in the 
appendix) 
Clontech, Palo 
Alto, CA, USA 
pEXPR IBA5  Mammalian Expression Vector (vector map in the 
appendix) 
IBA, Göttingen 
Snap-Strep The coding sequence of the hAGT protein 
(SNAP) was amplified using the pSNAP-tag (m) 
vector (NEB, Ipswich) as a template and 
subcloned in frame into BamHI/EcoRI digested 
pcDNA3 Strep vector. 
Frank Dietz 
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2.2.8 Antibodies 
2.2.8.1 Primary antibodies 
Primary antibodies Dilution Company/Source 
Goat anti pan-HDGF, polyclonal 
1:2000 (Wb); 
1:1000 (IF) 
R&D systems, 
Minneapolis 
Goat anti-kinesin 1, polyclonal 
1:500 (Wb); 
1:200 (IF) 
Thermo Fisher Scientific, 
Waltham  
Mouse anti-actin, pan 5, monoclonal 
1:2000 (Wb); 
1:1000 (IF) 
Dianova GmbH, Hamburg 
Mouse anti-dynein IC, 74.1 (74 kDa); 
monoclonal 
1:250 (Wb); 
1:200 (IF) 
Thermo Fisher Scientific, 
Waltham 
Mouse anti-HDGF (H3); monoclonal 1:500 (IF) Santa Cruz, Dallas 
Mouse anti-Hsc70 antibody 13D3; 
monoclonal 
1:1000 (Wb) 
Thermo Fisher Scientific, 
Waltham 
Mouse anti-nucleolin antibody ZN004; 
monoclonal 
1:2000 (Wb); 
1:1000 (IF) 
Thermo Fisher Scientific, 
Waltham 
Mouse anti-tubulin DM1A, monoclonal 
1:1000 (Wb); 
1:1000 (IF) 
Dianova, Hamburg 
Mouse anti-vimentin antibody; 
monoclonal 
1:250 (Wb); 
1:100 (IF) 
Sigma Aldrich, St Louis 
Mouse anti-YB-1 59-Q; monoclonal 
1:500 (Wb); 
1:200 (IF) 
Santa Cruz, Dallas 
Rabbit anti HDGF-A, -B and -C (isoform 
specific peptide antibodies) 
1:200 (Wb); 
1:100 (IF) 
Biomatik, Cambridge, 
Kanad 
Rabbit anti human HDGF, polyclonal 1:1000 (Wb) Frank Dietz 
Sheep anti mouse HDGF; polyclonal 1:1000 (Wb) Frank Dietz 
Sheep anti-Strep Tag 1:2000 (Wb) (IF) Frank Dietz 
 
2.2.8.2 Secondary antibodies 
Seondary antibody Dilution Company 
Cy3-conjugated donkey anti-goat antibody 1:500 Dianova, Hamburg 
Cy3-conjugated donkey anti-rabbit antibody 1:500 Dianova, Hamburg 
Cy5-conjugated donkey anti-mouse antibody 1:500 Dianova, Hamburg 
Peroxidase-conjugated affinity purified donkey 
anti-goat IgG 
1:20000 Dianova, Hamburg 
Peroxidase-conjugated affinity purified donkey 
anti-mouse IgG 
1:20000 Dianova, Hamburg 
Peroxidase-conjugated affinity purified donkey 
anti-rabbit IgG (H+L) 
1:20000 Dianova, Hamburg 
Peroxidase-conjugated affinity purified donkey 
anti-sheep IgG (H+L) 
1:20000 Dianova, Hamburg 
 
2.2.9 Devices 
Devices Company 
ApoTome, Axio Imager Z1 Zeiss, Jena 
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Devices Company 
Centrifuge (Benchtop minispin) Eppendorf AG, Hamburg 
Centrifuge rotor (Sorvall evolution RC) Sorvall GmbH, Bad Homburg 
DelsaTM Nano C particle analyser Beckmann Coulter, Krefeld 
Electrical power supply (SDS PAGE) BioRad Laboratories GmbH, München 
Electrical power supply (Western blotting) BioRad Laboratories GmbH, München 
Electrophoresis chamber BioRad Laboratories GmbH, München 
Fluorescence microscope  Olympus, Hamburg 
Heating block Eppendorf AG, Hamburg 
Ice machine Scotsman Ice Systems, Frimont 
Incubator (Bacteria) Unitron Infors AG, Bottmingen 
Incubator (Cell Culture) Heraeus Holding GmbH, Hanau 
Laminar air flow system Heto Holten GmbH, Wettenberg 
Magnetic stirrer IKA Werke GmbH & Co KG, Staufen 
MALDI-TOF mass spectrometer Bruker Daltonics GmbH, Bremen 
MicroAmp Fast Optical 96-Well Reaction 
Plate 
Thermo Fisher Scientific, Waltham 
Multipipette Eppendorf AG, Hamburg 
Nanodrop Thermo Fisher Scientific, Waltham 
Neubauer counting chambers Brandt GmbH & Co. KG, Wertheim 
pH Meter Inolab WTW GmbH; Weilheim 
Photometer Eppendorf AG, Hamburg 
Pipettes Eppendorf AG, Hamburg 
Pipette boy Eppendorf AG, Hamburg 
Refrigerator (4 °C) Liebherr AG, Bremen 
Refrigerator (-20 °C) Vestfrost, Esbjerg 
Refrigerator (-80 °C) Eppendorf, AG Hamburg 
Shaker Vibramax 100 Heidolph Instruments GmbH, Schwalbach 
StepOnePlus™ Real Time PCR Cycler Thermo Fisher Scientific, Waltham 
Thermocycler Eppendorf AG, Hamburg 
Ultracentrifuge, Le-80K Beckmann Coulter, Krefeld 
Ultracentrifuge, Optima MaxE Beckman Coulter, Krefeld 
Ultracentrifuge rotor, Ti45 Beckmann Coulter, Krefeld 
Ultracentrifuge rotor, TLA 55 Beckmann Coulter, Krefeld 
Ultrasonication Sonifier B12 Banson Sonic Power Company, Danbury 
Vacuum centrifuge Thermo Fisher Scientific, Waltham 
Vortex IKA Werke GmbH & Co KG, Staufen 
Weighing Balance Sartorius AG, Göttingen 
Weighing Balance (fine measurements) Sartorius AG, Göttingen 
Western blotting device (tank) BioRad Laboratories GmbH, München 
X-ray film developing machine (Curix) AGFA Gevaert, Mortsel 
X-ray film cassette GE Healthcare Europe GmbH, München 
 
2.2.10 Consumables 
Consumables Company 
96 well microtitre plate Greiner Bio-One GmbH, Frickenhausen 
Amersham Hyperfilm ECL GE Healthcare Europe GmbH, 
München 
Blotting paper GE Healthcare Europe GmbH, 
München 
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Consumables Company 
Cell filter (70 µm) Sarstedt AG & Co. KG, Nümbrecht 
Cell scraper Thermo Fisher Scientific, Waltham 
Double distilled water UltraClear UV, Richfield 
Glass Cover Slips Heinz Herenz Medizinalbedarf GmbH, 
Hamburg 
Mini Protean Precast gels TGX BioRad Laboratories GmbH, München 
MTP 384 well ground steel target plate Bruker Daltonics, Bremen 
Reactiontubes (1.5 mL) Eppendorf AG, Hamburg 
Reaction tubes (15 and 50 mL) Sarstedt AG & Co. KG, Nümbrecht 
Parafilm American National Can, New Jersey 
Pasteur pipettes (glas) Brand GmbH & Co. KG, Wertheim 
Pipette tips Sarstedt AG & Co, KG, Nümbrect 
Photometer plastic cuvettes Brand GmbH & Co. KG, Wertheim 
PVDF membrane Hybond P Carl Roth GmbH & Co. KG, Karlsruhe 
Scalpel Braun GmbH, Melsungen 
Serological pipettes (5 mL, 10 mL, 25 mL Sarstedt AG & Co. KG, Nümbrecht 
StrepTactin sepharose IBA GmbH, Göttingen 
Tissue cell culture plates (10 cm) Sarstedt AG & Co. KG, Nümbrecht 
Tissue cell culture plate (3.5 cm) Sarstedt AG & Co. KG, Nümbrecht 
Tissue cell culture plates (6; 24 ; 96 well) Sarstedt AG & Co. KG, Nümbrecht 
 
2.2.11 Protein and DNA ladder 
MassRuler DNA Ladder Mix    Thermo Fisher Scientific, Waltham 
Contains following fragment sizes (in bp): 80, 100, 200, 300, 400, 500, 600, 700, 800, 
900, 1031, 1500, 2000, 2500, 3000, 4000, 5000, 6000, 8000, 10000 
 
Prestained Protein Ladder:     Thermo Fisher Scientific, Waltham 
Contains following fragment sizes (in kDa): 10, 15, 25, 35, 40, 55, 70, 100, 130, 170 
 
2.2.12 Kits 
Kit Manufacturer 
BCA Protein Assay Kit  Thermo Fisher Scientific, Waltham 
Cell Proliferation ELISA, BrdU 
(chemiluminescent) 
Roche GmbH, Basel 
ECL advanced Western blotting detection kit GE Healthcare Europe GmbH, 
München 
Fast Digest restriction enzymes Thermo Fisher Scientific, Waltham 
GeneJET Gel Extraction Kit Thermo Fisher Scientific, Waltham 
GeneJET Plasmid Miniprep Ki Thermo Fisher Scientific, Waltham 
NucleoBondR Xtra Midi kit Macherey Nagel, Düren 
Pierce ECL Western blotting substrate Pierce Biotechnology, Rockford 
Revert Aid First Strand cDNA synthesis kit Thermo Fisher Scientific, Waltham 
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3. Results 
3.1 Identification and verification of alternatively spliced forms of HDGF 
3.1.1 Database analysis: HDGF-A in comparison to HDGF-B and HDGF-C 
Alternative splicing is a mechanism which results in high diversity of proteins. Studies 
estimated that 96 % of human genes undergo alternative splicing [133, 134]. 
Screening the NCBI database (www.ncbi.nlm.nih.gov/entrez) demonstrated that human 
HDGF belongs to this group of genes. Apart from the basic HDGF form, now termed 
HDGF-A during the course of this thesis, the sequences of two further N-terminal spliced 
sequences were recorded in the database, termed now HDGF-B (transcript variant 1; 
accession number NM_001126050.1) and HDGF-C (transcript variant 2; accession 
number NM_001126051). These sequences were identified in different cDNA libraries 
obtained from several human tissues. Respective accession numbers, length of mRNA 
transcript and of the resulting protein, as well as their respective molecular weights are 
given in table 5. 
Table 5: HDGF Isoforms HDGF-A, HDGF-B and HDGF-A Main NCBI database entries 
(Accession number, database names, length of transcripts and resulting proteins) as well as 
calculated molecular weights of the novel HDGF isoforms are given. 
Name in this study HDGF-A HDGF-B HDGF-C 
Accession number 
nucleic acids 
NM_004494.2 NM_001126050.1 NM_001126051 
Transcript name NCBI 
database 
transcript variant 
1 
transcript variant 
2 
transcript variant 
3 
Species Homo sapiens Homo sapiens Homo sapiens 
Length mRNA transcript  2397 bp 2208 bp 2183 bp 
Length coding sequence  723 nt 771 nt 702 nt 
Accession number protein NP_004485.1 NP_001119522.1 NP_00119523.1 
Protein name NCBI 
database 
Isoform A Isoform B Isoform C 
Length protein (aa) 240 aa 256 aa 233 aa 
Calculated molecular 
weight 
26.8 kDa 28.3 kDa 25.5 kDa 
 
In the human genome the HDGF gene is located on chromosome 1 (1q23.1) [135]. As 
shown in the splicing scheme (figure 6 A), the three HDGF isoforms are encoded by six 
exons. Isoform HDGF-B and isoform HDGF-C result from the usage of a first alternative 
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in-frame exon. In all three variants exon 1(a/b/c) - 3 are spliced to exon 5 - 7, leaving out 
exon 4.  
 
Figure 6: Alternative splicing of HDGF. A) Intron-exon organisation of HDGF-A, HDGF-B and 
HDGF-C. Exons 1-7 are depicted as boxes. Isoforms HDGF-A, -B and -C are encoded by six 
exons. The first three exons (1-3) are spliced to exon 5, 6 and 7 as shown in the schematic 
depiction. The alternative isoforms result from usage of a first alternative exon (1A/1B/1C). (B) 
Alignment of all resulting HDGF variants. (C) Alignment of HDGF variants displaying the presence 
of motifs (NLS1 & NLS2) and domains (red box = PWWP domain). 
The resulting novel isoforms HDGF-B and C differ slightly in their amino acid length and 
resulting from that, in their molecular weight (table 5).  
Since alternative splicing based on the usage of a first alternative exon, the generated 
isoforms HDGF-A, -B and -C consist of a different N-terminal part, while the C-terminal 
part remains unchanged. An amino acid alignment of HDGF-B and HDGF-C to HDGF-A 
(figure 7) revealed the affected parts of the proteins. 
A = 5970 nt
B = 6859 nt
C = 6665 nt1A
Start
2 3 4 5 6 7
Stop Stop Stop
1B
1C
A,B,C
A,B,C
A)
1A 2 3 5 6 7HDGF-A
Stop
1B 2 3 5 6 7HDGF-B
Stop
1C 2 3 5 6 7HDGF-C
Stop
hath region
PWWP-Domain
NLS1 NLS2 polyE
1A 2 3 5 6 7HDGF-A
Stop1B 2 3 5 6 7HDGF-B
Stop
1C 2 3 5 6 7HDGF-C
Stop
PHWP
B)
C)
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Figure 7: Amino acid alignment of the novel HDGF isoforms HDGF-A, -B and -C. Amino acid 
sequences, given in single letter code, are aligned. Identical amino acids are on a dark gray 
background, amino acids identical only in two HDGF isoforms are on a light gray background. The 
PHWP motif (aa 24 -27 in HDGF-A) is highlighted by a box. Above the amino acid sequence the 
secondary structure of HDGF-A hath region is depicted. The hath region consists of five β-sheets 
1-5 (blue arrows) followed by two α-helices (1&2) (red rectangles). Green rectangles depict the 
flexible loops between β-sheets and α-helices. Identified residues in HDGF-A for posttranslational 
modifications are highlighted by coloured box (red: phosphorylation Y23 [136], S103, T200 [36], 
S107 [137], S132, S133, S165 [34], S199, S202, S206, S239 [35], T225 [138] green: 
ubiquitination K11 [139]; K226 [140] yellow: acetylation K44 [141]; pink: SUMOlyation K80 [49]). 
The alignment demonstrated that HDGF-B and HDGF-C lack those amino acid residues 
of HDGF-A that constitute the first and the majority of the second β-sheet in HDGF-A 
(depicted by a blue arrow 1 & 2 in figure 7). The PHWP motif, which is located in the 
second β-strand of HDGF-A (highlighted by a black box in figure 7), is replaced by 
Arg40-Ala41-Thr42-Pro43 at the corresponding positions in HDGF-B. Respectively, only 
the fourth position of this motif is maintained in HDGF-B. Pro43 of HDGF-B corresponds 
to the Pro27 in HDGF-A.  
In HDGF-C no obvious similarities to the PHWP motif are available. Instead of the PHWP 
motif, Cys17-Ala18-Gly19-Ala20 can be found in HDGF-C at the corresponding position 
in the alignment. 
HDGF-A is a phosphoprotein with several potential phosphorylation sites mainly in its C-
terminal part (in the sequence highlighted by red boxes, figure 7) [34, 35, 136-138]. 
Moreover, an acetylation site (Lys44) (yellow box) [141], a SUMOylation site (Lys80) 
(pink box) [49] and two ubiquitinylation sites (Lys11 and Lys226) (green boxes) [139, 
140] have been reported in HDGF-A. Most of these sites were identified by large mass 
spectrometry proteome analysis and the function or biological relevance is barely known 
[34, 35, 136-141]. As shown in the alignment, these sites, with exception of Lys11 and 
Tyr23 are also potentially available in HDGF-B and HDGF-C. 
21
1 2 3 4 5 1HDGF-A
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Human HDGF-A and respective mouse HDGF share a high level of similarity (86 %). 
Furthermore, the number and the length of HDGF coding exons are the same in both 
species. However, alignments of the respective gene sequences demonstrated that the 
alternative first exons (1b and 1c), encoding the N-terminal part of HDGF-B and HDGF-
C, were not present in the mouse genome. Performing blast search led to the discovery 
that apart from Homo sapiens both alternative isoforms have been also predicted for 
different Old World monkeys (Cercopithecidae) (HDGF-B: Pan paniscus, Pongo abelii, 
Gorilla gorilla, Macaca fascicularis, Mandrillus leucophaeus) (HDGF-C: Pan paniscus). 
3.1.2 Gene expression of HDGF isoforms in human cell lines 
To verify gene expression of reported HDGF isoforms -A, -B, and -C, RNA was isolated 
from different human cell line (HeLa, HepG2, MCF-7, MDA-MB-231) and transcribed into 
cDNA. Subsequent PCR was performed using specific primer against the mentioned 
HDGF isoforms. In order to detect the obtained amplification products, agarose 
gelelectrophoresis was performed. The respective record of the gel is shown in figure 8. 
 
Figure 8: Gene expression of HDGF isoforms in different human cell lines. RNA was isolated 
from indicated cell lines (HeLa, HepG2, MCF-7 and MDA-MB-231) and mRNA was transcribed 
into cDNA using an oligo (dT) primer. PCR was performed with isoform specific primer (HDGF-A, 
-B, -C) and PCR products were separated by gelelectrophoresis in 1 % (w/v) agarose gel. First 
lane contained DNA ladder with following fragments (in bp) (300, 400, 500, 600, 700, 800, 900, 
1003). 
Amplification products contained an expected size of 727 bp (HDGF-A), 783 bp (HDGF-
B) and 714 bp (HDGF-C). Respective bands were observed at the expected position in 
the agarose gel (figure 8). Therefore, all isoforms were found to be expressed as mRNA 
in the studied cell types. 
As next step, sequences were cloned into pcDNA3 Amp vector (BamHI, EcoRI restriction 
sites) and resulting constructs were sequenced in order to validate the obtained PCR 
fragments. In all cases, the determined sequences matched with the reported sequences 
found in the NCBI database (data not shown) (corresponding NCBI accession numbers 
for each sequence of the HDGF isoforms are given in table 5). 
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3.1.3 Quantification of HDGF isoform expression in different human cell lines 
The analysis of expression pattern of several alternative isoforms within different cell 
lines demonstrated that several isoforms, deriving from the same gene, are often 
simultaneously expressed, but that in general one isoform is the dominant expressed 
isoform [142].  
In order to analyse the expression pattern of the novel HDGF isoforms HDGF-B and -C 
relative to HDGF-A and, furthermore, also to explore which of these isoforms is the main 
expressed form, real-time qPCR analysis was performed as described under section 
2.1.1.5. Therefore, cDNA was used from different human cell types (MDA-MB-231, MCF-
7, human dermal fibroblasts, HeLa, and HepG2). The obtained results are shown in 
figure 9 & 10. 
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Figure 9: Comparison of relative mRNA levels of HDGF-A, HDGF-B and HDGF-C. Relative 
mRNA expression of the three transcripts of the HDGF gene (HDGF-A, -B, -C) was determined by 
real-time quantitative PCR in primary human dermal fibroblasts or in human cell lines HeLa, MCF-
7, MDA-MB-231, HepG2. Each PCR was performed in triplicates and means were determined. 
Results were normalised to microglobulin expression. Vertical bars indicate expression of HDGF 
isoforms B and C relative to HDGF-A, which was set to 1. The standard deviation of triplicates is 
represented by error bars. 
In all investigated cell lines all three isoforms of HDGF were expressed at the same time. 
This was in agreement with the results of the first RT-PCR shown in figure 8. 
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HDGF-A was clearly the dominant expressed form in all investigated cell types, whereas 
HDGF-B and HDGF-C were only expressed at very low levels in relation to HDGF-A. In 
breast cancer cell lines (MCF-7 and MDA-MB-231) HDGF-B and HDGF-C expression 
were similar while in dermal fibroblasts HDGF-C expression was slightly stronger then 
HDGF-B. 
Comparing the expression of one HDGF isoform within one cell line exhibited distinct 
expression pattern for each isoform as shown in figure 10.  
 
Figure 10: Relative mRNA expression of HDGF isoforms within different cell types. Relative 
mRNA expression of the three HDGF isoforms HDGF-A, -B and -C was determined by real-time 
qPCR. Each reaction was performed in triplicates and means were determined. Results were 
normalised to microglobulin expression. Vertical bars indicate expression of HDGF isoform in 
HeLa, MDA-MB-231, MCF-7 and human dermal fibroblast relative to expression in HepG2 cells, 
which was set to 1. The standard deviation of triplicates is represented by error bars. 
Noticeably, expression of all three isoforms in primary dermal skin fibroblasts from 
human skin was relatively small compared to the expression of the other immortalised 
cell lines.  
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3.1.4 Ectopic expression of HDGF-Isoform 
3.1.4.1 Western blot analysis of ectopically expressed HDGF-Isoforms 
In order to receive more information about the HDGF isoforms, the coding sequences 
were subcloned into the mammalian expression vector pcDNA3 Amp vector (BamHI, 
EcoRI restriction sites) or cloned in frame to the Strep-tag into pcDNA3 Amp Strep vector 
(BamHI, EcoRI restriction sites). Obtained constructs were transiently overexpressed in 
HepG2 cells. After an incubation time of 24 h cells were lysed and cleared lysates were 
subjected to Western blot analysis using an anti pan-HDGF antibody, which was able to 
detect all three variants (figure 11). 
 
Figure 11: Ectopic expression of HDGF-A, HDGF-B and HDGF-C. HepG2 cells were 
transiently transfected with plasmids coding for untagged HDGF-A, HDGF-B and HDGF-C (panel 
1) or with plasmids coding for C-terminal Strep-tagged HDGF isoforms (panel 2). Cells were lysed 
and respective cleared cell lysate with DTT (panel 1a, 2a & 2b) or without DTT (panel 1b) were 
separated on 12 % SDS-PAGE gels, transferred to PVDF membranes and probed with goat anti 
pan-HDGF (panel 1a, 1b, 2b) or anti Strep-tag (panel 2a). Molecular mass marker lanes are 
shown on the left.  
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Human HDGF-A has a molecular weight of approximately 27 kDa (table 5), but in 
Western blot analysis it is usually detected at around 37 kDa (figure 11, panel 1a). 
Reason for this is an abnormal running behaviour during SDS PAGE [3]. Due to the 
presence of the Strep-tag, C-terminally Strep-tagged HDGF-A was detected at a slightly 
higher molecular weight position of 40 kDa compared to the untagged form. 
Also HDGF-B and HDGF-C migrated more slowly during SDS PAGE than was expected 
on the basis of their predicted molecular weights. The anti pan-HDGF antibody detected 
a triple band signal at positions of 37-40 kDa in those samples containing ectopically 
overexpressed untagged HDGF-B (figure 11, panel 1a). In contrast to this, the predicted 
molecular weight of HDGF-B was 28.3 kDa (table 5). The triple signal could be also 
observed for C-terminally Strep-tagged HDGF-B after detection with an anti pan-HDGF 
antibody at a slight higher position of approximately 39-44 kDa (panel 2b). The Strep-tag 
antibody only recognized the upper and lower signal, not the intermediate signal (panel 
2a).  
Ectopically expressed HDGF-C was observed at a molecular mass position of 
approximately 37 kDa (with Strep-tag at 40 kDa) (panel 1a, 2a respectively). By contrast, 
the predicted molecular weight of HDGF-C was only 25.5 kDa (table 5).  
In summary, all three HDGF isoforms exhibited a quite comparable discrepancy between 
calculated molecular weight and observed molecular mass position in SDS PAGE gels. 
A further interesting observation was obtained when comparing the signals of samples 
treated with or without reducing agent DTT. Under non-reducing conditions (figure 11, 
panel 1b) an additional strong signal was detected at a molecular mass position of 
approximately 90 kDa mainly for HDGF-A. Such a signal was detected also for HDGF-B 
and HDGF-C, but to a much weaker extent. These HDGF polypeptides were susceptible 
to DTT, since the respective signal disappeared in the presence of DTT (panel 1a).  
3.1.4.2 Subcellular localisation of ectopically expressed HDGF isoforms 
In general HDGF-A is targeted to the nucleus of cells due to the presence of two NLS 
sequences [8]. In this context Everett et al. demonstrated in vascular smooth muscular 
cells that nuclear location is required for the mitogenic activity of ectopically expressed 
HDGF [28]. However, some studies revealed that HDGF can be also present in the 
cytoplasm of cells [1, 29, 37] indicating that nuclear localisation is not exclusive 
intercellular localisation. 
In human HDGF-A NLS 1 encompasses aa 75 - 80, while the bipartite NLS 2 is 
positioned at aa 155 - 170 [8, 17]. As shown in the alignment (figure 7), the changes due 
to alternative splicing in N-terminal part of HDGF-B and HDGF-C did not affect these 
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parts of the protein. This led to the expectation that all variants are mainly located in the 
nucleus. 
To clarify whether both isoforms have the same localisation as HDGF-A in cells, Cos7 
cells grown on glass cover slips, were transiently transfected with an expression vector 
encoding C-terminally Strep-tagged HDGF isoforms HDGF-A, -B and -C. After 24 h 
incubation, cells were fixed, permeabilized and stained with monoclonal pan-HDGF 
antibodies (H3) as well as Strep-tag antibodies. Immunostained cells were imaged using 
a Zeiss Apotome fluorescence imager. The image is shown in figure 12.  
 
Figure 12: Subcellular localisation of HDGF-A, HDGF-B and HDGF-C. Cos-7 cells were 
transfected with plasmids coding for C-terminal Strep-tagged HDGF isoforms as indicated on the 
left side (HDGF-A, HDGF-B and HDGF-C). After 24 h cells were fixed and permeabilised as 
described under section 2.1.4. Cells were co-stained using an anti Strep-tag (red) and monoclonal 
anti HDGF (H3) (green) antibody. Immunostaining was analysed by fluorescence microscopy. The 
right panel (merge) shows the superposition of the red and green signals. DAPI (blue) was used 
for nuclear staining. Scale bar = 10µM (right corner). 
The application of Strep-tag antibodies (red signal), which recognized the C-terminal 
Strep-tag of the recombinant proteins, allowed the discrimination of ectopically 
expressed HDGF isoforms from the background caused by the presence of endogenous 
HDGF. Monoclonal anti-human HDGF (green signal) antibodies recognized both 
endogenous and recombinant protein. The majority of transfected Cos-7 showed a 
strong and dominant red fluorescence signal mainly in their nuclei. Therefore, besides 
HDGF-A also HDGF-B and HDGF-C were primarily translocated to the nucleus of cells. 
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Interestingly, compared to HDGF-A, HDGF-B and HDGF-C were more prominently 
detected in the cytoplasm of cells. 
3.1.5 Isoform specific antibodies 
Alternative splicing can produce a large variety of mRNA transcripts from the same gene 
[142]. However, not all alternatively spliced transcripts will result in expressed functional 
proteins [143]. In order to maintain high fidelity of gene expression different mechanisms 
exist on posttranscriptional level, which control the stability and decay of mRNAs and by 
that way influence subsequent translation into proteins [144]. Hence, the verification of 
the expressed protein is necessary. 
The similar running behaviour in SDS PAGE (figure 11) complicated the discrimination 
and identification of HDGF isoforms. For this reason isoform specific antibodies were 
required in order to verify protein expression of HDGF-B and HDGF-C. 
Most commercially available HDGF antibodies are raised against the C-terminal part of 
HDGF, which is unique part of HDGF within the HRP-family (see also figure 1). 
Consequently, these antibodies would allow discrimination between the different HRP 
family members but they cannot distinguish HDGF-A from the two novel HDGF isoforms 
HDGF-B and HDGF-C.  
3.1.5.1 Design and characterisation of isoform specific antibodies 
To develop isoform specific antibodies, the unique N-terminal peptides of each isoform 
were chosen as shown in table 6.  
Table 6: Selected isoform-specific peptides for antibody production. Selected amino 
acid residues for antibody production are given in the single letter code. In case of HDGF-A two 
peptides were selected as target sequence for antibody production. 
Name Peptide Sequence 
HDGF-A (1) SRSNRQKEYKC12 
HDGF-A (2) CGDLVFAKMGYPH25 
HDGF-B CTKLKRFLLSKGGRRAQ34 
HDGF-C EQRAGGNRVQTSTLNC17 
 
 
Blast search demonstrated that selected peptide sequences of HDGF-A (1), -B and -C 
are indeed unique and there are not any other proteins at least in the NCBI database 
available with a similar peptide sequence. Interestingly, Nakamura et al. used initially an 
HDGF antibody, directed against the same polypeptide like selected for HDGF-A 
antibody (1) [1]. Since obtained HDGF-A antibody (1) did not showed any binding in 
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Western blot analysis (data not shown), a second peptide sequence was selected as 
target sequence located more downstream from the first selected target sequence (table 
6; HDGF-A (2)). However, this sequence overlapped with the N-terminal part of all other 
HRP-family, which share a high homology in the hath region [10] (figure 1). Therefore, 
this antibody is theoretically able to discriminate HDGF-A from the isoforms B and C, but 
will additionally recognize LEDGF, HRP-2, HRP-3 and HRP-4 due to the similarity in the 
hath region. To circumvent this problem, co-staining with an HDGF specific antibody 
would be necessary in this case.  
The peptide production, immunisation and antibody purification was done by the 
company Biomatics (Kanada). Obtained affinity purified antibodies were tested for 
functionality and specificity. Therefore, the C-terminal Strep-tagged HDGF-isoforms 
HDGF-A, -B and -C were ectopically expressed in HepG2 cells and respective cleared 
cell lysates were subjected to Western blot analysis. The PVDF membranes were probed 
with the novel isoform specific antibodies and to exclude unspecific binding the pre-
immune sera were tested as well. As mentioned, the peptide antibody HDGF-A (1) (table 
6) was not functional and therefore was excluded from the subsequent studies. Instead 
the alternative peptide antibody (2) was used. The results of Western blot analysis are 
shown in figure 13. 
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Figure 13: Antibody characterisation of novel peptide antibodies. HepG2 cells were 
transiently transfected with mammalian expression plasmids coding for C-terminally Strep-tagged 
HDGF-A, HDGF-B and HDGF-C. Cells were lysed and respective cleared cell lysates were 
separated on 12 % SDS-PAGE gels, transferred to PVDF membranes and probed with novel 
peptide antibodies anti HDGF-A (2) (panel 1a), anti HDGF-B (panel 2a) or anti HDGF-C (panel 
3a) or respective pre-immune sera (panel 1b, 2b, 3b). Same lysates were probed anti Strep-tag 
antibody (panel II) to verify the expression of the different HDGF isoforms. Marker lanes are 
shown on the left. 
Only the application of anti HDGF-A (figure 13, panel 1a) and anti HDGF-C (figure 13, 
panel 3a) isoform specific antibodies gave a signal at expected position of approximately 
40 kDa for the Strep-tagged isoforms. Both antibodies were specific, since only the 
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corresponding isoform was recognized and not the remaining two alternative splice 
variants. Detection with respective pre-immune sera (figure 13, panel 1b & 3b) caused 
just weak background, a signal at the identical position of the corresponding HDGF 
isoforms was not observed. The affinity purified isoform specific HDGF-A and HDGF-C 
antibodies did not show any unspecific signals at a different molecular weight position. 
Isoform specific HDGF-B antibody did not recognize the overexpressed HDGF-B variant 
(figure 13, panel 2a), although its transient expression was verified by the use of anti 
Strep-tag (figure 13, panel II). Furthermore, not only the application of the affinity purified 
antibody but also the application of the pre-immune sera resulted in signals at 
approximately 20 kDa. 
Since lysates from HDGF expressing cells were used, there is of course endogenously 
expressed HDGF protein present in these samples. Hence, in all samples such a 
“background” staining in all three lanes should be visible. However, this was not the 
case, also after longer exposure times (data not shown). 
There are several potential reasons why HDGF-B antibody did not work. The simplest 
explanation would be that the HDGF-B peptide antibodies were not functional and could 
not bind the epitope. A further explanation could be that the selected region, which is 
recognized by the antibody, might undergo posttranslational modifications, which 
interfere with antibody binding. It is also possible that the isoform HDGF-B was N-
terminally truncated and therefore lost the epitope for antibody recognition. This would be 
also in line with the observation that transiently overexpressed HDGF produced triple 
signals in Western blot analysis (figure 11), which indicated the presence of several 
peptides of different length.  
In order to find out, whether the last hypothesis is applicable, N-terminal Strep-tagged 
EGFP-HDGF isoform (-A/-B/-C) constructs were cloned as follows: EGFP coding 
sequence was amplified and cloned in frame to the Strep-tag into EcoRI/BamHI digested 
pEXPR vector. HDGF isoform specific sequences were inserted in frame to the Strep-
tagged EGFP into BamHI and HindIII digested pEXPR EGFP vector. 
Obtained constructs were transiently expressed in HepG2 cells. Cleared lysates were 
subjected to Western Blot analysis. Results are shown in figure 14. 
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Figure 14: N-terminally-tagged HDGF variants. HepG2 cells were transiently transfected with 
mammalian expression plasmids coding for N-terminally Strep-tagged EGFP-HDGF-A, HDGF-B 
and HDGF-C. Cells were lysed and respective cleared cell lysate were separated on 12 % SDS-
PAGE gels, transferred to PVDF membranes and probed with novel peptide antibodies anti 
HDGF-A (2) (panel 1a), anti HDGF-B (panel 1b), anti HDGF-C (panel 1c) or anti Strep-tag (panel 
2). Molecular mass marker lanes are shown on the left. 
The resulting constructs were detected at a molecular weight position of approximately 
70 kDa. Strep-tag antibody yielded in a signal for all three variants (figure 14, panel 2), 
proving their expression. The application of all three isoform specific antibodies led to the 
detection of a specific signal in the cell lysates containing the respective ectopically 
expressed N-terminally tagged isoform (figure 14, panel 1a-c). Several polypeptides 
were visible, indicating that degradation products were also present. 
Strikingly, HDGF-B-antibody was able to recognize the N-terminal tagged form (figure 
14, panel 1b) although it did not bind the N-terminally untagged HDGF-B variant in the 
previous experiment (figure 13, panel 2). Hence, the HDGF-B antibody is basically 
functional in Western blot analysis and able to bind the epitope. However, again an 
unspecific signal at approximately 20 kDa was visible after usage of HDGF-B specific 
antibody. This signal, which was present in all three cell lysate samples, was as 
prominent as the specific signal for the N-terminal EGFP tagged form.  
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3.1.5.2 Endogenous expression of HDGF isoforms 
The characterisation of the peptide antibodies (figure 13 & 14) clearly demonstrated that 
in principle all three antibodies (in case of HDGF A the peptide antibody 2, table 6) are 
capable of binding the corresponding transiently overexpressed HDGF isoforms. In case 
of HDGF-B the N-terminal part of recombinant protein must be tagged to allow its 
detection (figure 14).  
Moreover the isoform specific peptide antibodies were clearly able to distinguish between 
the three HDGF isoforms. In order to verify endogenous expression of the two novel 
isoforms HDGF-B and HDGF-C cell lysates from different cell lines (HaCat, MDA-MB-
231, MCF-7, HepG2, HeLa) were collected, subjected to Western blot analysis and 
tested for the presence of respective endogenously expressed HDGF isoforms by using 
the novel isoform specific antibody.  
Neither endogenously expressed HDGF-A nor HDGF-B and HDGF-C could be detected 
in any of the investigated cell lysates when probing the corresponding PVDF membranes 
with the three different peptide antibodies (data not shown). The results of the real-time 
qPCR analysis (figure 9) already indicated that HDGF-B and HDGF-C were only 
expressed at low levels in comparison to HDGF-A. Since a sufficient amount of protein 
must be available to allow detection in Western blot analysis, the low expression of 
HDGF-B and HDGF-C might be the reason why these two isoform could not be observed 
in the different cell lysates. However, in case of HDGF-A, endogenous expression should 
be sufficient to allow detection in Western blot analysis.  
In a further approach immunoprecipitation was performed by using the isoform specific 
antibodies as described in the section 2.1.9.4. Immunoprecipitation allows crude isolation 
as well as enrichment of the target protein and thus facilitates detection of low 
concentrated proteins.  
Confluent grown HepG2 cells were lysed, and obtained cell lysates were added to 
protein A beads followed by an incubation under rotary condition in order to pre-clear 
lysates. The pre-cleared cell lysates were mixed with respective isoform specific peptide 
antibodies (A, B, C) or with the anti pan-HDGF antibody (H in figure 15), which served as 
positive control. To precipitate the endogenously expressed protein, new protein A beads 
were added to the samples and samples were incubated over night. The obtained 
eluates, pre-clearing (precipitation without antibodies) as well as pan-HDGF antibody 
were loaded to 12 % SDS PAGE gel and were separated in SDS PAGE, transferred to 
PVDF membranes and probed with the respective antibodies. Results are shown in 
figure 15. 
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Figure 15: Immunoprecipitation of endogenously expressed HDGF-isoforms. As indicated 
above, immunoprecipitation was performed by using isoform specific peptide antibodies against 
HDGF-A (A), HDGF-B (B), HDGF-C (C) or goat anti pan-HDGF antibody (H) from HepG2 cell 
lysates. Immunoprecipitates (A, B, C, H), pre-clearing (PC) and 5 µg of pan-HDGF antibody (AB) 
were separated on 12 % SDS PAGE gels and electroblotted on PVDF membranes. HC = Heavy 
chain. Arrows point to HDGF isoforms. Membranes were probed with isoform specific antibodies 
against HDGF-A (1), HDGF-B (2), HDGF-C (3) and goat pan-HDGF antibody (4). Molecular mass 
marker lanes are shown on the left. 
The strong signals at a molecular weight position of 55 kDa, visible in all eluate fractions 
(A, B, C, H) and in the antibody sample (AB) (figure 15, panel 1-4), resulted from the 
presence of the antibody’s heavy chain (position is marked with HC), which was still 
present in the final eluate fractions. 
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In the eluates from immunoprecipitation with the isoform HDGF-C specific peptide 
antibody a signal at a molecular weight position of 37 kDa was obtained after 
immunodetection with isoform HDGF-C specific antibody (figure 15, panel 3) as well as 
with the anti pan-HDGF antibody (figure 15, panel 4). This position corresponded to that 
of untagged recombinant HDGF-C as shown in figure 11. Hence, the HDGF-C antibody 
was able to precipitate a protein with the expected size in SDS PAGE and, moreover, the 
antibody was able to detect this protein in the subsequent Western blot analysis (panel 
3), strongly suggesting that the antibody is able to bind directly to the respective protein. 
Since the anti pan-HDGF antibody was able to detect the same signal, the 37 kDa signal 
in the HDGF-C immunoprecipitate was indeed HDGF protein (panel 4). In the same 
immunoprecipitate two additional signals were present after detection with HDGF-C 
antibody at a position of 60 kDa and 70 kDa. Signals were not detected by the anti pan-
HDGF antibody. Therefore, these signals derived from a source which did not contain 
HDGF proteins. 
Conversely, immunoprecipitate obtained with anti pan-HDGF antibody, contained a 
protein at a position of 37 kDa in Western blot analysis, which could be detected by both 
antibodies (anti HDGF-C and anti pan-HDGF) accordingly (panel 3 & 4, IP H) (marked 
with an arrow). As shown before (figure 11), anti pan-HDGF recognized all three HDGF 
isoforms, thus, corresponding immunoprecipitates would contain all three isoforms on 
condition that all three isoforms were available in the cleared cell lysates.  
The characterisation of isoform specific peptide antibodies clearly showed that HDGF-C 
antibody discriminated between the different HDGF isoforms and was only able to react 
with ectopically expressed HDGF-C (figure 13). Due to this, the signal in goat anti pan-
HDGF immunoprecipitate detected by anti-HDGF-C clearly verified the presence of 
endogenously expressed HDGF-C. 
Of note, the pre-clearing (PC), which was collected before the antibody was added to the 
samples, did not exhibit any signals. Consequently, there was not any unspecific binding 
to the protein A beads. 
With regard to the isoform specific peptide antibody HDGF-A (2), the respective 
immunoprecipitate exhibited a weak signal at 55 kDa after detection with anti-HDGF-A 
(figure 15, panel 1, IP A). On the other side, the anti pan-HDGF antibody was also able 
to detect the signal in the immunoprecipitate of HDGF-A (panel 4). However, in the 
immunoprecipitates of goat anti pan-HDGF antibody such a 55 kDa signal could not be 
detected by the HDGF-A specific antibody (panel 1) as well as by the anti pan-HDGF 
antibody (panel 4). Furthermore, the size of 55 kDa did not correlate with the expected 
size of 37 kDa. Therefore, the antibody failed to precipitate and detect HDGF-A. 
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By contrast, the immunoprecipitation with HDGF-B yielded in several proteins, which 
were detected in the range of 70-100 kDa (panel 2) after probing the respective PVDF 
membrane with anti-HDGF-B. These signals could not be detected after using goat anti 
pan-HDGF antibody (panel 4) or were present in the corresponding immunoprecipitate 
(panel 2 & 4). Signals of the expected size of 38-40 kDa were not visible. 
In summary, endogenous HDGF-C expression could be verified. However, the other two 
antibodies, directed against HDGF-A and HDGF-B, were not able to precipitate the 
respective HDGF isoform. Instead they appeared to detect proteins of different sizes. 
Therefore, further characterisation of these antibodies is necessary to clarify the identity 
of the respective proteins. 
3.1.5.3 HDGF-C in human tissue extracts 
In the investigated human cell lines HDGF-C expression was low and detection was only 
possible when proteins were enriched by immunoprecipitation. To find a condition in 
which HDGF-C is upregulated, would help to understand the biological role of this 
isoform and support the relevance of this isoform. 
Because in the investigated human cell lines expressed HDGF-C only at very low levels, 
the primary aim was to see whether any condition is available which leads to detectable 
HDGF-C protein levels. Different human tissue extracts, kindly provided by Dr. 
Mirastschijski, were examined for the presence of HDGF-C. Since the different samples 
derived from different patients with different backgrounds, there is not any statistical 
relevance regarding the type of skin or tissue and which kind of illness it underwent. The 
samples were analysed by Western blot and the obtained result is shown in figure 16. 
Results  
 
60 
 
Figure 16: HDGF-C expression in human tissues. Tissue extracts were lysed in TNE buffer, 
homogenized and cleared by centrifugation at 12 000 x g. Same amounts of different human 
tissue extracts, obtained from different patients, were analysed by Western blot using isoform 
specific anti HDGF-C (panel 1), goat anti pan-HDGF (panel 2), anti-actin (panel 3). Tissue 
extracts (1-6) are described in the caption on the right site. Molecular mass marker lanes are 
shown on the left. 
In these samples the pan-HDGF antibody detected a main signal at a position of 37 kDa 
(figure 16, panel 1). Interestingly, in one sample (sample no 3) an additional double 
signal appeared at 40 kDa on the same membrane. Moreover, this double signal at 
40 kDa was also recognized by the isoform C specific antibody, whereas this antibody 
did not recognize the 37 kDa signal (figure 16, panel 2). Therefore, it is likely that that the 
detected polypeptide in sample number 3 was HDGF-C. However, the position of 40 kDa 
in the gel was slightly higher compared to the 37 kDa signals obtained from 
overexpression (figure 11) and immunoprecipitations (figure 15).  
3.2 Functional analysis and characterisation of HDGF isoforms 
Alternative splicing is a way to modulate properties and functions of proteins [145].This 
includes features such as altered protein binding properties [146, 147], intracellular 
localisation [148, 149], protein stability [150], or enzyme activities [151]. 
HDGF-B and HDGF-C might have complete different functions and biological roles 
compared to HDGF-A. To get a first impression about their functional roles, HDGF-B and 
HDGF-C were examined with regard to some of the known features of HDGF-A. 
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3.2.1 Transient overexpression of HDGF-A and -B promotes cell growth 
Numerous studies demonstrated that HDGF-A acts as mitogen and enhances 
proliferation of a wide variety of cells [1, 2, 17, 28, 50, 152]. It is suggested that this 
functional property of HDGF-A is associated with cancer development and progression 
[45, 152, 153]. Against this background it is important to investigate whether the novel 
isoforms HDGF-B and HDGF-C possess same abilities.  
Cos7 cells were transiently transfected with HDGF isoforms HDGF-A, HDGF-B, HDGF-C 
and with pcDNA3 as mock condition. To determine the effect of HDGF overexpression 
on cellular proliferation, BrdU proliferation assay was performed as described under 
method section (2.1.5.1). In this assay BrdU, a synthetic nucleotide analogon, was used. 
When provided, cells can incorporate BrdU instead of the cellular nucleotide thymidine 
during DNA synthesis. Antibodies specific for BrdU can detect the incorporated BrdU and 
thereby enable measurement of proliferation [154].  
The results of the BrdU proliferation assay are shown in figure 17. 
 
Figure 17: Overexpression of HDGF-A and -B enhances cell proliferation.  Cos7 cells were 
transiently expressed with vectors encoding HDGF isoforms HDGF-A, HDGF-B, HDGF-C (A, B, 
C) and empty vector (Mock). 24 h posttransfection under serum-free conditions cells were 
provided with nucleotide analogon BrdU for 6 h. As described under methods, cells were fixed, 
stained with anti-BrdU-POD, and incubated in substrate solution. Absorbance was measured at 
450 nm. Experiment was performed three times with each experiment consisting of 10 replicates. 
Data are given as the mean ± standard deviation (n=30). Analysis of significance of differences 
was performed by ANOVA, followed by the Bonferroni post hoc test ***P ≤ 0.005, compared to 
mock. 
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As shown already in other studies for other cell types [2, 17], HDGF-A overexpression 
yielded in an increase of Cos7 cell proliferation compared to the mock transfection 
(empty vector) (P≤0.005). Likewise, HDGF-B transient overexpression had a similar 
enhancing effect on Cos7 cell proliferation compared to the mock transfection. However, 
the overexpression of HDGF-C did increased cell proliferation, suggesting that unlike 
HDGF-A and HDGF-B this isoform was not able to promote cell synthesis. 
3.2.2 Chromatin association: HDGF-A and HDGF-C associate with chromatin 
Chromatin is a macromolecule complex, which consists of nucleic acids and variety of 
different proteins [155]. Majority of PWWP domain-containing proteins have the ability to 
bind to this complex structure [20] and thereby influence features or processes such as 
transcription activity [25], DNA architecture [156] or DNA methylation [157, 158]. 
Previous studies provided evidence that HDGF bears the potential to bind DNA [16, 25]. 
This binding property is mediated by the PWWP domain of HDGF [16, 25, 159]. 
Furthermore, the binding property appeared to be sequence specific since Yang et al. 
were able to identify a 39 bp DNA fragment as a specific target sequence for HDGF [25].  
As shown in the alignment (figure 7), HDGF-B and HDGF-C undergo remarkable 
changes in their N-terminal part, including the loss of the PHWP motif. In order to 
investigate whether these changes affect chromatin association, the chromatin-binding 
assay, adapted from Llano et al. [160] and Thakar et al. [49] with minor modifications, 
was performed (see section 2.1.5.2).  
This assay exploits the property that chromatin-bound proteins are not released after cell 
lysis with non-ionic detergents such as Triton X-100 [160, 161]. For this purpose a 
combined treatment with DNase and salt is necessary [160, 162]. A schematic depiction 
of the assay, including the collected fractions S1, S2, T, P1, P2, is shown in figure 18, 
panel I. The results of the chromatin-binding assay for the HDGF isoforms are presented 
in figure 18, panel II.  
Endogenous tubulin (panel II, 1b, 2b, 3b, 4b) served as internal control and its missing in 
the Triton-insoluble, nuclear fractions (P1, S2, P2) illustrated that there were no 
impurities caused by the S1 fraction containing Triton-soluble proteins (such as cytosolic 
proteins). Furthermore, to confirm assay specificity, ectopically overexpressed LaminB1-
Strep was utilized as second control. The respective Western blot (panel II, 5a) showed 
strong signals in the P1 and P2 fractions and a weak signal in the T fraction. This was in 
line with the expectations, since other studies demonstrated already that LaminB1 is a 
matrix bound protein [163] and therefore enriched in the nuclear insoluble, high salt 
resistant fraction [164]. 
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Figure 18: Chromatin-binding assay of HDGF-isoforms. Panel I: Schematic depiction of the 
chromatin-binding assay which is showing the collected fractions: T (total lysate), S1 (Triton-
soluble fraction), P1 (Triton-insoluble fraction: chromatin-bound, nuclear matrix-bound, insoluble 
proteins), S2 (chromatin-bound, DNase and high salt released fraction: chromatin-bound 
proteins), P2 (Triton-insoluble, DNase and high salt non-released fraction: insoluble, cytoskeletal, 
nuclear matrix protein). Panel II: HepG2 cells were transiently transfected with plasmids coding for 
HDGF isoforms HDGF-A-Strep (panel 1), HDGF-B-Strep (panel 2) and HDGF-C-Strep (panel 3) 
as well as for Snap-Strep (panel 4) and Lamin B1-Strep (panel 5). 24 h after transfection cells 
were lysed and the fractions were prepared as described under method section 2.1.5.2: 10 µg of 
each sample were loaded to 12 % SDS PAGE gel, separated and transferred to PVDF-
membranes. Membranes were probed with goat anti pan-HDGF (panel 1a, 2a, 3a), anti Strep-tag 
(panel 4a, 5a) or anti-tubulin (1b, 2b, 3b, 4b, 5b). Molecular mass marker lanes are shown on the 
left. 
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For HDGF-A the same signal distribution was obtained as shown already by Thakar et al. 
[49, 165]. HDGF-A was present in the Triton-soluble (S1) and Triton-insoluble fractions 
(P1, P2, S2) (figure 18, panel II, 1a). Treatment with DNase and high salt caused the 
release of majority of HDGF-A, thus it was detected in the S1 fraction. A smaller amount 
remained in the P2 fraction, which consisted of insoluble proteins such as matrix and 
cytoskeleton proteins.  
HDGF-C exhibited the same distribution (figure 18, panel II, 3a) as HDGF-A. Therefore, 
this protein was still able to bind to chromatin. Surprisingly, HDGF-B was found only in T 
and S1 fraction and was completely excluded from the Triton-insoluble fractions (P1, P2 
and S2 fractions) (figure 18, panel II, 2a). Consequently, HDGF-B lost the ability to bind 
to chromatin and was additionally absent the insoluble, DNase resistant, nuclear matrix 
fraction, although immunofluorescence analysis detected HDGF-B in the nucleus of 
Cos7 cells (figure 12). The analysis of Snap-Strep (figure 18, panel 4) protein 
demonstrated that the overexpression did not artificially lead to presence in the 
chromatin associated fractions. 
3.2.3 Protein-protein interaction of HDGF-isoforms 
The analysis of the interactome of a protein can provide insight into molecular functions 
and might help to understand the biological role. As mentioned in the beginning HDGF-A 
is known to interact with a wide number of different proteins [5]. Moreover, it has the 
ability to form homodimers [26].  
3.2.3.1 Homo- and Heterodimerisation of HDGF isoforms 
Many proteins are able to self-associate in order to form homodimers or even oligomers. 
Self-association is an important subgroup of protein-protein interactions and was proven 
for diverse functional proteins such as enzymes, transcription factors, or receptors. 
Accordingly, functional consequence of dimer or oligomer formation can be diverse [166]. 
HDGF belongs to this group of proteins. Sue et al. studied the underlying dimerisation 
mechanism and demonstrated that dimerisation depends on an unusual domain swap 
mechanism. This domain swap mechanism is mediated by the PWWP domain and 
results in a higher binding affinity to the glycosaminoglycan heparin [26]. Binding to 
heparin is known to be essential for the internalisation of HDGF and consequently 
cellular entry might be influenced [167].  
In addition to this, Thakar et al. suggested the presence of disulfide bridged homodimers 
via Cys108 in mouse HDGF [33]. In the HRP-family dimerisation was also proven for 
LEDGF but whether PWWP domain of LEDGF is involved in the dimer formation such as 
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shown for HDGF was not investigated [168]. Furthermore, HDGF and HRP-2 are able to 
interact with each other and thereby forming heterodimers [165]. 
To study the possible formation of HDGF isoform specific homodimers or heterodimers, 
the bimolecular fluorescence complementation (BiFC) assay was used which allowed the 
investigation of protein-protein interactions in the living cell. The principle of the assay, 
depicted in figure 19 (panel I), based on the formation of a functional fluorescent EYFP 
protein complex when non-functional N-terminal and C-terminal fragments of EYFP are 
brought in close proximity. This occurs when two interaction partners, each fused to one 
part of EYFP, associate with each other [169].  
 
Figure 19: BiFC assay. Panel I: Schematic diagram of the BiFC assay. The non-functional N-
terminal and C-terminal fragment of EYFP are fused to the potential interaction partners A and B. 
Interaction of A and B enables the formation of a biomolecular fluorescent EYFP complex. 
Panel II: COS-7 cells were co-transfected with plasmids coding for the different EYFP fragment 
fusion constructs of HDGF-A, -B and -C or with the non-fused EYFP fragments as indicated at the 
sites. BiFC was performed for visualisation of HDGF isoform interactions. EYFP fragment 
complementation signals were detected 30 min after exposure to 30 °C and visualised by 
fluorescence microscopy. DAPI was used for nuclear staining. Scale bar = 10 µm (right corner). 
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For this assay the three isoforms HDGF-A, -B and -C were fused to the N-terminal or C-
terminal fragment of EYFP. The result of the BiFC assay is shown in figure 19, panel II. 
The BiFC assay revealed that all HDGF isoforms appeared to be able to form 
homodimers since respective combinations resulted in a positive nuclear EYFP signal.  
Furthermore, heterodimerisation between the different HDGF isoforms seemed to be 
possible as well because respective combinations showed also a positive EYFP signal. 
Interestingly, combinations with HDGF-A resulted in a more homogenously distributed 
nuclear signal compared to the HDGF-B/ HDGF-C combination where the respective 
signal appeared more condensed. 
3.2.3.2 Interaction with other proteins 
The analysis of potential interaction partners can provide insights into the biological role 
of the respective protein.  
HDGF-A is able to interact with a wide variety of proteins suggesting that HDGF might 
have functions in different cellular processes. The multi-interactome study by Zhao et al. 
revealed the presence of at least 106 interactions partners [5]. Proteins participate in 
cellular processes such as RNA splicing, ribosome biogenesis, chromatin remodelling or 
DNA repair. Most interestingly, interaction depends mainly on the N-terminal hath region 
of HDGF. Since alternative splicing leads to the changes in the hath region, the question 
raised how these resulting changes in the hath region affect the interaction properties of 
the novel isoforms HDGF-B and HDGF-C.  
3.2.3.2.1  Identification of putative interacting proteins of HDGF-B and HDGF-C in 
co-precipitates 
To study whether the unique N-terminal parts of the isoforms have an impact on protein-
protein interactions, the C-terminally Strep-tagged HDGF isoforms were transiently 
overexpressed in HepG2 cells. Strep-tagged proteins were precipitated from the cleared 
lysate using StrepTactin coated beads. Respective eluates were separated by SDS-
PAGE and, in order to visualise potential co-precipitated interaction partners, gels were 
stained with Coomassie stain. The respective recording of the gel is shown in figure 20 
(panel 1). 
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Figure 20: HDGF isoforms associate with different proteins. HepG2 cells were transiently 
transfected with a plasmid coding C-terminally Strep-tagged HDGF isoforms ( -A, -B, -C) or empty 
vector (con). After 24 h incubation cells were lysed and HDGF-Strep variants were precipitated 
using StrepTactin beads. Precipitates and an aliquot of the respective cleared lysate (input) were 
separated by SDS-PAGE. Panel 1: MALDI-TOF MS analysis was performed from selected protein 
bands excised from the Coomassie stained SDS-PAGE gel and subjected to in-gel trypsin 
digestion. Identified co-precipitated proteins in SDS-PAGE gel are marked by numbered spots. 
Caption below lists the identified proteins with the respective number. 2) Subsequent to SDS 
PAGE, samples were transferred to PVDF membranes and PVDF membranes were 
immunodetected using indicated antibodies: anti-nucleolin (panel 2a), anti-YB-1 (panel 2b), anti-
tubulin (panel 2c), anti-actin (panel 2d), anti-vimentin (panel 2e), anti-dynein (panel 2f), anti-
kinesin antibody (panel 2g), anti-Hsc70 (panel 2h), respectively. To detect Strep-tagged HDGF 
isoforms anti Strep-tag antibody was used. Molecular mass marker lanes are indicated on the left. 
The staining of the gels revealed a complex banding pattern, especially for HDGF-A and 
HDGF-C (figure 20, panel 1). In accordance to the multi-interactome study of Zhao et al. 
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[5], the co-precipitates of HDGF-A but also of isoform HDGF-B and HDGF-C exhibited 
multiple bands, indicating the presence of various putative interaction partners. Some 
bands occurred in all three precipitates while others were only identified in one or two 
precipitates. Thus, interaction pattern varied from each other. This demonstrated that 
alteration in HDGF-B and HDGF-C influences at least partly the interactions to proteins. 
To identify possible interaction partners, stained bands were excised from the gel and 
subjected to MALDI-TOF MS based peptide analysis (complete MALDI-TOF results can 
be found in the appendix, table A1). Respective excised bands are marked with a spot in 
figure 20, panel 1. Main information about the identified proteins is listed in table 7. 
Table 7: Co-precipitated proteins identified by MALDI-TOF MS.  Spot number and 
corresponding protein as well as Swiss Prot ID number, main function and molecular weight are 
listed. 
Spot 
no. 
Identified in 
co-precipitate 
of HDGF 
Identified 
protein 
Swiss 
Prot ID 
Function 
Molecular 
weight 
(kDa) 
1 A, B, C 
heat shock 
cognate 71 kDa 
(Hsc70) 
P11142 chaperone 70.9 kDa 
2 B, C tubulin alpha 1C Q9BQE3 
constituent of 
microtubules 
49.9 kDa 
2 B, C 
tubulin alpha-8 
chain 
Q9NY65 
constituent of 
microtubules 
50.1 kDa 
2 B, C 
tubulin beta 
chain 
P07437 
constituent of 
microtubules 
49.7 kDa 
3 A 
Y-box binding 
protein (YB-1) 
P67809 
DNA/RNA 
binding factor 
35.9 kDa 
4 C 
actin, 
cytoplasmic 1 
P60709 
cytoskeletal 
protein 
41.7 kDa 
5 A, B, C 
ADP/ATP 
Translocase 2 
P05141 antiporter 32.9 kDa 
6 A 
60S ribosomal 
protein L6 
Q02878 
ribosomal 
protein 
33.4 kDa 
 
All three isoforms co-precipitated heat shock cognate 70 (Hsc70) and ADP/ATP 
translocase 2. ADP/ATP translocase 2 has been already reported as interaction partner 
of HDGF-A by Zhao et al. [5].  
In the co-precipitate of HDGF-B and -C a prominent band was visible at approximately 
55 kDa. Subsequent MALDI-TOF-MS analysis revealed that these bands contained α- 
and β-tubulin. As a further cytoskeleton protein actin was found at around 40 kDa 
exclusively in the HDGF-C precipitate. Both cytoskeletal proteins have not been 
described as human HDGF interacting proteins before. 
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In addition to this, only HDGF-A co-precipitated the Ybox binding protein (YB-1), a 
protein which was described to be involved in a variety of DNA/RNA dependent 
processes [170]. Furthermore, the 60S ribosomal protein L6 was identified in the eluate 
of HDGF-A, which is a component of the 60S ribosomal subunit. Several other 
components of ribosomes were already discovered in the interactome of HDGF-A [5]. 
To affirm the identified interaction partners, HDGF co-precipitates were further analysed 
by Western blot using antibodies directed against tubulin, actin, Hsc70 and YB-1 (figure 
14, panel 2). 
In line with MALDI-TOF-MS results, Hsc70 could be detected in all three HDGF isoform 
precipitates (panel 2h). By contrast, YB-1 was only present in the precipitate of HDGF-A 
(panel 2b). Precipitates were examined also for the presence of nucleolin, an already 
known interaction partner of HDGF-A [5, 123]. Interestingly, HDGF-B and HDGF-C did 
not co-precipitate this nuclear protein. 
Strikingly, α-tubulin could be detected in the precipitates of HDGF-B and HDGF-C 
whereas it was completely absent in the precipitate of HDGF-A (panel 2c). Furthermore, 
the microfilament protein actin was only precipitated by HDGF-C (panel 2d). 
Due to the finding that tubulin and actin were able to interact with the novel HDGF 
isoforms, precipitates were analysed by Western blot for the presence of other proteins 
of the cytoskeleton. Vimentin as a representative of the intermediate filaments [171] as 
well as dynein and kinesin as tubulin-dependent motor proteins [172] were selected. 
Also the intermediate filament vimentin could be detected only in the HDGF-C precipitate 
(panel 2e). Furthermore, HDGF-B and HDGF-C co-precipitated the motor protein dynein 
but not kinesin (panel 2f and 2g). 
In all cases the control precipitate (panel 2a-2i, con), obtained from Strep-precipitation 
with mock transfected lysates, did not exhibit the corresponding signal, indicating no or 
only low unspecific binding. 
To further validate the association of HDGF-C with tubulin and dynein, co-
immuoprecipitation with endogenously expressed HDGF-C was performed. HepG2 cells 
were lysed, and cleared lysates were incubated with HDGF-C antibody. 
Immunoprecipitation was performed by using protein A sepharose beads. Obtained 
samples were analysed by subsequent Western blot and the results are shown in figure 
21. Similar experiments for HDGF-B and HDGF-A could not be performed due to the 
missing of appropriate antibodies. 
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Figure 21: Co-Immunoprecipitation of HDGF-C Co-immunoprecipitation was performed from 
cleared HepG2 lysates using the HDGF-C antibody as described in the method section. Obtained 
immunoprecipitates (IP C), pre-clearing (PC) and 10 µg anti HDGF-C antibody (Ab) were 
separated on 12 % SDS PAGE gels, transferred to PVDF membranes. Membranes were 
incubated with anti-dynein (panel 1), anti-tubulin (panel 2) or goat anti pan-HDGF (panel 3). The 
asterisk (*) indicates the co-precipitated tubulin. Molecular mass marker lanes are indicated on 
the left. 
The results of the immunoprecipitation from an endogenous expressing source (HepG2 
cells) (figure 21) supported the previous result obtained with ectopically expressed 
protein (figure 20). 
Endogenous HDGF-C was able to co-precipitate dynein (panel 1) as well as tubulin 
(panel 2). Due to the similar running behaviour of heavy chain and tubulin, the tubulin 
signal (marked with an asterisk) could not be further separated from the heavy chain 
signal. Pre-cleared samples did not show any corresponding signal, indicating that there 
was not any unspecific binding to the protein A beads.  
Since HDGF-A was not able to co-precipitate dynein or tubulin (figure 20), this result 
confirmed once more, that the HDGF-C specific antibody did precipitate HDGF-C. 
3.2.3.2.2 N-terminal peptide of HDGF-A determines interaction behaviour 
As shown in the previous chapter, HDGF-B and HDGF-C exhibited a quite different 
interaction behaviour compared to that of HDGF-A. Nucleolin and YB-1, which interact 
with HDGF-A, were not co-precipitated by HDGF-B or HDGF-C. In contrast, the co-
precipitated tubulin and dynein could not be co-precipitated by HDGF-A.  
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The alignment of HDGF isoforms (figure 9) revealed that there were not any obvious 
similarities between the altered N-termini of HDGF-B and HDGF-C and moreover, 
similarities were only present in that part, which is also present in HDGF-A. From this 
point of view it is surprising that HDGF-B and -C interacted with the same proteins, 
although these particular proteins could not be found in the interactome of HDGF-A. In 
addition, with regard to the interacting proteins of HDGF-A, they also lost the same 
interaction partners. 
However, both miss the first N-terminal amino acid residues of HDGF-A. Therefore, the 
differences in the interaction pattern to HDGF-A might depend rather on the loss of the 
respective peptide as on the altered N-termini. To study this, a truncated HDGF-A 
variant, deleted in the first N-terminal 15 amino acid residues (NΔ15) [33] was subjected 
to StrepTactin precipitations as described before. Obtained results are shown in figure 
22, panel 1. 
 
Figure 22: N-terminal peptide determines interaction behaviour of HDGF. HepG2 cells were 
transiently transfected with plasmids encoding C-terminal Strep-tagged HDGF-A, HDGF-B and 
HDGF-C; an N-terminally truncated HDGF-A variant (NΔ15), which was deleted in the first 15 N-
terminal amino acid residues, as well as constructs containing the first 30 (N30), 15 (N15), 10 
(N10) N-terminal amino acid residues of HDGF-A followed by a SNAP-Strep sequence (see 
section 2.2.7). Cleared lysates were subjected to StrepTactin co-precipitation. Eluates were 
analysed by Western blot using antibodies against nucleolin (panel 1a & 2a), YB-1 (panel 1b), 
tubulin (panel 1c), pan-HDGF (panel 1d) and Strep-tag (panel 2b). Marker lanes are indicated on 
the left. 
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Strikingly, the co-precipitates of NΔ15 HDGF-A variant (figure 22) resembled that of 
HDGF-B and HDGF-C (figure 20). NΔ15 HDGF-A lost almost completely its ability to co-
precipitate nucleolin (panel 1, 1a) and YB-1 (panel 1, 1b). By contrast, it was capable to 
co-precipitate tubulin (panel 1d). 
Consequently, deleting the first 15 amino acid residues of HDGF-A was sufficient to 
change the interaction pattern referring to tubulin, YB-1 and nucleolin. However, the first 
N-terminal amino acid residues of HDGF-A were not sufficient to mediate interaction to 
nucleolin or Yb-1 alone, as shown in figure. 22, panel 2. Corresponding eluates of the 
constructs, containing either the first 10 (N10), 15 (N15) or the first 30 (N30) amino acid 
residues of HDGF-A, did not exhibit a signal for the mentioned proteins. 
3.2.3.2.3 RNA dependent interaction of HDGF-A to nucleolin and YB-1 
The interaction of HDGF-A and nucleolin depends on RNA association [123]. Like 
nucleolin YB-1 has RNA binding properties and participates in RNA related processes 
such as transcription and splicing or regulation of mRNA stability [170]. Furthermore, in 
both cases the outermost N-terminal amino acid residues of HDGF-A were essential for 
the association as shown in figure 22 and in addition, the novel isoforms HDGF-B and -C 
failed to co-precipitate both proteins. 
Due to these parallels between nucleolin and YB-1, the association of YB-1 and HDGF-A 
might follow a similar RNA dependent interaction pattern as observed for HDGF-A and 
nucleolin. To test this, the protocol from Bremer et al. [123] was adapted by which 
lysates from Strep-tagged HDGF-A expressing cells were pre-treated with RNase A 
followed by StrepTactin co-precipitation. Resulting eluates were analysed by Western 
blot for the presence of YB-1 as well as nucleolin, which served as positive control. 
Corresponding results are shown in figure 23. 
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Figure 23: RNA dependent interaction of HDGF-A and YB-1. HepG2 cells were transiently 
transfected with C-terminally Strep-tagged HDGF-A. Cleared lysates were incubated in the 
presence as well as in the absence of RNase A over night followed by StrepTactin precipitation as 
described under section 2.1.9.5. Obtained precipitates were analysed by Western blot using anti-
YB-1 (panel 1), anti-nucleolin (panel 2) or anti Strep-tag antibody (panel 3). Molecular mass 
marker lanes are indicated on the left. 
Pre-treatment with RNA led to an apparent loss of co-precipitated YB-1 (figure 23, panel 
1) as previously shown for nucleolin [123] (panel 2). This result strongly suggested that 
YB-1 – HDGF-A complex formation depended also on the presence of RNA.  
3.2.3.2.4 HDGF-C and its co-localisation with other proteins 
To investigate further the putative interaction of HDGF-C with elements of the 
cytoskeleton (figure 20 & figure 21), immunofluorescence analysis was performed to 
observe potential co-localisations of endogenously expressed HDGF-C with some of the 
putative interaction partners.  
Therefore, human dermal fibroblasts were fixed and permeabilized as described in the 
method section (2.1.4). Cells were treated with HDGF-C specific antibody in combination 
with further antibodies, directed against following proteins of interest: nucleolin, Yb-1, 
tubulin, actin, vimentin, kinesin and dynein. Obtained images are represented in figure 
24. 
Results  
 
74 
 
Figure 24: Co-localisation of HDGF-C with dynein and tubulin.  For immunofluorescence 
analysis human dermal fibroblast were fixed and permeabilized as described in the method 
section. Cells were incubated with anti HDGF-C (panel I A-H, red) in combination with monoclonal 
anti-HDGF H3 (panel II B, green), anti-nucleolin, (panel II B, green) anti-YB-1 (panel II C; green), 
anti-actin (panel II D, green), anti-vimentin (panel II E, green), anti-tubulin (panel II F), anti-dynein 
(panel II G, green) and anti-kinesin (panel II H, green). Cells were counterstained with DAPI 
(panel III, A-H). Panel IV (A-H) shows the superposition of the red, blue and green signals. Insets 
display zoomed views of the indicated area. Scale bars: 10 µm (right corner). 
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HDGF-C was detected in nucleus as well in the cytoplasm of cells (figure 24, panel I, A-
H). Its endogenous appearance resembles that obtained after ectopically overexpression 
(figure 12). However, the dominant nuclear staining as observed after overexpression 
was not that pronounced in the images of endogenous HDGF-C.  
The cytoplasmic staining revealed granules-like structures. Staining with a monoclonal 
pan-HDGF antibody (H3) resulted in a predominant nuclear staining and very weak 
cytoplasmic staining (panel II, A), which is in line with the observation of numerous other 
studies [3, 17, 29]. Considering the huge dominance of HDGF-A towards HDGF-B and 
HDGF-C in dermal fibroblasts (figure 9), the monoclonal pan-HDGF antibody detected 
most probably mainly HDGF-A in the specimen. Nevertheless, co-localisation of signals 
obtained with isoform specific antibody and pan-HDGF antibody could be observed 
mainly in the nucleus (panel IV, A). 
According to the results obtained from co-precipitations (figure 20) HDGF-C is able to 
interact with the cytoskeleton proteins actin, vimentin and tubulin and not with the nuclear 
proteins Yb-1 and nucleolin. As expected, a co-localisation of HDGF-C with YB-1 (figure 
24 panel IV, C) or nucleolin (panel IV, B) was not detected. Co-staining of HDGF-C with 
actin and vimentin revealed that HDGF-C did not really co-localise with vimentin (panel 
IV, E) and actin (panel IV, D), although the analysis of the co-precipitates would suggest 
this. Co-staining with tubulin (panel IV, F) demonstrated that the granule-like structures 
of HDGF-C superimposed on the tubulin network (panel IV, F).Furthermore, a strong co-
localisation was observed when cells were stained with HDGF-C antibody and dynein 
antibody (panel IV, G). By contrast, the motorprotein kinesin did not co-localise 
considerably with HDGF-C (panel IV, H) which corresponded to the previous obtained 
results of the co-precipitations (figure 20). 
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3.3 The secretion of HDGF 
HDGF was originally identified as secreted factor from the conditioned medium of the 
hepatocellular carcinoma cell line Huh-7 [1]. Also other studies demonstrated that HDGF 
is present in the secretome of different cell types such as endothelial cells [37], neural 
stem cells [55], glioblastoma cells [55] or skeletal muscle cells [78]. These data refer to 
HDGF-A, whether the two novel HDGF isoforms HDGF-B and HDGF-C are secreted is 
not known. 
Proteins secreted via classical secretion pathway require an N-terminal signal peptide 
leader sequence, which spans the first N-terminal 16-30 amino acid residues [90, 173]. 
This sequence mediates the transfer into the ER. In this cellular compartment the protein 
is folded and modified before it is secreted into the extracellular space via exocytosis 
[174].  
A typical secretion signal sequence consists of some positively charged amino acid 
residues, a central hydrophobic region of 6-12 amino acid residues followed by more 
polar C-terminal part which contains the cleavage site [173]. The N-terminal sequence of 
the HDGF isoforms does not contain such a long hydrophobic as depicted in table 8.  
Table 8: N-terminal amino acid Sequences of HDGF-A, -B and -C does not contain 
a signal sequence: The first 33 N-terminal amino acid residues of each isoform are given as 
single letter code. Hydrophobic/unpolar amino acid residues are coloured red, basic amino acid 
residues are blue, acidic amino acid residues are green and neutral/polar amino acid residues are 
black. SignalP 4.1 prediction tool was used with default settings to estimate the probability of 
signal sequence for the isoforms. The calculated D-score (discrimination score) was in each case 
below the default cut-off value of 0.45, thus, sequences did not contain signal peptides. 
Isoform N-terminal Sequence D-score Signal?  
HDGF-A MSRSNRQKEYKCGDLVFAKMKGYPHWPARIDEM33 0.107 no 
HDGF-B MHPEGGQFVPQLLGHLLATKLKRFLLSKGGRRA33 0.272 no 
HDGF-C MEQRAGGNRVQTSTLNCAGAAVIDEMPEAAVKS33 0.126 no 
 
The analysis of the three HDGF sequences by the use of the prediction tool SignalP 4.1 
(http://www.cbs.dtu.dk/services/SignalP) [175], an online tool which is able to predict 
signal sequences in proteins, supported the notion. The discrimination-scores (D-score) 
obtained with SignalP 4.1 were 0.107 (HDGF-A), 0.207 (HDGF-B) and 0.126 (HDGF-C) 
deceeding considerably the default cut-off value of 0.45. Therefore, HDGF isoforms are 
not likely secreted via the ER/Golgi pathway. The corresponding Signal IP outputs are 
shown in the appendix (A1-A3).  
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3.3.1 Time dependent secretion of HDGF isoforms 
Thakar et al. demonstrated that the first 11 amino acid residues of HDGF-A play an 
essential role in the unconventional HDGF-A release. N-terminally truncated HDGF-A 
proteins, missing this specific peptide sequence, were not present in the conditioned 
media 24 h after ectopic overexpression while the full length form can be detected at the 
same time [33]. Interestingly, N-terminal truncation of the first 12-21 amino acid residues 
(exact number could not be determined) can be induced by exchanging the putative 
phosphorylation site Ser165 to an Ala [33].  
HDGF-B and HDGF-C do not possess this HDGF-A specific N-terminal peptide, which 
mediates the secretion of HDGF-A. This led to the question whether HDGF-B and 
HDGF-C are secreted or whether they remain in the cell like observed for other truncated 
HDGF-A forms [33]. 
In order to address this question HepG2 cells were transiently transfected with respective 
plasmids encoding HDGF-A, HDGF-B and HDGF-C as well as with the Ser165 to Ala 
mutant of HDGF-A, termed HDGF-A S165A in the following. The conditioned media was 
collected to different time points (8 h, 20 h, 26 h, 30 h, 44 h after transient transfection) 
and acetone precipitated to concentrate the protein content. In order to detect the 
presence of HDGF variants these samples were subjected to Western blot analysis. The 
results of Western blot analysis are shown in figure 25. 
Proteins can also be released passively when cells lose their membrane integrity as a 
consequence of cell death. In order to exclude this possibility, extracellular LDH activity 
was monitored in each supernatant as indicator for leakage [120]. The corresponding 
LDH values are given below the corresponding Western blots (figure 25). In all cases the 
activity was below 5 %, indicating that the loss of membrane integrity was low. 
Since a goat anti pan-HDGF antibody was used, there was of course the possibility of 
background staining due to the presence of endogenous HDGF. However, HepG2 cells 
did not release endogenously expressed HDGF isoforms in such amounts, that it was 
detectable in Western blot analysis. Therefore, background staining caused by 
endogenous HDGF could be excluded in the supernatant samples. 
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Figure 25: Secretion of HDGF isoforms and HDGF-A S165A. HepG2 cells were transiently 
transfected with plasmids encoding HDGF isoforms HDGF-A (panel 1), HDGF-B (panel 2), 
HDGF-C (panel 3) or the HDGF-A S165A (panel 4). Over the course of time supernatants (SN) 
were collected from the transfected cells at the indicated time points (8 h, 20 h, 26 h, 30 h, 44 h). 
Finally cells were lysed. Supernatants (SN) (panel I) and cell lysates (CL) (panel II) were 
separated on 12 % SDS PAGE gels and transferred to PVDF-membranes. Membranes were 
probed with goat anti pan-HDGF. Molecular mass marker lanes are indicated on the left. As 
described under method section 2.1.7 extracellular LDH activity was determined in each collected 
SN and is given below the corresponding Western blot. Data (given in % of total extracellular 
LDH) represent the means ± standard deviations for triplicate assays. 
HDGF-A could be detected after 20 h incubation time (panel 1), a timeframe that was not 
sufficient to detect the other HDGF forms in the conditioned media (panel 2-4). Isoform 
HDGF-B (panel 2) and mutant HDGF-A S165A (panel 4) could not be detected after 44 h 
either. HDGF-C (panel 3) was present in the incubation medium in detectable amounts 
after 30 h but signals were weaker compared to HDGF-A.  
The analysis of the respective cell lysates demonstrated that all proteins were ectopically 
expressed (panel II). 
3.3.2 DMA inhibits secretion of HDGF-A, HDGF-C and endogenous HDGF 
Since HDGF-A and HDGF-C did not contain a secretion peptide (table 8) but could be 
detected in the surrounding media of cells (figure 25), the question remained open how 
these proteins leave the cell. 
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Several alternative secretion pathways have been described in literature, which are 
independent from the ER/Golgi route [92]. To identify the putative secretion pathway, 
initial experiments were performed using different inhibitors that interfere with different 
alternative secretion pathways (Kappelmann, unpublished data). Interestingly, when 
transiently transfected Cos7 cells were treated with DMA, recombinant HDGF-A release 
was significantly decreased. 
The drug DMA inhibits Na+/H+ exchanger and Na+/Ca2+ exchanger [176]. Furthermore, it 
was reported that treatment of cells with DMA reduces the release of exosomes probably 
caused by a decrease of intracellular Ca2+ levels [177].  
To verify the effect of DMA on HDGF-A secretion and to see whether the drug DMA 
inhibits also the secretion of ectopically expressed HDGF-C, similar inhibitor experiments 
were performed in the present work. Since ectopically expressed HDGF-B and HDGF-A 
S165A could not be detected in the surrounding media after 40 h (figure 25, panel I.2 & 
I.4, respectively), these proteins were excluded from the following inhibitor experiments.  
HepG2 cells were transiently transfected with a plasmid encoding HDGF-A, HDGF-C or 
Luciferase-Strep, which served as control protein in this experiment. The gaussia 
Luciferase-Strep construct contained an artificial classical N-terminal signal peptide and 
therefore was released from cells into the extracellular space by the ER/Golgi driven 
secretion pathway. 
Furthermore, the effect of DMA on endogenously expressed HDGF isoforms was 
examined. Since endogenous HDGF could not be found in the surrounding media of 
HepG2 cells, this cell type was inappropriate for this experiment. Instead, HeLa cells 
were selected because prior experiments revealed that endogenous HDGF could be 
detected in their conditioned media after 40 h incubation.  
As mentioned before, the new identified isoforms have a similar molecular weight and a 
similar running behaviour in Western blot analysis. For the following analysis a goat anti 
pan-HDGF antibody was used, which is able to recognize all three HDGF isoforms 
(figure 11). Consequently, the following analysis did not reveal which endogenous HDGF 
isoform was detected in the supernatants from HeLa cells. Therefore, in these cases the 
term “HDGF” was used and the isoform A/B/C was not further specified. 
To exclude the possibility that HDGF proteins were passively released into the 
extracellular space, the extracellular LDH activity was determined simultaneously. Values 
are given below the respective Western blots images (figure 26). 
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Figure 26: Inhibitory effect of DMA on HDGF Secretion. HepG2 cells were transiently 
transfected with plasmids encoding HDGF-A (panel 1), HDGF-C (panel 3) or control protein 
Luciferase-Strep (panel 2) with an additional N-terminally added secretion signal peptide. 4 h after 
transfection, serum was changed to serum free medium and cells were incubated in the presence 
of the indicated inhibitors (see methods section), or with respective solvents DMSO or EtOH; con 
(control, no treatment). In case of endogenous HDGF, HeLa cells were incubated (panel 4) in 
medium containing DMA or the solvent DMSO. After 24 h (HDGF-A; Luciferase-Strep) or 42 h 
(HDGF-C; non-transfected HeLa cells) supernatants (SN) were collected. Cleared cell lysates 
(CL) and acetone precipitated SN were analysed by Western blot using anti pan-HDGF antibody. 
Molecular mass marker lanes are indicated on the left. As indicator for cell viability extracellular 
LDH activity was determined in each supernatant. Values from triplicate measurements are given 
as mean in % of total LDH ± standard deviation. 
DMA treatment decreased the release of ectopically expressed HDGF-A (figure 26, 
panel 1a). Furthermore, Western blot analysis of corresponding total cell lysates (panel 
1b) demonstrated that transfection was successful in each case and protein levels were 
in a similar range.  
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In contrast to DMA, Monensin (Mon), a well known inhibitor of the ER/Golgi mediated 
secretion pathway [178], did not result in lower amounts of extracellular HDGF-A (panel 
1a). Indeed, Mon even increased the level of extracellular HDGF-A. At the same time the 
corresponding solvent of Mon ethanol (EtOH) did not influence secretion levels of HDGF-
A and the detected extracellular HDGF-A signals were comparable to that of the control. 
In each case the intracellular protein level remained also here constant, as shown by the 
Western blot analysis of the cleared lysates (panel 1b).  
The measured extracellular LDH activity (given below the corresponding Western blots) 
was in a similar low range, indicating that the putative passive release was comparably 
low in each sample. 
In order to confirm that DMA did not influence secretion of proteins, which were exported 
via the classical secretion pathway, HepG2 cells were transiently transfected with a 
plasmid encoding Strep-tagged gaussia Luciferase (panel 2). The Western Blot analysis 
of the supernatants (panel 2a) demonstrated that Mon was indeed able to inhibit the 
ER/Golgi driven secretion of Luciferase-Strep, the corresponding signals were 
considerably lower compared to the control sample. In contrast to this, DMA treatment 
did not reduce Luciferase secretion and the corresponding protein signal was 
comparable to that of the control. At the same time inhibitor treatment did not have any 
significant impact on the intracellular protein levels (panel 2b). 
Like HDGF-A secretion also HDGF-C secretion could be decreased by treating the 
transiently transfected cells with DMA. The respective Western blot (panel 3a) showed 
that the signal was weaker compared to that of the control. Simultaneously, the solvent 
DMSO did not reduce secretion of HDGF-C. Worthy of note, the DMA-induced decrease 
of HDGF-C release was not as strong as observed for HDGF-A.  
Also the effect of Mon on HDGF-C release was studied. But majority of cells died after 
40 h incubation in presence of this inhibitor, leading to unreliable results. Thus, this 
experiment was excluded from the results. 
In order to see whether DMA is able to decrease the secretion of endogenous HDGF, 
HeLa cells were incubated in presence of DMA or DMSO for 40 h (non-transfected, 
panel 4a). DMA treatment reduced HDGF release. Hence, observed DMA effect was not 
an artificially induced phenomenon only observed for transiently over-expressed HDGF 
proteins. However, due to longer incubation times the extracellular LDH values were 
slightly increased in these samples.  
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3.3.3 The presence of HDGF in extracellular vesicles 
3.3.3.1 Presence of HDGF isoforms and HDGF-A S165A in extracellular 
vesicles 
The inhibitory studies demonstrated that DMA treatment led to a reduction of HDGF-A, 
HDGF-C and of endogenous HDGF release (figure 26). Since DMA was shown to 
decrease exosome release [177], the observed effect provided indication that those 
proteins might be released via the exosome mediated pathway.  
Exosomes are commonly isolated on basis of their size by a centrifugation protocol 
involving several centrifugation steps at different velocities [105]. The respective protocol 
is depicted in figure 27 (panel I). It is necessary to consider that the separation is not 
leading to an absolutely pure exosome fraction. Apoptotic blebs and shedding 
microvesicles, both extracellular vesicles which derive from the plasma membrane and 
not from the endosomal compartment, can be still present. In general these vesicles are 
greater than exosomes and therefore sediment already at velocities of 10 000 x g. But 
since apoptotic blebs and shedding microvesicles are very variable in size and shape, it 
is possible that subfractions of smaller size are present, which does not sediment at 
10 000 x g and therefore can be found in the exosome fraction [99, 179].  
In order to examine whether HDGF-A and HDGF-C are present in exosome-enriched 
fraction, HepG2 cells were transiently transfected with plasmids encoding respective 
HDGF constructs and isolated the corresponding exosomes. Although HDGF-B and the 
HDGF-A mutant HDGF-A S165A could not be identified in the conditioned media, these 
variants and the possible presence in extracellular vesicles were studied as well. 
Samples were analysed by Western blot analysis using pan-HDGF antibody and 
antibodies against exosomal proteins CD63 and actin. Results are shown in figure 27 
(panel II). 
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Figure 27: HDGF isoforms in exosome-enriched fractions. HepG2 cells were transiently 
transfected with plasmids encoding HDGF isoforms HDGF-A, HDGF-B, HDGF-C and HDGF-A 
S165A. After 40 h incubation in serum free medium, cell culture medium was collected. Exosomes 
were enriched as described under method section 2.1.8.1 and as depicted in panel I. During each 
centrifugation step aliquots of the supernatants were collected (SN1-SN5) and concentrated by 
acetone precipitation. SN1-SN5 and exosome-enriched fraction (Ex) were separated on 12 % 
SDS PAGE gels, transferred on PVDF membranes and probed with goat anti pan-HDGF (panel II 
1a, 2a, 3a, 4a), anti-CD63 (panel II 1b, 2b, 3b, 4b) or anti-actin (panel II 1c, 2c, 3c, 4c) as 
indicated on the right. Molecular mass marker lanes are shown on the left.  
HDGF-A could be detected in all supernatants as well as in the exosome-enriched 
fraction (figure 27, panel II, 1a). During the centrifugation protocol supernatants were 
collected (SN1- SN5) after each centrifugation step. SN5 was that fraction, which was 
collected after the sedimentation of exosomes as depicted in panel I. Consequently, 
SN1-SN4 contained exosomes. However, a significant decrease in the HDGF-A signal 
intensity due to a putative exosome depletion in SN5 was not observe. Furthermore, the 
HDGF-A signal in the exosome fraction was significantly weaker compared to those in 
the concentrated supernatants. 
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CD63, a family member of the tetraspanin family, is highly abundant in exosomal 
membranes [107]. Due to this CD63 immunodetection served as positive control for the 
presence of exosomes. The core protein CD63 has a molecular weight of 26 kDa, due to 
high glycolysation the actual molecular weight ranges from 30-60 kDa [180, 181]. The 
immunodetection demonstrated that CD63 was highly enriched in the exosome fraction 
(panel II, 1b). While a strong signal in the exosome fraction was present, it was nearly 
completely absent in the corresponding supernatants. Hence, this signal distribution of 
CD63 between supernatants and exosome enriched fraction formed a considerable 
contrast to that obtained for HDGF-A. 
In addition membranes were probed with anti-actin antibody (panel II, 1c). In SDS PAGE 
gels actin runs at a molecular weight position of approximately 40 kDa. Since the 
cytoskeleton protein actin is also a common component in exosomes [182, 183], the 
detection of actin served as further positive control for the presence of exosomes. 
Compared to CD63, actin was not enriched in the exosome fraction to the same extent. 
Most strikingly, HDGF-B (panel II, 2a) and the mutant HDGF-A S165A, (panel II, 4a) 
were heavily enriched in the final exosome fraction. Both were below detection limits in 
the corresponding supernatants. Consequently the signal distribution was comparable to 
that of the exosomal marker protein CD63, shown in panel 2b and 4b, respectively. While 
Western blot analysis of the total cell lysates resulted in a triple signal for HDGF-B, 
detected at a molecular weight position between 35 and 40 kDa in SDS PAGE gels 
(figure 11), corresponding exosome fractions comprised only double signals of a 
comparable molecular weight range. 
Like HDGF-A, HDGF-C was detectable in the surrounding media and in the respective 
exosome containing fraction. Interestingly, in the exosome fraction a second weaker 
signal became visible at a lower molecular weight position of approximately 35 kDa, 
which was not detected in the supernatants and in cell lysates (figure 11). This 
suggested that this smaller protein variant was enriched in the exosome fraction, which 
corresponded more to the results of HDGF-B and HDGF-A S165A 
3.3.3.2 Endogenous HDGF in extracellular vesicles 
Since overexpression of proteins is always afflicted with artefacts, studies under 
physiological conditions are necessary. Therefore, several different human cell lines 
were selected. Incubation media were collected after 40 h from HepG2 cells, HaCat 
cells, HeLa cells as well as from the two breast cancer cell lines MCF-7 and MDA-MB-
231. Exosome fractions were obtained by stepwise centrifugation, as described before. 
At every centrifugation step an aliquot of the supernatant (SN1-SN5) was taken. Final 
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exosome enriched fraction and supernatants were examined by Western blot analysis. 
Results are shown in figure 28.  
 
Figure 28: Endogenous HDGF in exosome containing fractions.  Panel I: HaCat cells (panel 
1), HeLa cells (panel 2), MDA-MB-231 cells (panel 3), MCF-7 cells (panel 4) and HepG2 cells 
(panel 5) were incubated in serum free medium for 40 h. Total lysates (CL), supernatants (SN) 
and corresponding exosome fraction (Ex) were collected from the indicated cell lines and were 
analysed by Western blot using rabbit anti pan-HDGF (panel I: 1a, 2a, 3a, 4a, 5a), anti-CD63 
(panel I: 1b, 2b, 3b, 4b, 5b) or anti-actin (panel 1c, 2c, 3c, 4c, 5c) as indicated on the right side. 
Molecular mass marker lanes are shown on the left. Panel II: Dynamic light scattering (DLS) 
measurement of cell type specific exosome fractions and extracellular LDH activity (%) measured 
at the time of collection. LDH measurement was performed in triplicates; values are given in % of 
total LDH ± standard deviation. DLS was recorded with 6 replicate measurements. Mean values 
are given ± standard deviation.  
Furthermore, corresponding extracellular LDH activity was determined as indicator for 
cell leakage (figure 28, panel II).  
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To characterise the obtained final exosome containing fraction dynamic light scattering 
(DLS) analysis was performed. DLS analysis revealed the presence of particles with a 
hydrodynamic diameter of 100-150 nm (panel II, 6). This increased values corresponded 
to the reported size of exosomes obtained in DLS measurements [184].  
Interestingly, secretion of HDGF is cell-type specific. Western Blot analysis demonstrated 
that endogenous HDGF could be detected in supernatants and exosome fraction 
collected from HaCat cells (figure 28, panel 1a) HeLa cells (panel 2a) and MCF-7 (panel 
4a). Endogenous HDGF was below detection levels in supernatants collected from MDA-
MB-231 (panel 3a) and HepG2 cells (panel 5a) although analysis of respective total cell 
lysates demonstrated that all examined cell lines expressed HDGF at comparable levels 
(figure 29, panel 2a).  
 
Figure 29: Comparison of endogenous HDGF in exosome containing fractions.  Exosome 
fractions (Ex) were collected from HaCat, HeLa; MDA-MB-231, MCF-7 and HepG2 as described 
under the method section 2.1.8.1. Protein amounts of exosome-enriched fractions (1) and CL (2) 
were determined by BCA assay and same protein amounts (2 µg) were subjected to Western blot 
analysis using goat anti pan-HDGF (1a, 2a), anti-CD63 (1b) or anti-actin (1c, 2b). Molecular mass 
marker lanes are indicated on the left. 
A further interesting observation was the identification of two HDGF polypeptides and 
their diverse distribution in different samples. The goat anti pan-HDGF antibody detected 
two polypeptides at a position of 37 kDa and 39 kDa in the supernatants of HaCat cells, 
the smaller form being predominant in all five supernatants. In the corresponding HaCat 
exosome fraction the 39 kDa protein signal was as strong as the 37 kDa signal.  
This clear enrichment of the 39 kDa signal in exosome fraction compared to the 
supernatants could not be observed in the samples of the other cell types. In 
supernatants and exosome-enriched fractions of HeLa and MCF 7 cells the higher 
39 kDa molecular weight form appeared only as weak signal. HDGF was also absent in 
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the collected exosomes from HepG2 cells while in exosomes from MDA-MB-231 only a 
weak 39 kDa signal was detectable.  
It is important to note, that in cell lysates the 37 kDa signal is by far the dominant band 
whereas the 39 kDa signal is hardly detectable.  
3.3.3.3 HDGF-A and endogenous HDGF are present in vesicle-depleted 
supernatants 
SN5, collected after sedimentation of exosomes (figure 27, panel II), still contained 
detectable amounts of HDGF-A and HDGF-C (figure 27, panel II). A similar picture was 
obtained for endogenous HDGF, released from the different cell types (figure 28). On the 
contrary, exosomal marker CD63 as well as HDGF-B and HDGF-A S165A could not be 
detected in the SN5. This observation suggests that only a fraction of HDGF-A or -C is 
vesicle-associated, whereas HDGF-B and HDGF-A S165A are exclusively in the vesicle 
fraction. 
To address this, SN5 was subjected to an additional ultracentrifugation at 112 000 x g for 
24 h (figure 30, panel I). According to Théry et al., this timeframe should be sufficient to 
deplete the remaining exosomes [99]. The obtained supernatant was labelled as SN5* in 
the following. The samples were analysed by Western blot using goat anti pan-HDGF 
antibody or anti-CD63 antibody, respectively. Results are shown in figure 30 (panel 2). 
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Figure 30: Recombinant HDGF-A and endogenous HDGF are still present in vesicle-
depleted supernatants. Panel I: After 40 h incubation supernatants were collected and subjected 
to stepwise centrifugation to isolate exosomes as described before. SN5, collected after 120 000 
x g step, was centrifuged a second time for 24 h at 112 000 x g to deplete the supernatant 
completely from extracellular vesicles (SN5*). Panel II: SN4, SN5* and exosome fraction (Ex) 
were collected from HDGF- A/B/C (panel II 1-3) or HDGF-A S165A (panel 4) overexpressing and 
from non-transfected (nt) HepG2 cells (panel 5) or nt HeLa cells (panel 6). Samples were 
analysed by Western blot using anti pan-HDGF (panel 1-5) or anti-CD63 antibodies (panel 6) as 
indicated on the right. Marker lanes are shown on the left. 
In fact exosomal marker CD63 was not detected in this supernatant obtained after 24 h 
ultracentrifugation at 112 000 x g, indicating that the majority of exosomes were 
sedimented at this step (figure 30, panel II 6). A similar picture was observed for HDGF-
B (panel II 2), HDGF-C (panel II 3) and HDGF-A S165A (panel II 4). In each case the 
recombinant protein was not detectable in the final, exosome-depleted supernatant 
SN5*.  
By contrast, ectopically overexpressed HDGF-A (panel II 1) as well as endogenous 
HDGF (panel II 5), released from HeLa cells, were still present in this exosome-depleted 
supernatant SN5*. Interestingly, in both exosome-depleted supernatants SN5* a 
significant decline of protein compared to SN4 (collected after 15 000 x g) could be 
observed, indicating that only parts remain in the exosome-depleted supernatants while 
the remaining subfraction can be sedimented in the final exosome enriched fraction. In 
agreement with the observation of this decline is the presence of these proteins in the 
exosome containing-fraction. In this context it is necessary to consider that the proteins 
are concentrated to different amounts in Ex fraction and corresponding SN fraction. 
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3.3.3.4 Localisation in or on extracellular vesicles 
Exploring the localisation of HDGF in or on extracellular vesicles will provide more insight 
in the role of the delivered cargo. Proteins on the surface might be involved in 
communication processes between extracellular vesicle and recipient cell or can be 
integrated in the plasma membrane by fusion of vesicles with recipient cells. Proteins in 
the lumen of vesicles can enter the cytoplasm of cells when extracellular vesicles are 
internalised and elicit inside different cell responses [185]. 
To clarify the localisation of HDGF inside or outside of extracellular vesicles a stripping 
assay was applied, which was used by several other groups [186, 187]. Obtained 
exosome containing fractions were treated with the protease trypsin in presence or 
absence of the detergent Triton X-100. Trypsin treatment alone can digest proteins on 
the vesicle surface but proteins within vesicles are not affected due to the surrounding 
vesicle membrane. Treating vesicles with the detergent Triton X-100 leads to the lysis of 
the membrane, without affecting the vesicle associated proteins. Only the combined 
treatment of detergent and trypsin leads to the digestion of intravesicular proteins.  
 
3.3.3.4.1 Localisation of HDGF isoforms and HDGF-A S165A in extracellular 
vesicles 
First, HepG2 cells were transiently transfected with plasmids encoding HDGF-A, HDGF-
B and HDGF-C and HDGF-A S165A. Exosome containing fractions were collected and 
subjected to the described procedure. The obtained fractions were analysed by Western 
blot using either goat pan-HDGF antibody or anti-actin antibody. According to Théry et al. 
actin is localised in the lumen of exosomes [105]. Consequently, the detection of actin in 
those samples that were exposed to trypsin, demonstrated the presence of intact 
vesicles. The corresponding results are shown in figure 31. 
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Figure 31: Localisation human HDGF-A, -B, -C and HDGF-A S165A in extracellular vesicles. 
Exosome enriched fractions were collected from HepG2 cells transfected with plasmids encoding 
HDGF-A (panel 1), HDGF-B (panel 2) or HDGF-C (panel 3) or HDGF-A S165A (panel 4). As 
described under Methods, aliquots of freshly isolated extracellular vesicles were subjected either 
to mock conditions without treatment of the vesicles, only trypsin digestion, only Triton X-100 lysis 
or Triton X-100 lysis prior to trypsin digestion. Samples of all four conditions were separated on 
12 % SDS-gels and transferred to PVDF membranes. Membranes were immunoblotted with goat 
anti pan-HDGF (panel a), followed by anti-actin (panel b) as indicated on the right side. Marker 
lanes are shown on the left.  
HDGF-A was resistant to trypsin treatment in the absence of Triton X-100 (figure 31, 
panel 1), indicating that this protein was located in the lumen of extracellular vesicles like 
the control protein actin. Combined treatment of Triton X-100 and trypsin resulted in the 
complete loss of HDGF-detection. This demonstrated that the trypsin protease was 
functional under the used conditions. Interestingly, in contrast to HDGF-A, HDGF-B 
(panel 2), HDGF-C (panel 3) and HDGF-A S165A (panel 4) were sensitive to trypsin 
digest in the absence of the detergent. The corresponding immunodetection of actin 
demonstrated that in all cases vesicles remained intact. Therefore, this experiment 
suggested that these alternative isoforms and the mutant were located on the surface of 
extracellular vesicles, where they were accessible to trypsin treatment. 
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A similar result was obtained also for mouse HDGFwt and mHDGF S165A as shown in 
figure 31. As mentioned before, in the mouse genome isoform HDGF-B and isoform 
HDGF -C does not exist. 
 
Figure 32: Localisation of murine HDGF wt and HDGF S165A in extracellular vesicles. 
Exosome containing fractions were collected from Hek293 cells transfected with plasmids 
encoding murine HDGF wt (panel 1) or murine HDGF S165A (panel 2). As described under 
Methods, aliquots of freshly isolated extracellular vesicles were subjected either to mock 
conditions without treatment of the vesicles, only trypsin digestion, only Triton X-100 lysis or Triton 
X-100 lysis prior to trypsin digestion. Samples of all four conditions were separated on 12 % SDS 
gels and transferred to PVDF membranes. Membranes were immunoblotted with anti-mouse 
HDGF (panel a), followed by anti-actin (panel b) as indicated on the right side. Marker lanes are 
shown on the left.  
This result indicated that the phenomenon of alternative vesicular localisation, induced 
by the exchange of serine residue 165, is not species specific or more precisely at least 
available for mouse and human HDGF.  
While murine HDGF was not digested in the presence of trypsin (panel 1), the respective 
mutant HDGF S165A (panel 2) were susceptible to the trypsin exposure. 
Murine HDGF appeared as double signal in Western blot analysis. The reason is an 
unusual caspase cleavage site in murine HDGF [188]. 
3.3.3.4.2 Vesicular localisation of endogenously expressed HDGF 
The same experiment was performed with exosome containing fractions obtained from 
HeLa, HaCat and MCF-7 cells. Since MDA-MB-231 and HepG2 cells did not release 
endogenous HDGF in detectable amounts (figure 28 & 29), these cell lines were not 
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included in this experiment. The results of the Western blot analysis are depicted in 
figure 33. 
 
Figure 33: Localisation of endogenous HDGF in extracellular vesicles. Exosome containing 
fractions were collected from the indicated cell lines HaCat (panel 1), HeLa (panel 2) or MCF-7 
(panel 3). As described under Methods, aliquots of freshly isolated extracellular vesicles were 
subjected either to mock conditions without treatment of the vesicles, only trypsin digestion, only 
Triton X-100 lysis or Triton X-100 lysis prior to trypsin digestion. Samples of all four conditions 
were separated on 12 % SDS gels and transferred to PVDF membranes. Membranes were 
immunoblotted with rabbit anti pan-HDGF (panel 1a, 2a, 3a), followed by immunodetection with 
anti-actin (panel 1b, 2b, 3b) as indicated on the right side. Marker lanes are shown on the left.  
The Western blot analysis, shown in figure 33, demonstrated that endogenous HDGF 
was resistant to trypsin digest in the absence of the detergent Triton X-100. This 
provided evidence that for all tested cell types endogenous HDGF is located 
predominantly inside of extracellular vesicles, where it is protected from trypsin 
degradation. Combined treatment with Triton X-100 and trypsin led to a complete 
degradation. 
3.3.3.4.3 Phosphorylation mutants and their localisation in extracellular vesicles 
The finding that the exchange of one single phosphorylation site Ser165 to Ala led to 
alternative localisation on extracellular vesicles prompted to the question whether the 
exchange of other putative phosphorylation sites in HDGF have a similar effect on the 
presence in extracellular vesicles. Apart from serine residue at position 165 [48], HDGF 
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contains several other putative phosphorylation sites, which are experimentally 
confirmed such as Ser132 and Ser133 [48] or Ser103 [36]. In contrast to S165A mutant, 
all these mutants are released in the conditioned media [33].  
 
Figure 34: Localisation of phosphorylation mutants in extracellular vesicles. HepG2 cells 
were transiently transfected with plasmids encoding different HDGF mutants either with single Ser 
to Ala exchanges (panel 2: S132A; panel 3: S133A), with double Ser to Ala exchanges (panel 1: 
S102/S103A; panel 4: S132/S133A panel 5 S132/S165A) or with triple exchanges (panel 6 
S132/S133/S165A) as indicated above. Panel I: Exosome fractions were collected from 
conditioned media as described under Methods and corresponding cells were lysed. Aliquots of 
Ex were left either untreated or incubated with trypsin, with 1% Triton X-100 or with 1% Triton X-
100 followed by trypsin treatment as described under Methods. Samples of all four conditions 
(panel I) and cleared lysates (CL) (panel II) were separated on 12 % SDS PAGE gels and 
transferred to PVDF membranes. Membranes were probed with anti-mouse HDGF (panel I 1a -6a 
and panel II) or anti-actin (panel 1b-6b). Molecular mass marker lanes are indicated on the left. 
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HepG2 cells were transiently transfected with plasmids encoding different mouse HDGF 
mutants with different Ser to Ala exchanges. Exosomes were collected and subjected to 
the protease treatment as described beforehand. Obtained fractions were analysed by 
Western blot, the respective results are shown in figure 34. 
Remarkably, while HDGF-A S165A was sensitive to trypsin digest in absence of Triton X-
100 (figure 31), the double Ser to Ala mutant S132/S165A (figure 34, panel I.5) and the 
triple mutant HDGF S132/133/165A (figure 34, panel I.6) were resistant to trypsin digest. 
This provided evidence that these HDGF mutants were differentially located in 
extracellular vesicles. HDGF-A S165A was located at the surface of vesicles. The 
respective double and triple mutants of HDGF appeared to be within extracellular 
vesicles. Consequently, the alternative vesicular localisation, caused by the exchange of 
the Ser165, was abolished when Ser132 and/or Ser133 were additionally exchanged to 
an Ala in HDGF. 
Furthermore, while the exchange of the Ser132 (panel I.2) did not lead to any noticeable 
difference compared to the wildtype HDGF, mutants with single exchanged Ser 133 
(panel I.3) could not be detected in exosome containing fractions anymore. Again only 
single deletion led to the described effect. Mutants with double (S132/133A) (panel I.4) or 
triple exchanges (S132/133/165A) (panel I.6) were detected in the exosome containing 
fractions and moreover like the wildtype form of HDGF they were located within vesicles. 
The analysis of the respective cell lysates demonstrated that transfection was successful 
in all cases (panel II). 
3.3.3.4.4 N-terminus influences the localisation of HDGF in extracellular vesicles 
The present data demonstrated that HDGF-A S165A was not detected in the conditioned 
media. Nevertheless it could be still identified in the exosome containing fraction (figure 
27). Moreover, the present results revealed that this protein is localised at the surface of 
extracellular vesicles (figure 31). Thakar et al. demonstrated that N-terminal truncation of 
the first 11 amino acid residues of HDGF is sufficient to block its secretion [33]. This 
prompted to the question whether truncation of the first N-terminal amino acid residues 
itself is also sufficient for the observed extravesicular location. 
To address this issue murine HDGF constructs, deleted in the first N-terminal 8-12 amino 
acid residues were transiently overexpressed in HepG2 cells and exosome containing 
fractions were collected as described before. With respect to localisation on or in 
extracellular vesicles murine and human HDGF and respective S165A mutants exhibited 
the same pattern (figure 31 and 32). Therefore, the use of these mouse HDGF 
constructs should not make a difference in the final result. Isolated exosome containing 
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fractions were subjected to trypsin in presence or absence of Triton-X 100 The Western 
blot analysis of the corresponding samples is shown in figure 34. 
 
Figure 35: N-terminally truncated HDGF-A mutants are located at the surface of 
extracellular vesicles. Panel I: HepG2 cells were transiently transfected with plasmids encoding 
different N-terminal truncated mouse HDGF mutants, deleted in the first 8 (NΔ8) – 12 (NΔ12) 
amino acid residues. ). As described under Methods, aliquots of freshly isolated extracellular 
vesicles were subjected either to mock conditions without treatment of the vesicles, only trypsin 
digestion, only Triton X-100 lysis or Triton X-100 lysis prior to trypsin digestion. Samples were 
subjected to Western blot analysis and membranes were probed with anti-mouse HDGF (panel a) 
or anti-actin (panel b). Marker lanes are indicated on the left. Panel II: Schematic depiction of full 
length HDGF with highlighting of the first N-terminal 20 amino acid residues. Amino acid residues 
are given in the single letter code. 
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While N-terminally truncated mutants, missing not more than 10 amino acid residues 
(figure 35, panel 1 & panel 2), were not affected by addition of trypsin, the remaining N-
terminally truncated HDGF variants, deleted in 11 or more amino acid residues, were 
sensitive to trypsin digest (panel 3 and 4). The present result clearly demonstrated that 
the deletion of 11 amino acid residues or more led to a shift from the intravesicular 
presence to the surface of vesicles.  
Thakar et al. figured out, that N-terminally truncated HDGF mutants (NΔ11, NΔ13, NΔ15) 
cannot be detected in the conditioned media collected after 24 h [33]. Like the ΝΔ11, 
ΝΔ13, ΝΔ15 HDGF mutants, also HDGF-A S165A and the human isoform HDGF-B were 
not detected in the conditioned media. Consequently, all these proteins have following 
features in common: An alternative N-terminus compared to HDGF-A (HDGF-B, HDGF-
C) or they missed at least the first N-terminal 11 amino acid residues (HDGF-A S165A, 
NΔ11); they were not detected in the conditioned media after 24 h incubation time; they 
were highly enriched in the exosome containing fraction compared to the supernatants 
and last but not least they were sensitive to trypsin exposure.  
Figure 35 (panel II) shows the N-terminal sequence of HDGF. Amino acid residue 11, 
which seemed to be in the critical position regarding the localisation of the N-terminally 
truncated HDGF forms (figure 20), is occupied by a Lys. One scenario could be that the 
presence of this special lysine residue at position 11 is the actual reason why HDGF-A 
exhibited a complete different secretion behaviour than the other isoform. For example 
Lys11 could be the target of a posttranslational modification denoting the protein for 
loading into exosomes. 
In order to see whether exchange of single Lys11 have the same effect like observed for 
N-terminal truncation of HDGF, murine HDGF constructs containing an Arg instead of the 
Lys at position 8 or 11 were used. Resulting exosome containing fractions were 
subjected to trypsin treatment in presence or absence of Triton X-100 and samples were 
analysed by Western Blot. Corresponding results are shown in figure 36. 
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Figure 36: HDGF-K8R and -K11R are present within vesicles. HepG2 cells were transiently 
transfected with plasmids encoding murine C-terminal Strep-tagged Lys to Arg mutants K8R 
(panel 1) and K11R (panel 2). As described under Methods, aliquots of freshly isolated 
extracellular vesicles were subjected either to mock conditions without treatment of the vesicles, 
only trypsin digestion, only Triton X-100 lysis or Triton X-100 lysis prior to trypsin digestion. 
Samples were subjected to Western blot analysis and membranes were probed with anti-mouse 
HDGF. Molecular mass marker lanes are indicated on the left. 
Both lysine mutants were resistant to trypsin digest (figure 36). Consequently, both 
mutants were located within extracellular vesicles displaying the same localisation as the 
HDGF wildtype. The exchange of Lys11 or Lys8 did not lead to alternative localisation of 
HDGF. However, since Strep-tagged variants were used in this experiment, the 
possibility remained that the C-terminal Strep-tag interfered in some way. Due to time 
constraints untagged lysine mutants could not be tested anymore. 
Apart from the Lys 11, the neighbouring Cys at position 12 might be interesting. Thakar 
et al. showed that this Cys is part of intramolecular disulfide bond which can be formed 
between Cys12 and Cys108 [33].  
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Figure 37: HDGF disulfid mutants and their presence in extracellular vesicles. Panel I: 
HepG2 cells were transiently transfected with plasmids encoding mouse HDGF mutants with an 
Ala instead of Cys at position 12 and/or 108 (panel 1 C12A; panel 2 C108A; panel 3 C12/108A). 
Exosome containing fractions were collected from conditioned media. Panel I: Exosome 
containing fractions were left untreated, incubated with trypsin, treated with 1 % Triton X-100 or 
incubated with Triton X-100 for 30 min at 4 °C followed by trypsin treatment. Panel II: 
Corresponding supernatants SN1-SN5 obtained upon each centrifugation step and exosome 
containing fraction (Ex) were separated on 12 % SDS PAGE gels and transferred to PVDF 
membranes. Membranes were probed with anti-mouse HDGF or anti-actin as shown on the right 
site. Molecular mass marker lanes are indicated on the left. Signals corresponding to potentially 
N-terminal truncated HDGF are marked by asterisks. 
Western blot analysis resulted in two signals at a position of approximately 37 kDa and 
36 kDa in the exosome containing fraction collected from HepG2 cells transiently 
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transfected with HDGF-C12A (figure 37, panel 1). Remarkably, the signal, which 
appeared at a slightly higher position, was resistant to the trypsin digest, whereas the 
second lower signal was sensitive so trypsin exposure. This indicated that the 
overexpression of HDGF C12A led to the presence of two subpopulations within the 
specimen, one which was within extracellular vesicles and the second one, which was 
located at the surface of vesicles. Furthermore, the analysis of supernatants collected 
upon each centrifugation step and the respective final exosome fraction (panel II, 1) 
revealed that the lower signal was nearly not detected in the supernatants but was 
enriched in the exosome containing fraction. Such enrichment could not be observed for 
the upper signal. 
Regarding the result from the N-terminally truncated variants (figure 35) the respective 
protein was deleted in 11 or more N-terminal amino acid residues. The same result was 
obtained when exchanging both Cys residues C12 and C108 to Ala. 
However, the exchange Cys108 did not lead to the formation of a second smaller 
fraction, which was sensitive to trypsin exposure (figure 37, panel I.2). In the respective 
Western blots only a single signal was detectable. 
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4. Discussion 
4.1 Alternative Splicing and functional consequences 
Alternative splicing is a key mechanism for the generation of high diversity in the 
proteom. Recent studies estimated that the majority of the human genes undergo 
alternative splicing [133]. On the basis of this estimation the finding that human HDGF is 
alternatively spliced is not surprising. In accordance, alternative splicing events have 
been observed also in other members of the HRP family like LEDGF [11] and HRP-2 
[165]. Moreover, in case of HRP-3 a putative alternative splicing variant can be found in 
the NCBI database (HRP-3: transcript X1 XM_006720554), even though this variant has 
not been verified experimentally. 
In the following the expression of the novel HDGF isoforms and their potential functional 
roles are discussed. 
4.1.1 Gene expression of alternative HDGF isoforms 
The results of the present work revealed that alternative splicing of human HDGF mRNA 
generates at least two further isoforms, HDGF-B and HDGF-C. These two isoforms differ 
in the N-terminal part from HDGF-A. Interestingly, the novel isoforms HDGF-B and -C 
are not present in the genome of mice, although human HDGF-A and murine HDGF 
share a high similarity (86 %). In line with this observation are other studies, which 
demonstrated that alternative splicing events are relatively low conserved between the 
human and the mouse genome [189, 190].  
Searching nucleotide databases for orthologous sequences revealed that the alternative 
exons for HDGF-B and -C can be found only in closely related species of the anthropoid 
lineage. This indicated that the event, which led to the existence of these alternative 
isoforms, occurred relatively late in evolutionary history. 
Even though this is not issue of this work it should be mentioned that further predicted 
alternative HDGF transcripts in the NCBI database are available, indicating that there 
might be more than three different HDGF variants.  
However, the presence of the mRNA is not immediately the verification that the 
respective sequence is translated into a protein and it is not that simple to distinguish 
biologically important variants from erroneous transcripts. The nature evolved several 
mechanisms which tightly control the subsequent translation process in order to prevent 
the expensive production of defective and potential harmful translation products [191]. 
One of the major surveillance mechanisms is the non-sense mediated mRNA decay 
(NMD) which eliminates transcripts with a premature stop codon [192]. A recent study, 
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working with EST-suggested alternative human isoforms, estimated that 35 % of these 
human EST-suggested isoforms are target for NMD surveillance process [193].  
This NMD process does not concern one of the novel HDGF isoforms HDGF-B and 
HDGF-C, since they do not contain a premature Stop codon. 
RNA expression of the two novel HDGF isoforms HDGF-B and HDGF-C could be 
verified (figure 8). The results of real-time qPCR analysis demonstrated that the 
previously described HDGF-A form is clearly the predominant form. HDGF-B and HDGF-
C are expressed only at very low levels compared to HDGF-A (figure 9) in all 
investigated human cell lines under the tested conditions. This seems in line with the 
observations from Djebali et al. [142]. Their analysis of expression patterns revealed that 
cell lines tend to express several alternative transcripts at the same time but that in most 
cases one transcript is the dominating form. Such a dominant expression of one isoform 
seems to be the case also on protein levels [143]. Certainly, the result of the qPCR does 
not reveal whether cells express all variants at the same time or the majority of cells 
express solely the dominant HDGF-A form whereas a few cells of the studied population 
express one of the novel alternative isoforms at high levels. 
Nevertheless, there might be specific conditions available, which lead to an upregulation 
of HDGF-B and/or HDGF-C and simultaneously in a decrease of HDGF-A expression 
levels. Such changes of alternative splicing patterns are observed for specific genes 
under different circumstances for example as a response to specific stimuli [194, 195] or 
as consequence of differentiation processes [196]. Also cancer related changes are 
known [197]. Regarding the role of HDGF-A in cancer development [31, 42, 62] these 
cancer-related changes are an interesting aspect. The identification of specific conditions 
which lead to an upregulation of the novel HDGF isoforms HDGF-B and -C would reveal 
more about physiological function and their biological relevance and is therefore an 
interesting and important project for the future.  
4.1.2 Protein expression of alternative HDGF isoforms 
HDGF-A exhibits an abnormal electrophoretic running behaviour in SDS PAGE [3]. A 
similar observation was obtained for HDGF-C and HDGF-B. Both migrated more slowly 
in SDS PAGE than was expected on basis of their predicted molecular weights. HDGF-C 
appeared at a molecular weight position of 37 kDa whereas HDGF-B was detected as a 
triple signal at around 37 - 40 kDa.  
An interesting observation was that under non-reducing conditions a prominent signal 
was visible at a molecular weight position of about 90 kDa in case of HDGF-A. Similar 
signals were also detected for HDGF-B and HDGF-C but considerably weaker (figure 
11). Thakar et al. provided evidence that mouse HDGF is able to form disulfide bridged 
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dimers via Cys108 [33]. The same Cys residues is available in human HDGF-A 
sequence (Cys108, figure 7) indicating that an identical mechanism is existent and most 
probably the reason for the observed 90 kDa signal in Western blot analysis. 
In the corresponding samples containing ectopically expressed HDGF-B and HDGF-C 
such a strong 90 kDa signal was not detectable. Apparently, HDGF isoforms have lost 
the ability to form such disulfide bridged dimers in a similar extent. This is surprising 
since the responsible Cys is present in both proteins (HDGF-B: Cys124; HDGF-C: 
Cys101) (figure 7). Possibly, the overall changes in HDGF-B and -C lead to an 
unfavourable position of the responsible Cys residues that reduces formation and/or 
stability of such disulfide bridged dimers. 
The detection of the novel HDGF isoforms as endogenously expressed protein is 
challenging due to the limited sequence differences, the similar running behaviour and 
the low expression levels of HDGF-B and -C relative to HDGF-A (figure 9). 
Although the sequences of alternative isoforms have been present in the database for a 
while, only a limited number of studies designed their experiments in such a way, that 
HDGF-A was specifically addressed. One problem is that most commercially available 
HDGF antibodies will recognize all three HDGF isoforms. The similar electrophoretic 
running behaviour aggravates this problem. On the one hand the dominance of HDGF-A 
and the resulting strong signals in Western blot analysis may overwhelm weaker signals 
derived from HDGF-B or HDGF-C. On the other hand, situations in which HDGF-B 
and/or HDGF-C are indeed highly expressed in relation to HDGF-A, the respective 
signals may be accidentally assigned to HDGF-A due to similar positions in Western blot 
analysis. This underlines the necessity of isoform specific antibodies. 
Interestingly, Nakamura et al. used initially an antibody which was directed against the 
outermost amino acid residues (SRSNRQKEYKC12) of HDGF-A. In immunofluorescence 
analysis using this specific antibody, a cytoplasmic staining was obtained in hepatoma 
HuH-7 cells [1]. This observation is in contrast to the majority of later studies which found 
that HDGF is mainly located in the nucleus of cells [17, 27, 77]. However, not much is 
known about the quality of the respective antibody, also because this specific antibody 
has not been used in later studies. Moreover, a novel antibody, directed against the 
same outermost amino acid residues of HDGF-A, was not functional in this present work 
(data not shown).  
As consequence a second HDGF-A specific peptide antibody was produced, which was 
directed against another HDGF-A specific peptide (table 6, no 2). However, this antibody 
has a strong disadvantage in terms of specificity. It recognizes also other family 
members of the HRP-family. In contrast to the first HDGF-A specific antibody, this 
antibody was able to detect ectopically expressed HDGF-A (figure 11) and moreover did 
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not produce a signal in that samples which contained overexpressed HDGF-B and 
HDGF-C. Despite its ability to detect recombinant HDGF-A, this antibody failed 
completely in the recognition of endogenously expressed HDGF-A (figure 15, panel 1). 
Since qPCR revealed the dominance of HDGF-A, low endogenous protein levels are not 
the reason for this failure. Consequently, another explanatory model is required for this 
discrepancy. Endogenously expressed HDGF-A might undergo a posttranslational 
modification in the region that contains the epitope for the HDGF-A specific antibody 
(CGDLVFAKMGYPH25) and these changes might prevent antibody binding. This 
explanatory model requires that this modification does not occur or only partially in 
ectopically expressed HDGF-A. The high amounts of HDGF-A, that are obtained after 
transient overexpression, could overload the machinery responsible for the respective 
modification. Hence, a strong proportion of unmodified HDGF-A would be left, which can 
be still recognized by HDGF-A specific antibody. 
In order to verify endogenous protein expression of HDGF-B and HDGF-C, peptide 
specific antibodies were used. Interestingly, HDGF-B specific antibody recognized only 
N-terminally tagged HDGF-B and failed to detect C-terminally tagged HDGF-B (figure 13 
& 14). This led to the assumption that recombinant HDGF-B was N-terminally truncated 
while this process did not occur or only partly in case of N-terminally tagged HDGF-B. 
This truncation process might be artificially induced by its overexpression in cells. 
However, if truncation occurs also in the case of endogenously expressed HDGF-B, the 
detection will be anyway problematic due to the potential loss of the HDGF-B specific 
epitope. 
Unfortunately, the HDGF-B specific peptide antibody failed to precipitate and detect 
HDGF proteins in cell lysates. Instead, the antibody precipitated and detected proteins in 
the respective precipitate with an electrophoretic mobility in the range of 70 to 100 kDa 
that were not detected by the goat anti pan-HDGF antibody (figure 15, panel 2 & 4). This 
strongly indicates that this antibody recognizes other proteins than HDGF. Due to this the 
antibody was firstly excluded from further studies. On the basis of this data, it cannot be 
answered whether HDGF-B protein is expressed. 
Endogenous protein expression was confirmed for HDGF-C by the use of HDGF-C 
specific peptide antibodies. In immunoprecipitates HDGF-C was detected (figure 15, 
panel 3), indicating that HDGF-C is expressed in cells. The examination of human tissue 
samples (figure 16) provides a further hint for the presence of HDGF-C. Interestingly, 
detected signals were detected at a slight higher molecular weight position as observed 
for ectopic overexpression and immunoprecipitation. Posttranslational modifications 
could be a reason. 
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4.1.3 Structural differences in HDGF isoforms  
HDGF-A consists of the structured N-terminal hath domain (1-100 amino acid residues) 
and the not well defined C-terminal part (101-240 amino acid residues) (figure 2) [13]. 
The alignment of the sequences revealed that changes in HDGF-B and HDGF-C affect 
the first two β-strands, which are part of the anti-parallel β barrel (figure 7). Such splicing 
events that affect rather structured and well-conserved regions of a protein than non-
structured and more variable parts are not that rare as might be expected beforehand. 
Indeed, a study from Birzele et al. demonstrated that from the studied set of data 
approximately only half of the splice events affect variable protein regions, whereas the 
other half concerned well defined structures of proteins [198]. However, screening the 
literature did not lead to the discovery of further alternative isoforms within the PWWP 
protein family with alterations in the PWWP domain. 
In silico models for the first N-terminal 116 and 93 amino acids of HDGF-B and HDGF-C, 
calculated by Dr. Waespy for our publication, demonstrated that the splicing events 
resulted in drastic structural differences [132]. In HDGF-B the first two β-strands can be 
formed by amino acid residues of the new alternative N-terminal part, so that the 
characteristic β-barrel still appears in the model with an extended loop between the β-
strands β1 and β2. Strikingly, the extended loop consists of an additional α-helix. By 
contrast, in the model of HDGF-C β1 and β2 strands are completely lost and as 
consequence the characteristic β-barrel cannot be formed at all. 
A further distinguishing feature of HDGF-B and -C was the loss of the PHWP motif, that 
constitutes the N-terminal part of the second β-strand in HDGF-A (Pro24-His25-Trp26-
Pro27 in HDGF-A) (figure 7). At the respective position in HDGF-B (Arg40-Ala41-Thr42-
Pro43) only the Pro residue at the fourth position (Pro43) can be found which 
corresponds to the Pro 27 in HDGF-A. In HDGF-C no obvious similarities to the PHWP 
are available. In the view of the fact that the PHWP motif contributes to the overall 
stability of the PWWP domain by forming hydrogen bonds with adjacent amino acid 
residues in the β-strands as well as by supporting a specific loop conformation [199], the 
loss of the PHWP motif in HDGF-B and HDGF-C is even more intriguing.  
4.1.4 Functions and binding properties of the novel HDGF isoforms 
Several groups used siRNA to silence HDGF expression. Only in some cases they used 
sequences which were directed against the N-terminal part, so that they specifically 
silenced only HDGF-A and not the two remaining isoforms [64, 153]. However, most 
groups utilized siRNA for their experiments which are able to silence all three isoforms 
[40, 63]. In general all these studies showed that reduction of HDGF expression results 
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in reduced proliferation, migration and invasion behaviour of cells. Consequently, it is not 
possible to conclude a specific function for one of the novel isoforms from these studies. 
4.1.4.1 Proliferation 
Growth stimulating activity belongs to one of the most studied effects of HDGF-A [1, 2, 
17, 28, 50]. However, how HDGF-A exerts exactly its proliferative effect has not been 
clarified yet. Two independent pathways were suggested [41]. The first pathway requires 
nuclear localisation and the C-terminal non-hath region of HDGF-A [17]. The second 
pathway depends on the amino acid residues 81-100 in HDGF-A which provide a 
putative binding site for a yet unknown extracellular plasma membrane receptor [41]. 
Recently, surface nucleolin was discussed as potential receptor of HDGF [42]. 
On basis of theoretical considerations HDGF-B and –C should have the ability to 
promote cell growth, because they fulfil the mentioned criteria. Both contain the two NLS 
sequences and can be found in the nucleus upon transient overexpression (figure 12). In 
addition, both have the full non-hath region as well as the putative receptor binding site 
(figure 7). Therefore, both putative pathways are reasonable. 
Indeed, like already observed for HDGF-A overexpression of HDGF-B stimulated actually 
the growth of Cos7 cells (figure 17). Surprisingly, such an effect could not be determined 
for HDGF-C. In the light of the study of Kishima et al., who demonstrated that 
overexpression of HDGF specific non-hath part alone is able to stimulate proliferation 
[17], this is surprising because the complete non-hath region is present in HDGF-C. 
Hence, the N-terminal part of HDGF-C seems to interfere in some way.  
Whether the isoform HDGF-B and HDGF-C are able to utilize the putative receptor 
mediated pathway, cannot be answered from our data. Treatment with recombinant 
protein did not result in a significant enhanced proliferation, neither for HDGF-B and 
HDGF-C nor for HDGF-A (data not shown). Since different independent studies 
demonstrated that exogenous supplied HDGF-A stimulates cell growth, either the 
recombinant protein was not functional or the selected conditions of the assay were not 
appropriate. Nevertheless, the results of the secretion behaviour revealed that HDGF-B 
and HDGF-C are not present as free protein in the extracellular space but on the surface 
of extracellular vesicle (figure 31). Thus, the surface localisation would theoretically allow 
that HDGF-B and HDGF-C interact with the receptor protein. However, respective 
experiments with exosome collected from overexpressing cells did not show any 
proliferative effect on cells (data not shown). But also here it remains questionable 
whether appropriate conditions were selected. 
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4.1.4.2 Chromatin association 
During this work the interaction to chromatin was studied, which is an established 
interaction of HDGF-A [49] as well as of HDGF related proteins LEDGF [160] and HRP-2 
[49]. Chromatin association depends on the PWWP domain [16], therefore the altered N-
termini of HDGF-B and -C might change interaction to this complex structure in some 
way. To address this question a chromatin binding assay was performed. Chromatin 
binding can be complex and depends on protein-DNA interaction and/or on protein-
protein interaction. However, the performed assay cannot reveal how the protein of 
interest associates with this complex molecule. 
Like HDGF-A, HDGF-C was identified in the chromatin associated fractions (figure 18). 
Surprisingly, HDGF-B was not able to interact with chromatin, demonstrating that this 
protein cannot fulfil chromatin-related functions of HDGF-A. The Western blot analysis of 
overexpressed HDGF-B indicated that this protein loses its N-terminal part. Whether the 
overall changes or the loss of the N-terminal part is the reason cannot be answered. 
The PWWP domain of HDGF has been reported to contain DNA binding ability due to its 
characteristic positive patches on the surface [16]. Yang et al. demonstrated that HDGF-
A binds to a specific DNA sequence and by that mediates transcription repression with 
subsequent consequences in differentiation processes [25, 200]. Until now, this is the 
only function of HDGF which is directly linked to its chromatin association.  
The same study revealed that binding to the specific DNA element requires the full length 
PWWP domain. Variants, which were truncated in the first 30 N-terminal amino acid 
residues bound to the DNA element only weakly. Hence, due to the missing N-terminal 
part also HDGF-C might not be able to bind this specific DNA sequence.  
Other studies suggested that the PWWP domain facilitates DNA binding in a more 
unspecific manner [16, 158, 201]. Lukasik et al. suggested that the positive surface of the 
PWWP domain, constituted by the positively charged Lys residues (position 8, 19, 21, 
61, 72, 75, and 80 in HDGF-A) and Arg79 mediate binding to the negatively charged 
DNA molecule. Interestingly, HDGF-C as well as HDGF-B lacks of amino acids 
corresponding to lysine residues Lys8, Lys19 and Lys21 (figure 7). 
Furthermore, PWWP domain mediates binding to another chromatin component. The 
HRP family members HRP-2 [202] and LEDGF [203] as well as other PWWP domain 
containing proteins such as bromo and plant homeodomain finger-containing protein 1 
(BRPF1) are able to bind to lysine methylated histones [202]. Although this interaction to 
methylated histones was not exactly shown for HDGF-A, the high similarity of the 
corresponding PWWP domains, especially in the HRP family (figure 1), suggests that a 
similar interaction can be expected for HDGF-A, too. Along this line Zhao et al. identified 
several histone proteins in the interactome of HDGF-A [5].  
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All histone binding proteins of the PWWP protein family contain a conserved aromatic 
cage, constructed by three aromatic residues, which allows the specific recognition of 
methylated lysine residues of histones. This aromatic cage (in HDGF-A constituted by 
following residues Tyr23, Trp26 and Phe44) is not available in HDGF-B and HDGF-C 
due to the missing Tyr23 and Trp26, indicating that such an interaction to methylated 
histones is not likely.  
Furthermore, interaction to other chromatin associated proteins might mediate the 
chromatin association. Zhao et al. identified several other chromatin associated proteins 
in the interactome of HDGF-A [58] which may also interact with HDGF-C but with respect 
to the present results not with HDGF-B.  
Interestingly, chromatin binding seems not to correlate with proliferation activity of HDGF 
isoforms. Although HDGF-B could not associate with chromatin, it was still able to 
stimulate proliferation, indicating that proliferation is independent from chromatin 
interaction. The reversed effect was observed for HDGF-C. Although it is able to 
associate with chromatin, it does not enhance cell proliferation. This is in line with the 
observations that the non-hath region of HDGF, which does not participate in chromatin 
association [13, 16, 25], is able to enhance proliferation [17]. 
4.1.4.3 Dimerisation of HDGF isoforms 
HDGF-A is able to dimerise via an unusual domain swap mechanism, mediated by the 
PWWP domain [26]. According to Sue et al. [26], the dimerisation mechanism depends 
on the N-terminal β1 and β2 strands, which are exchanged between the two HDGF-A 
monomers. The long flexible loop, localised behind the second β strand, serves thereby 
as hinge loop and connects both monomers with each other. 
Considering that the N-terminal part including the first two β-strands, is altered in HDGF-
B and -C, it seems reasonable to suppose that dimerisation behaviour is changed, too. 
According to the in silico model, HDGF-B contains the required structural elements, since 
the altered N-terminus consists of two β-strands and also the flexible loop is available 
[204]. Thus, theoretically dimerisation can be possible. However, the loop, placed 
between β1 and β2, is extended compared to HDGF-A and might influence the dimer 
formation in some way. By contrast, the in silico model of HDGF-C revealed that HDGF-
C lost both N-terminal β-strands nearly completely [204], making the domain swap 
mediated dimerisation rather unlikely. 
In the view of this theoretical considerations the result of BiFC assay (figure 19) is 
surprising because not only HDGF-A and HDGF-B but also HDGF-C have been found to 
form HDGF dimers. Moreover, according to the results of this assay all possible 
combinations of HDGF isoforms appeared to be feasible. 
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As mentioned before, dimerisation can also depend on disulfide bridges. Thakar et al. 
demonstrated that murine HDGF dimerise via Cys108 [33]. Indeed, after overexpression 
of HDGF isoforms signals at about 90 kDa, especially for HDGF-A, were obtained in 
Western blot analysis under non-reducing conditions, which disappeared under reducing 
conditions (figure 11). 
However, although BiFC assay is an established way to study direct interaction 
processes in the living cell, a further explanation for the observed BiFC signal cannot be 
excluded. It is possible that a third mutual interaction partner brings the HDGF molecules 
in such a close proximity, that complementation of the respective linked EYFP fragments 
arises by this way and not by a direct interaction.  
The functional consequence of homo- and heterodimerisation can be only speculated. 
Homodimerisation of HDGF-A enhances binding affinity to heparin probably by the 
formation of a contiguous and consequently increased binding site [26]. Since binding to 
DNA depends on the same binding site [16], homodimerisation of HDGF-A might also 
increase the affinity to DNA. Whether putative heterodimerisation of HDGF-A with one of 
the novel isoforms leads to a similar effect is unclear. However, as described before, 
some of the positively charged amino acid residues of the heparin/DNA binding site in 
HDGF-A are not available in HDGF-B and HDGF-C. Therefore, such an enhancement of 
the binding affinity to the same extent is doubtful. 
Heterodimerisation of isoforms, deriving from the same gene, can be observed for 
several splice variants such as for isoforms of the inderminate domain (IDD) 14 
transcription factor [205] or the prolactin receptor (PRLR) [206]. In both cases the 
heterodimerisation has a regulative consequence [205, 206]. In case of IDD14 
transcription factor the alternative isoform, which lacks a functional domain, attenuates 
the activity of the IDD14 transcription factor by binding to the active factor [205]. Such a 
model would be interesting, in particular when regarding the pathophysiological role of 
HDGF in cancer and tumour development. Besides, heterodimerisation might combine 
different functions or interaction partners. Regarding that HDGF-B and -C exhibited quite 
different interaction behaviour; this opens up entirely new possibilities. 
4.1.4.4  Interaction patterns of HDGF isoforms 
HDGF-A has been described as multifunctional protein, which participates in different 
cellular processes. This multifunctional role is also mirrored by the identification of 
diverse HDGF-A interaction partners [5, 7]. Zhao et al. discovered in their multi-
interactome study that most protein-protein interactions depend on the N-terminal hath 
region of HDGF-A. From the 106 identified proteins only 5 proteins were detected in co-
precipitations of the C-terminal non-hath region, displaying the importance of the hath 
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region in the majority of HDGF-A -protein interactions [5]. In line with this observation are 
the results of the present co-precipitations within this study (figure 20).The N-terminally 
altered isoforms were not able to interact with some of the known HDGF-A interaction 
partners and beyond that they co-precipitated other proteins, which in turn were not 
present in the co-precipitates of HDGF-A. However, the alteration in HDGF-B and 
HDGF-C were negligible for interactions to Hsc-70 and ADP/ATP Translocase 2, 
because these proteins were identified in all three co-precipitates of HDGF-A, -B and -C 
(figure 20). 
The interactome of HDGF-A consists of multiple RNA binding proteins. This discovery 
led to the assumption that HDGF-A is involved in different RNA related processes such 
as RNA splicing or translation [5, 7]. Besides, the identification of numerous ribosomal 
proteins in the interactome suggested that HDGF-A is a putative candidate involved in 
ribosome biogenesis [5]. In line with this is the detection of a further ribosomal protein 
(60S ribosomal protein L6) in the co-precipitate of HDGF-A (figure 20). Interestingly, this 
ribosomal component was not observed in the corresponding eluates of HDGF-B and 
HDGF-C. However, the present data is not nearly sufficient to allow a complete exclusion 
of an interaction of HDGF-B and -C with this specific ribosomal protein as well as with 
other ribosomal components. Subsequent Western blot analysis with corresponding 
antibodies would clarify the question whether these isoforms are able to interact with 
some ribosomal components.  
Another RNA binding protein found in the HDGF-A co-precipitate was nucleolin [5, 123] 
(figure 20). Nucleolin plays among other RNA related functions also a role in ribosome 
biogenesis [207]. Interestingly, nucleolin has been reported to function as surface 
receptor [208, 209] and moreover HDGF-A is able to interact with surface nucleolin [42]. 
Strikingly, in contrast to HDGF-A, the novel isoforms HDGF-B and HDGF-C lost the 
ability to co-precipitate nucleolin. Furthermore, the first 15 amino acid residues of HDGF-
A are essential for its capability to co-precipitate nucleolin and their missing in HDGF-B 
and -C is probably the reason why nucleolin was not detected in the corresponding co-
precipitates. This became evident by the analysis of co-precipitates obtained with the 
NΔ15 HDGF-A variant. This construct was deleted in the first 15 N-terminal amino acid 
residues. Respective Western blot analysis of its eluate exhibited substantially 
decreased levels of co-precipitated nucleolin (figure 22).  
Although the presence of the first 15 N-terminal amino acids in HDGF-A are essential for 
its nucleolin interaction (figure 22), a respective construct containing solely these first 15 
or 30 amino acid residues added to SNAP-Strep sequence, was not able to co-
precipitate nucleolin (figure 22). In line with this are the observations from Zhao et al. [5]. 
They identified nucleolin in the eluate obtained from the HDGF-A full length protein, but 
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not in the precipitates obtained from the HDGF-A hath region. This suggests that the 
complete protein is involved in the interaction. 
Apart from nucleolin also YB-1 was detected in HDGF-A co-precipitates, while it was 
absent in co-precipitates of HDGF-B, -C and the NΔ15 HDGF-A variant. Again the first 
15 amino acid residues of HDGF-A appeared to be critical for the co-precipitation, an 
obvious similarity to the co-precipitation of nucleolin. Similar to nucleolin YB-1 is a RNA 
and DNA binding protein thought to be involved in multiple RNA and DNA related 
processes [170]. As already shown for nucleolin [123], the interaction of HDGF-A with 
YB-1 relies on the presence of RNA. Pre-treatment with RNase abolished the co-
precipitations of these proteins (figure 23). 
Whether HDGF-A has the ability to bind to RNAs directly has not been resolved until now 
albeit Zhao et al. [5] discovered some rRNAs in HDGF-A precipitates. Interestingly, like 
observed for the majority of protein interactions, the non-hath region of HDGF-A was 
dispensable for the co-precipitation of these rRNAs. It is conceivable that a putative RNA 
binding potential of HDGF-A hath region relies on the same binding site as suggested for 
DNA binding [16]. Correspondingly, as discussed beforehand (section 4.1.4.2), the 
binding potential might be reduced in HDGF-B and HDGF-C due to the loss of some of 
those positively charged amino acid residues that comprise the DNA and with that also 
the potential RNA binding site in the hath region [16]. The lost or reduced RNA binding 
potential might be also the reason why HDGF-B and -C as well as the constructs 
containing the first 15 or 30 N-terminal amino acid residues of HDGF-A failed to co-
precipitate nucleolin and YB-1. However, the results of Zhao et al. [5] implicate that at 
least in the case of nucleolin the C-terminal non-hath region of HDGF-A seems to be 
involved in the interaction in some way. 
Interestingly, Chen et al. were able to co-precipitate nucleolin and YB-1 with each other 
from Jurkat cytoplasmic extracts and also this interaction between these two proteins 
was abolished by RNase pre-treatment. They discovered that YB-1 and nucleolin are 
required for the stabilisation of interleukin-2 (IL-2) mRNA by the formation of a mRNP 
complex [210]. Both proteins are also present in other mRNP complexes and both 
influence stability and mRNA turnover [211-213]. For instance, nucleolin was described 
as B-cell lymphoma 2 (bcl-2) stabilizing factor [214]. As a matter of fact HDGF-A is a 
component of this complex [123] but its functional role in this complex has remained 
mostly unknown.  
Whether HDGF-A forms a mutual RNP complex with nucleolin and YB-1 or individual 
complexes with each protein cannot be answered from this set of data but further 
clarification would be interesting, since this may enlighten also the functional role of 
HDGF-A in such RNP complexes.  
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In addition to its function in these RNP complexes, HDGF-A interacts with surface 
nucleolin [42]. Since HDGF-B and -C are not able to interact nucleolin, it is unlikely that 
they are able to induce downstream signalling pathway via this HDGF/nucleolin axis. 
Strikingly, while HDGF-B and -C were not able to interact neither with YB-1 nor with 
nucleolin, they co-precipitated proteins of the cytoskeleton, which in turn were not found 
in the co-precipitate of HDGF-A. Among these cytoskeleton proteins tubulin was 
identified. The observed co-precipitation of tubulin and HDGF-C coincided with the 
immunofluorescence analysis. HDGF-C appeared in granule-like structures, which 
clearly co-localised with the microtubulin network (figure 24). 
The absence of tubulin in the HDGF-A is in agreement with other interactome studies [5, 
7], since these studies did not identified tubulin as an interaction partner of human 
HDGF-A either. Furthermore, also in the interaction database Biological General 
Repository for Interaction Datasets (BioGRID) (http://thebiogrid.org) [215] tubulin was not 
among the 213 entries for human HDGF-A interaction partners.  
Interestingly, tubulin interaction is also known for another HRP family protein [216]. HRP-
3, whose expression is restricted to neurons and glial cells [3, 9], binds directly to tubulin 
and by that stabilises microtubules and facilitates their proliferation. Its tubulin promoting 
role was linked to its positive effects on neurite outgrowth. Intriguingly, the binding to 
tubulin is mediated by the hath domain of HRP-3 while the non-hath domain is again 
dispensable for the binding [216]. In the view of the fact that the hath domains of HDGF-
A and HRP-3 share such a high homology (figure 1), it is quite surprising that HDGF-A 
failed to bind to tubulin. This is even more intriguing regarding that HDGF-B and HDGF-
C (figure 20) and furthermore also the NΔ15 HDGF-A Strep variant were able to co-
precipitate tubulin (figure 22). Of course, whether direct binding to tubulin is involved as 
observed for HRP-3 [216] or indirect binding cannot be decided on the basis of the 
present data. But due to the similarity to HRP-3 a direct interaction is likely and in this 
line HDGF-B and HDGF-C might be two further candidates, which trigger microtubule 
assembly and stability.  
Taken together, the results of the precipitation experiments indicate that the first N-
terminal amino acid residues of HDGF-A prevent the interaction to tubulin in some way. 
However, a simple explanation how tubulin binding occurs and beyond that how binding 
is disturbed by the outermost N-terminal peptide of HDGF-A cannot be provided.  
The overall defined structure of the hath domain does not seem to be required for tubulin 
interaction since HDGF-C, which undergoes drastic structural changes in the hath 
region, is still able to interact with tubulin. Tubulin-binding motifs are commonly 
characterised by the presence of positively charged amino acids which mediate binding 
to the C-terminal acidic part of tubulin [217-219]. Indeed, in the C-terminal part of the 
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hath region several positively charged amino acid residues are available in all three 
HDGF isoforms (in HDGF-A Lys70, Lys72, Lys75, Lys78, Arg79, Lys80) (figure 7). These 
residues are also present in HRP-3 (in HRP-3 Lys69, Lys71, Lys74, Lys77, Arg78, 
Lys79) (figure 1). Actually, El-Tahir et al. provided first valuable hints that the mentioned 
region is involved in tubulin binding. The mutation of the positively charged Lys and Arg 
residues (Lys74, Lys77, Arg78 and Lys79) to an uncharged Asn in HRP-3 reduced the 
stabilisation activity on microtubules significantly [216]. However, whether these amino 
acid residues participate in tubulin binding needs to be addressed in future studies.  
Intriguingly, the HDGF-A interaction partner YB-1 is also a tubulin-binding protein and 
like HRP-3 it promotes microtubule assembly [220]. The release of YB-1 from inactive 
mRNPs, relieves transcriptional repression of the respective mRNA [221]. Chernov et al. 
proposed that YB-1 dissociation from mRNPs occurs through tubulin binding [220]. 
Interestingly, posttranslational phosphorylation decreases affinity of YB-1 to RNAs and 
might be a tool for its regulation [221]. Regarding that first 15 aa of HDGF-A are essential 
for YB-1 co-precipitation and at the same time the presence of this peptide in HDGF-A 
prevents its tubulin binding, a comparable mechanism is conceivable for HDGF-A. 
Thakar et al. proposed that dephosphorylation of Ser165 results in N-terminal truncation 
[33]. Hence HDGF-A release from mRNPs and the subsequent binding to tubulin might 
be induced by posttranslational dephosphorylation at Ser165 and subsequent N-terminal 
truncation.  
A further interesting result was the detection of dynein, a microtubuli minus end directed 
motor protein [172], in the co-precipitates of HDGF-B and -C (figure 20). This finding 
leads to the assumption that HDGF-B and HDGF-C might be involved in transport related 
processes either as cargo or as part of the transport machinery, for example as cargo 
linker. While dynein was clearly present in co-precipitates, its antagonist kinesin, a motor 
protein which is directed to the plus end of microtubulis [172], was absent. Consequently, 
the involvement in transport refers rather to processes from the cell periphery towards 
the cell centre. In case of HDGF-C this could be further confirmed by the 
immunfluorescence analysis (figure 24). Strong co-localisation was observed for HDGF-
C and dynein. Due to the lack of a functional HDGF-B specific antibody, similar 
immunofluorescence analysis could not be performed. 
Surprisingly, HDGF-C appeared to interact directly or indirectly also with other elements 
of the cytoskeleton. Actin and vimentin were identified in the co-precipitates of this 
isoform (figure 20). Regarding that vimentin, tubulin and actin belong to distinct elements 
of the cytoskeleton, this was unexpected. Nevertheless, linkages between the 
cytoskeleton elements are well known and several proteins have the ability to interact 
with the different cytoskeletal proteins and thereby serve as a linker between these 
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elements [222]. This linker protein interacts directly as reported for CacyBP/SIP 
(calcyclin (S100A6) binding protein and Siah-1 interacting protein), that binds actin as 
well as tubulin directly [223]. In other cases interactions are more indirect and mediated 
by auxiliary binding partners [224]. A further link is given by the observation that the 
motorproteins dynein and kinesin are responsible for the transport and distribution of 
vimentin within the cell, a process required for the organisation and maintenance of 
vimentin networks [225, 226]. Moreover, also direct interaction between actin and 
vimentin has been reported [227].  
The discovery of these cytoskeletal interaction partners opens a wide field of possibilities 
about the functional role of HDGF-C and also HDGF-B. The co-precipitation of different 
interaction partners conveys the impression that their role is quite distinct from that of the 
main HDGF-A form. HDGF-C might constitute a further direct or indirect linker protein 
between the cytoskeleton elements; it might participate in retrograde vimentin transport 
or in other transport related processes. Like suggested for HRP-3 [216], HDGF-B and -C 
might be also involved in cytoskeleton dynamics through the stabilisation and promotion 
of microtubule assembly. To clarify the exact role further studies are required. 
However, overlapping roles or functions cannot be excluded, on the one hand due to the 
presence of common interaction partners such as Hsc70 (figure 20) and on the other 
hand due to the finding that heterodimerisation of the isoforms (figure 19) seems to be 
possible. Interestingly, the different interaction partners of HDGF-A, -B and -C can be 
found in Staufen-2 protein complexes. Staufen-2 proteins bind directly to Hsc-70 and are 
associated to RNA binding protein YB-1 through RNAs. Moreover, the cytoskeletal 
proteins tubulin and actin were identified in corresponding precipitates [228]. Several 
studies suggested that this complexes are transported in kinesin and dynein dependent 
mRNP transport along microtubules [228-230]. However, Stau2 protein is mainly 
expressed in brain and only expressed at low levels in other tissues [229], thus in the 
studied cell systems (HepG2 cells and dermal fibroblast) it does not seem to be relevant. 
Nevertheless, since all the different interaction partners are involved in mRNP transport, 
this mechanism is interesting for future studies. 
4.1.5 HDGF and Secretion 
Numerous studies demonstrated that exogenous supplied HDGF-A stimulates migration 
[66] and proliferation [1, 2, 37, 38, 50], indicating that HDGF-A realizes in addition to its 
intracellular functions also extracellular functions. This is consistent with other studies 
demonstrating that HDGF-A can be found in the surrounding media from different cells 
like neurons [77], glioblastoma [55], and muscle cells [78] or in serum collected from lung 
cancer patients [80]. Nevertheless, until now not much is known about its cellular 
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trafficking, how exactly HDGF-A exits the cell and about possible underlying regulatory 
processes. 
Some studies discussed that the extracellular presence of HDGF is more a consequence 
of passive release [44, 77]. Indeed, cells that undergo necrosis but not apoptosis release 
HDGF passively [77]. However, passive release does not rule out the possibility of active 
secretion. For instance, HMGB1, which shares 35 % similarity with HDGF-A [1], can 
leave the cell by both active secretion and passive release [81, 231, 232].  
HDGF-A does not contain a N-terminal hydrophobic signal sequence required for the 
ER/Golgi mediated pathway (table 8; appendix A1) and simultaneously, the changes 
through alternative splicing in the N-terminal part of HDGF-B and HDGF-C does not 
create a novel secretion peptide either (table 8; appendix A2-A3). As consequence 
putative active secretion of all these HDGF isoforms has to occur via alternative 
secretion pathways. 
As described in the previous chapters, alternative splicing of HDGF leads to the 
generation of isoforms with key changes in their overall structure, their function as well 
as in their interaction behaviour. It appears obvious that also secretion of HDGF-B and 
HDGF-C is altered, especially since the outermost N-terminal amino acids of mouse 
HDGF are critical in its secretion [33]. In contrast to the full length mouse HDGF, 
truncated HDGF, deleted in 11 or more N-terminal amino acid residues, could not be 
found in extracellular media after 24 h incubation. The same was found for mouse HDGF 
S165A, a variant which is N-terminal truncated, too [33].  
Indeed, a comparison of human HDGF release into the conditioned media over the 
course of time (figure 25) revealed that HDGF-B like HDGF-A S165A was below the 
detection limit in the extracellular media. In addition, extracellular levels of HDGF-C were 
considerably lower compared to HDGF-A. According to this result HDGF-A is the main 
secreted HDGF variant and, as discussed by Thakar et al. [33], its secretion can be 
controlled by absence/presence of the outermost N-terminal amino acids. 
The fact that alternative spliced variants exhibit different secretion behaviours was also 
described for other growth factors such as transforming growth factor beta (TGF β) [233] 
or vascular endothelial growth factor (VEGF) [234]. On the condition that expression 
levels are comparable, the release of different protein levels over the course of time hints 
towards different underlying regulatory processes and/or alternative secretion processes. 
4.1.5.1 HDGF and the presence in extracellular vesicles 
As mentioned, none of the HDGF isoforms contains a classical secretion signal, thus 
putative active secretion has to occur via an alternative pathway. In line with this was the 
observation that the inhibitor Mon [178], which interferes with the ER/Golgi mediated 
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secretion pathway, did not inhibit HDGF-A release (figure 26, panel 1). Instead, HDGF-A 
secretion was inhibited specifically by treating the cells with DMA. Along this line, the 
release of ectopically expressed HDGF-C (figure 26, panel 3) and of endogenous HDGF 
(figure 26, panel 4) from HeLa cells decreased after DMA treatment, too. The observed 
decline, induced by DMA, was not as strong as observed for ectopically expressed 
HDGF-A. However, since longer incubation times were required (up to 42h) to be able to 
detect HDGF-C and endogenous HDGF in the conditioned media, the direct comparison 
of the observed DMA effects is certainly difficult. For instance, cells might become 
accustomed with the course of time to the changed conditions and are able to 
compensate effects. However, literature addressing such specific long term effects of 
DMA on secretion is not available. 
The identification of a specific inhibitor supports the concept of an active secretion 
mechanism indirectly. DMA is a known inhibitor of exosome release [177], decreasing 
the exosome mediated release of several proteins such as Hsp90 [235], Hsp60 [236] or 
the receptor protein sortilin [237]. Hence, it is an obvious possibility that HDGF-A and -C 
leave the cell via exosomes. This assumption is consistent with the recent proteomic 
studies which identified HDGF in exosomes [87, 89, 94].  
Savina et al. [177] assumed that the decrease of exosome release caused by DMA, 
depends on a decline in intracellular Ca2+ levels. However, the observation of the 
inhibitor assay does not exclude other alternative secretion pathways. An elevation of 
intracellular Ca2+ levels was reported to induce fusion of lysosomes with the plasma 
membrane [238]. Furthermore, microvesicle release through shedding from the plasma 
membrane is also stimulated by an increase of intracellular Ca2+ levels [239]. Thus, 
changes in intracellular Ca2+ levels might control also other pathways than the exosome 
mediated pathway. But respective literature concerning such DMA effects on other 
alternative secretory pathways was not found. 
Nevertheless, the analysis of exosome enriched samples led to the same conclusion 
(figure 27 & 28). Endogenously expressed HDGF as well as all ectopically expressed 
HDGF isoforms and HDGF-A S165A were detectable in exosome enriched fractions 
(figure 27 & 28).  
As mentioned earlier, in the present study differential centrifugation was performed to 
isolate exosomes from the conditioned media. It is commonly known that smaller 
amounts of shedding microvesicles and apoptotic blebs of equal size may co-sediment 
with the exosomes. Therefore, obtained fractions might contain subpopulations of other 
extracellular vesicles, which potentially can be the source for the detected HDGF 
variants [99, 240].  
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However, Xu et al. used an elaborate purification method and could demonstrate that 
HDGF is also present in these highly purified exosome fraction [89], strongly suggesting 
that HDGF can use indeed this vehicle to exit the cell. Which HDGF isoform was 
identified by Xu et al. cannot be answered on basis of their published data. But the 
general dominance of HDGF-A in all investigated cell lines (figure 9) implicates that they 
detected HDGF-A. 
Most strikingly, even though HDGF-B and HDGF-A S165A were below detection limits in 
the conditioned media (figure 25), they were identified highly enriched in the exosome 
fractions (figure 27). The same kind of enrichment was observed for exosomal marker 
protein CD63 (figure 27), a protein which is commonly known to be highly enriched in 
exosomes [107, 241]. 
In contrast, HDGF-A, HDGF-C (figure 25) as well as endogenous HDGF from some of 
the studied cell lines (HeLa, HaCat, MCF-7) (figure 28) were not only detectable in those 
supernatants (SN1-SN4), collected before the actual exosome sedimentation step, but 
also in the SN5, collected after exosome sedimentation. In all cases these respective 
proteins were not enriched in the final exosome containing fraction to the same extent 
like CD63. This obvious difference to the exosomal marker CD63 leads to the 
assumption that these proteins exist additionally as free protein in the extracellular 
space.  
Indeed, subfractions of HDGF-A and endogenous HDGF were still detectable in the 
exosome depleted supernatants (SN5*), obtained after an additional ultracentrifugation 
for 24 h (figure 30). Therefore, these subfractions are not vesicle associated and present 
as free protein in the media. Like the exosomal marker CD63, the other HDGF variants 
(HDGF-B, HDGF-A S165A and also HDGF-C) were not detectable in SN5*, indicating 
that these proteins are only present in the vesicle associated fraction.  
Of note, another explanation for the detection of HDGF-A in exosome depleted 
supernatants could be that the protein derived from defect vesicles. But since HDGF-B 
and HDGF-A S165A were not detected in the vesicle depleted supernatants under the 
same conditions, this is unlikely. 
The presence in the extracellular medium as free protein or within vesicles can have 
different consequences in terms of function and half life. While proteins located within 
extracellular vesicles are protected by the vesicular membrane, free proteins might have 
shorter half times in the extracellular medium. Furthermore, functional roles might be 
different. Previous studies have not directly examined whether HDGF-A is present as 
free protein or within vesicles but numerous studies demonstrated that extracellular 
supplied HDGF-A induces cell growth and migration [1, 38, 46, 50, 66]. Indeed, several 
studies suggested that HDGF-A is able to exert its proliferative effect via until now 
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unknown receptor(s) present on the plasma membrane [41, 79]. Intra-vesicular HDGF-A 
would not be able to interact with surface receptors. Furthermore, cells are able to 
internalise free HDGF-A [167]. 
Nonetheless, the detection of additional free HDGF-A and free endogenous HDGF raises 
the question which further alternative pathway, apart from an extracellular vesicle 
mediated pathway, is used by these proteins to leave the cell and end up as free protein 
in the extracellular space. 
It has been reported that multiple secretion mechanisms can be involved in the release 
of the same protein like for the cytokine interleukin-1beta (IL-1β). IL-1β can leave the cell 
via different types of vesicles including exosomes [242] and shedding microvesicles [243] 
derived from the plasma membrane. Moreover, it is able to exit the cell via secretory 
lysosomes [244, 245]. HMGB1, a protein which shares 35 % similarity with HDGF-A [1], 
was identified in extracellular vesicles [246]. In the same study it was shown, that 
HMGB1 was still detectable in exosome-depleted supernatants, likewise indicating that 
more than one secretion process might be involved at the same time. This finding was 
supported by another study reporting that HMGB1 leaves the cell via secretory 
lysosomes [232].  
4.1.5.1.1 Endogenous HDGF in extracellular vesicles 
Consistent with the recent proteomic studies [87, 89, 94], endogenous HDGF was 
detected in exosome fractions enriched from different cell types. As discussed in the 
beginning, with the discovery of the novel HDGF isoforms, there remains always an 
uncertainty, which isoform is detected when using an anti pan-HDGF antibody. This is 
strengthened by the discovery that all HDGF isoforms appeared to be released via 
extracellular vesicles. Thus, the detected signal could derive from the presence of all 
three isoforms. But, due to the great dominance of HDGF-A in all studied cell types 
(figure 9) it is more than likely, that HDGF-A will be found in these cells as well as in their 
surroundings. 
An interesting finding was that endogenous HDGF was not detected in all exosome 
fractions. Exosome enriched fractions collected repetitive times from HepG2 cells did not 
contain HDGF in detectable amounts. However, overexpressed HDGF variants in these 
cells can be released by these cells (figure 25 & 28). In extracellular vesicles collected 
from MDA-MB-231 cells HDGF signals appeared only weak in Western blot analysis 
(figure 29). But according to literature HDGF could be isolated from the conditioned 
medium of MDA-MB-231 cells after purification with heparin binding columns [247], 
indicating that HDGF is also secreted from those cells but probably in lower amounts so 
that it remained almost below the detection limit. The simultaneous analysis of the 
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cleared lysates demonstrated that different cell types expressed HDGF at comparable 
levels (figure 29). Therefore, cell specific HDGF abundance in exosome fractions 
seemed to be rather caused by different selective protein loading into extracellular 
vesicles and was not a consequence of different expression levels.  
Along this line Jeppesen et al. demonstrated that HDGF belonged to that group of 
proteins, which were more abundant in exosomes derived from metastatic cells 
compared to those derived from non-metastatic cells. These observed changes in 
exosomes did not correlate with changes on mRNA levels. However, since they did not 
compare corresponding protein expression levels, observed changes in protein 
abundance as consequence of altered protein levels within the cell cannot be excluded 
completely [87]. This is even more important in the light of those studies, which 
correlated elevated HDGF protein levels with metastasis and cancer progression [32, 61, 
248, 249]. 
The molecular protein composition of exosomes is not just a simple reflection of protein 
composition in cells. Exosomes are enriched in specific proteins, whereas others are 
lower concentrated or completely absent [105, 183]. Therefore, protein sorting into 
exosomes is regarded as specific process, which is regulated. Underlying sorting 
processes are far from being understood [112].  
In this context the cell type specific appearance of two HDGF polypeptides in exosome 
enriched fractions at molecular weight positions of 37 and 39 kDa is interesting (figure 
29). The 39 kDa HDGF signal is the predominant form in HaCat derived extracellular 
vesicles while this variant is underrepresented in the total cell lysate and hardly 
detectable. This clearly shows that this 39 kDa HDGF form is highly enriched in exosome 
fractions and consequently in the underlying loading process into extracellular vesicles 
preferred over the smaller form.  
The slower running behaviour in SDS PAGE might be caused by changes in the protein 
either by posttranslational modifications or by alternative splicing. However, the 
immunodetection with the HDGF-C antibody did not lead to signals in the respective 
samples (data not shown). 
4.1.5.1.2 Posttranslational modification directs presence in extracellular vesicles 
Posttranslational modifications are indeed a tool to denote proteins for exosome 
mediated transfer. For example some but not all proteins require ubiquitination to be 
sorted into exosomes [250]. Also other posttranslational modifications seem to play a 
role for some proteins. There are a few hints that phosphorylation is involved in these 
sorting processes at least for a few proteins. Mass spectrometry analysis demonstrated 
that phosphorylated tau proteins were enriched in exosomal fraction compared to the 
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respective cell lysates [251]. Furthermore, N-terminal phosphorylation of Annexin A2 is 
required for sorting into exosomal membranes [252].  
The idea of posttranslational modifications as a regulatory element influencing the sorting 
of HDGF-A into exosomes was supported by another finding. Ectopically expressed 
HDGF-S133A mutant was repeatedly not present in the exosome fraction indicating that 
the deleted phosphorylation site at this position might be essential for the sorting process 
into exosomes (figure 34). Combining exchange of Ser133 to Ala with other Ser to Ala 
exchanges such as Ser132 to Ala or Ser165 to Ala did not abolish the extracellular 
vesicle mediated secretion. This indicates that specific patterns of phosphorylation might 
control the sorting of HDGF-A into extracellular vesicles. However, further experiments 
are necessary to explore the role of phosphorylation HDGF pattern. 
4.1.5.1.3 N-terminus of HDGF-A is critical for localisation in vesicles 
The most striking finding was that the novel isoforms HDGF-B and HDGF-C are located 
at the surface of extracellular vesicles, while the HDGF-A isoform is located within these 
vesicles (figure 31). Like HDGF-A also endogenous HDGF was found in the lumen of 
extracellular vesicles, clearly supporting the assumption that the detected endogenous 
HDGF in the different exosome enriched samples from different celltypes is mainly 
HDGF-A and not HDGF-B or HDGF-C (figure 33). However, if there is any condition, 
where one of the HDGF isoforms HDGF-B and -C is expressed that strong, that it can be 
detected on the surface of extracellular vesicles, remains uncertain.  
The presence or absence of the outermost N-terminal amino acid residues seems to 
control the localisation in or on extracellular vesicles. Not only HDGF-B and HDGF-C but 
also all N-terminal truncated HDGF-A variants, deleted in 11 or more amino acid 
residues were found at the surface of extracellular vesicles (figure 35). The missing of 
the respective peptide seems to be likewise the reason for the surface localisation of 
HDGF-A S165A, which is reported to be N-terminal truncated [33].  
Interestingly, Jeppesen et al. could show that HDGF is associated with the exosomal 
membrane. However, the applied protocol could not distinguish between intra- and 
extravesicular localisation [87].  
Since extravesicular position was shown for HDGF isoforms -B and -C as well as HDGF-
A S165A it seems that the position can be achieved by different modulation ways, 
alternative splicing on posttranscriptional level or by posttranslational modifications in 
form of dephosphorylation at position Ser165.  
Different proteins have been identified as localised on the exosomal surface such as 
galectin-5 [253], annexin A2 [252] or Hsp60 [236]. It was proposed that the release of 
these proteins is mediated by an unconventional pathway including the secretion as free 
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protein into the extracellular medium, the subsequent binding to lipid rafts present at the 
plasma membrane followed by internalisation via endocytosis and the final entrance into 
the MVB. Exosomes, deriving from the respective MVB, carry the protein on their 
membrane surface [236, 252]. 
Such a model is also conceivable for the HDGF forms (HDGF-B, HDGF-C and HDGF-A 
S165A). As indicated in figure 38, the proposed secretion mechanism involves the 
crossing of the plasma membrane by an unknown alternative secretion mechanism (B1), 
the binding to lipid rafts present in the plasma membrane (B2), the endocytosis (B3), the 
maturation to MVBs accompanied by the formation of ILV (B4), and the final release of 
exosomes carrying the respective lipid rafts decorated with the respective HDGF protein 
variants (B5).  
 
 
Figure 38: Hypothetical model for the secretion mechanisms of HDGF isoforms. HDGF-A 
(red spots) can be sorted into exosomes (A1) or might be secreted as free protein via a yet 
unknown pathway (A2). In contrast to the truncated HDGF forms HDGF-A probably does not bind 
to lipid rafts present on the plasma membrane (A3). HDGF variants with an altered N-terminus 
(HDGF-B, HDGF-C, HDGF-A S165A) (blue spots) cannot be sorted into exosomes (B1). They 
cross putatively the membrane (B2), possibly by the same unknown route as HDGF-A (A2) but 
bind to lipid rafts (grey rectangles), present in the plasma membrane (B3). Lipid rafts are 
internalised by endocytosis (B4) and enter the MVB (B5). Formation of exosomes from this MVB 
would result into exosomes with HDGF proteins on their surface (B6). 
As mentioned earlier the presence of other extracellular vesicles (apoptotic blebs and 
microvesicles), which derive from the plasma membrane cannot be excluded completely 
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and they might be the actual source for the detection of the HDGF variants. 
Nevertheless, also in this case the corresponding HDGF variants have to cross the 
plasma membrane in order to end up on the surface of those extracellular vesicles. 
According to the depletion experiment the mutant HDGF-A S165A as well as HDGF-B 
and -C are not present as free proteins in the conditioned media. Consequently, on the 
basis of the proposed secretion model this would require that these proteins bind back 
with such a high efficiency to the plasma membrane after crossing the membrane so that 
none or only low levels are released as free protein (B3).  
Furthermore, the results of the depletion experiment give rise to the speculation that 
HDGF-A is released from the cell via an additional alternative pathway, by that HDGF-A 
ends up as free protein in the extracellular space. Of course it is conceivable that HDGF-
A as well as HDGF-B, HDGF-C and the N-terminal truncated HDGF-A use the same 
pathway in order to cross the membrane, but only the full length HDGF-A does not have 
the ability to bind back to the cell membrane, probably mediated through inhibition by its 
specific N-terminus.  
Of particular note is that the presence or absence of outermost N-terminal part of HDGF-
A is again the critical point as already observed for the interaction behaviour. With 
respect to the parallels in interaction and secretion behaviour of the different examined 
HDGF variants, it is reasonably assumed that the altered secretion behaviour is 
connected to the differential interaction behaviour. The N-terminally altered HDGF 
variants might be able to bind to a specific protein, which is located at the surface of 
extracellular vesicles and therefore the actual reason for the differential localisation of 
those HDGF variants. Conversely, HDGF-A might be sorted into exosomes since by 
contrast to the other HDGF variants it binds to a specific protein, which is targeted to 
exosomes. Interestingly, both nucleolin [254] and YB-1 [254] were identified in these 
vesicles. However, tubulin and actin, binding partners of HDGF-C, are both present in 
exosomes, too. Therefore, interaction to any protein, which is localised in exosomes, 
does not directly lead to intraexosomal localisation. 
In this context it is interesting that YB-1 is required for the sorting of microRNAs into 
exosomes [255]. Considering that HDGF-A is interaction partner of YB-1, the interaction 
depends on the presence of RNA and it is like YB-1 present in exosomes, HDGF-A might 
adopt a similar function and supports YB-1 in some way. 
4.2 N-terminal truncation of HDGF-A 
The different experiments regarding interaction and secretion behaviour revealed that the 
outermost N-terminal amino acid residues are critical for the function of HDGF-A. 
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Regarding the drastic changes, the N-terminal truncation of HDGF-A appears like an 
internal switch.  
Until now, there has not been any evidence that N-terminal truncation of HDGF-A occurs 
upon dephosphorylation of Ser165 under physiological conditions, as proposed by 
Thakar et al. [33], but its discovery would be worthwhile. Intriguingly, N-terminal 
truncation has been described for HMGB1. Extracellular dipeptidyl peptidase IV cleaves 
HMGB1 in its N-terminal part and by that abolishes its angiogenic activity. Moreover, 
DPP-IV inhibition in vivo decreases the levels of truncated HMGB1 [256]. Apart from 
DPP-IV also thrombin cleaves HMGB1 N-terminally [257]. 
As suggested by Thakar et al., the N-terminal part of HDGF-A contains a putative MAPK 
docking site KEYKCGDLVF17 with 100 % identity to the consensus sequence [33]. Apart 
from the mentioned changes in secretion and interaction behaviour, truncation would 
also lead to the loss of this putative site [258]. Moreover, a further really interesting 
aspect might be that the peptide itself gains a function after cleavage and by that 
becoming a bioactive peptide. 
The Cys12 in HDGF-A appears to influence truncation process in some way because in 
exosome enriched fractions collected from HDGF C12A expressing cells an additional 
protein signal with faster electrophoretic running behaviour could be detected, which was 
sensitive to trypsin digest (figure 36). The enrichment in the exosome containing fraction 
and moreover the extravesicular localisation corresponded to the results obtained for 
those HDGF variants, which were either N-terminally truncated in 11 or more amino acid 
residues (HDGF-A S165A; NΔ11/12 HDGF) or exhibited an alternative N-terminal 
sequence (HDGF-B and HDGF-C) compared to HDGF-A. This analogy and the lower 
molecular weight strongly suggested that the detected variant was N-terminally truncated 
in 11 or more N-terminal amino acid residues. 
Thakar et al. demonstrated that an intramolecular disulfide bridge can be formed 
between Cys12 and Cys108 [33]. On the basis of this observation, deletion of the 
intramolecular disulfide bridge through the loss of Cys12 might improve the accessibility 
for the N-terminal truncation mechanism. However, in extracellular vesicles of HDGF 
C108A overexpressing cells a similar additional truncated fragment was not observed. 
Since the intramolecular disulfide bridge cannot be formed in this HDGF mutant either, it 
seems unlikely that the formation or deletion of this disulfide bridge is directly involved in 
the truncation process.  
On the basis of the present data it is difficult to give an explanation for the truncation 
mechanism. One possibility is that the exchange of Cys12 to an Ala introduces a better 
motif for the N-terminal truncation mechanism. In addition it is conceivable that with the 
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exchange of Cys12 to Ala the respective N-terminal peptide adopts a position more 
accessible for the truncation mechanism. To clarify this further studies are necessary.  
4.3 Conclusion and perspectives 
One of the major objectives of this thesis was the verification and characterisation of 
novel HDGF isoforms HDGF-B and HDGF-C. Both were identified to be expressed on 
mRNA level within this present work and HDGF-C could be also verified as expressed 
protein by the use of a novel peptide specific antibody. The missing proof of HDGF-B as 
expressed protein was due to the lack of a fully characterised HDGF-B specific antibody 
and its verification on protein level remains for future studies. The discovery of the 
isoforms raises new questions regarding their biological role that can be initially 
answered with the present study. At the same time the results open various new 
questions, which need to be responded in future studies. 
On the basis of the present results, it becomes obvious that the novel isoforms broaden 
the functional spectrum of HDGF-A and extend the interactome. Nevertheless, also 
overlaps regarding function and interaction exist. This includes the common interaction 
partner Hsc-70 as well as the proliferation activity on cells upon overexpression, which 
was observed for HDGF-A and HDGF-B but not for HDGF-C.  
Exploring the co-precipitates of each isoform revealed quite differential interaction 
behaviour. The distinct interactions indicate that HDGF-B and –C participate at least 
partly in different cellular processes than HDGF-A. Only HDGF-B and -C have the ability 
to co-precipitate the cytoskeleton protein tubulin, whereas HDGF-A does not have this 
ability. On the one hand it opens new potential functional aspects such as cell migration 
or cargo transport. In this context further studies need to clarify whether these variants 
bind directly to tubulin as observed for HRP-3 and which functional consequence can be 
linked to this interaction. On the other hand this finding is notable because the interaction 
did not depend on the new alternative N-termini of HDGF-B and -C, but on the lack of the 
N-terminus of HDGF-A. An opposite result was obtained for the interaction with nucleolin 
and YB-1. Here the outermost N-terminal amino acid residues of HDGF-A are essential 
for the interaction with the mentioned proteins, the deletion of them in HDGF-A leads to 
its loss. In this context, HDGF-B and HDGF-C, missing the respective peptide, are also 
not able to co-precipitate these proteins. This observation raises the fascinating question 
in which way the outermost N-terminal peptide can influence the interaction behaviour of 
HDGF-A, an important question which needs to be answered by further investigations.  
It remains unclear whether a direct link can be drawn between differential interactions 
and the distinct secretion behaviours, but the parallels are obvious. While HDGF-A is 
located within extracellular vesicles and moreover seems to exit the cell via an additional 
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pathway, all other HDGF variants (HDGF-B, -C and HDGF-A S165A) with an altered N-
terminal part were located at the surface of the extracellular vesicles and could not be 
found as free protein in the surrounding media. Again N-terminal truncation of HDGF-A is 
sufficient to induce the alternative secretion behaviour. In theory, this could mean that 
the cell has two different modes to intervene in secretion and interaction. First, it induces 
this alternative behaviour in secretion and interaction on posttranscriptional level by the 
generation of alternative isoforms through alternative splicing. Second, assumed that 
such a mechanism proposed by Thakar et al. [33] exists and the dephosphorylation at 
Ser165 in HDGF-A results in N-terminal truncation, the cell can control this on 
posttranslational level, too. 
The subsequent different modes of localisation in the extracellular space might result in 
different communication pathways. With respect to the generally accepted fact that 
HDGF is an factor involved in cancer development and progression [40, 45, 50, 57, 62] 
and the demonstration that HDGF is secreted differentially by extracellular vesicles as an 
important tool for cancer cells to influence their microenvironment [259], studies in this 
direction would be a necessary future approach. 
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6. Appendix 
6.1 Peptide mass fingerprints of proteins by SDS-PAGE and MALDI-TOF 
 
Table A1:Identication of potential interaction partners by MALDI-TOF mass 
spectrometry and peptide mass fingerprinting. Spot Number (see figure 20) and the 
respective identified protein, its Swiss Prot ID as well obtained scoring values are given below.  
Spot 
No. 
Identified 
in co-
precipitate 
of HDGF 
Protein 
name 
Swiss 
prot ID 
Score Expect Mass 
values 
searched 
Mass 
values 
matched 
Sequence 
coverage 
(%) 
RMS 
error 
ppm 
1 A, B, C 
heat shock 
cognate 71 
kDa 
(Hsc70) 
P11142 62 0.013 29 8 16 45 
2 B, C 
tubulin 
alpha 1C 
Q9BQE3 62 0.012 42 8 25 36 
2 B, C 
tubulin 
alpha-8 
chain 
Q9NY65 55 0.091 27 7 16 29 
2 B, C 
tubulin beta 
chain 
P07437 78 0.00038 27 9 14 20 
3 A 
Y-box 
binding 
protein (YB-
1) 
P67809 88 4.4e-05 39 9 34 33 
4 C 
actin, 
cytoplasmic 
1 
P60709 70 0.002 27 7 26 7 
5 A, B, C 
ADP/ATP 
Translocase 
2 
P05141 90 1.9e-05 28 9 26 44 
6 A 
60S 
ribosomal 
protein L6 
Q02878 72 0.0015 32 10 23 70 
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6.2  SignalP 4.1 prediction results 
HDGF-A 
 
Figure A1: Prediction result for the presence and location of a putative signal peptide and 
cleavage site in the HDGF-B amino acid sequence using SignaI 4.1 with default settings.  
The graphical output shows three scores: C (raw cleavage site score), S (signal peptide score) 
and Y (combined cleavage site score of the C-score and the slope of the S-score) for each 
position in the sequence. The D-score (discrimination score, combined score of the mean S and 
the max Y score) is used to discriminate signal peptides from non-signal peptides. The D- cut off 
was set at 0.45 (default settings).  
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HDGF-B 
 
Figure A2: Prediction result for the presence and location of a putative signal peptide and 
cleavage site in the HDGF-B amino acid sequence using SignaI 4.1 with default settings. 
The graphical output shows three scores: C (raw cleavage site score), S (signal peptide score) 
and Y (combined cleavage site score of the C-score and the slope of the S-score) for each 
position in the sequence. The D-score (discrimination score, combined score of the mean S and 
the max Y score) is used to discriminate signal peptides from non-signal peptides. The D- cut off 
was set at 0.45 (default settings). 
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HDGF-C 
 
 
Figure A3: Prediction result for the presence and location of a putative signal peptide and 
cleavage site in the HDGF-C amino acid sequence using Signal 4.1 with default settings. 
The graphical output shows three scores: C (raw cleavage site score), S (signal peptide score) 
and Y (combined cleavage site score of the C-score and the slope of the S-score) for each 
position in the sequence. The D-score (discrimination score, combined score of the mean S and 
the max Y score) is used to discriminate signal peptides from non-signal peptides. The D- cut off 
was set at 0.45 (default settings).  
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6.3 Expression plasmids 
 
pcDNA3 
 
 
Figure A4: Vector Map of pcDNA3 (Invitrogen). The graphical output was obtained from:  
http://www.snapgene.com/resources/plasmid_files/image_consortium_plasmids/pcDNA3/ 
(24.04.2016; 18:15. 
 
pEGFP-N3 
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Figure A5: Vector Map of pEGFP-N3 (Clonetech).  The graphical output was obtained from:  
http://old-site.bioss-freiburg.de/www.bioss.uni-freiburg.de/toolbox/productsf427.html?PL-
823&cPath=6_43 (24.04.2016; 18:00) 
pEXPR-IBA5 
 
Figure A6: Vector Map of pEPR-IBA5 (IBA).  The graphical output was obtained from: 
http://search.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/IBA_/21905000.20060609.pdf 
(24.04.2016; 18:30) 
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